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Abstract 
 
Axon-oligodendrocyte interactions are vital for the propagation of fast saltatory nerve 
impulses in the central nervous system (CNS).  Axonal signals are involved in the 
survival and maturation of oligodendrocytes during development but are poorly 
characterised.  Early in Multiple Sclerosis (MS) remyelination of demyelinated axons is 
common.  However, the hallmark of MS pathology is the demyelinated plaque.  
Oligodendrocyte precursor cells (OPCs) are present in the adult CNS and can 
remyelinate axons.  OPCs have been found in chronically demyelinated lesions and 
appear to contact axons but not to engage in myelin formation, suggesting that they may 
not be receiving the correct signals.   
 
Molecules that are expressed on the axon and interact with molecules expressed on the 
surface of the pre-myelinating oligodendrocyte are candidates to mediate contact-
dependent signalling, which may control the late stages of oligodendrocyte 
differentiation and myelination.  These molecules could also have a role in MS 
pathology.  We have investigated the role that neural cell adhesion molecule (NCAM) 
might play in such axon-oligodendrocyte interactions using an in vitro system.  NCAM 
has been shown to have a role in neurite outgrowth and neuronal survival.  OPCs were 
isolated from the neonatal rat brain and differentiated in vitro to the O4
+
 pre-
oligodendrocyte stage.  Western blotting and immunofluorescence confirmed the 
expression of NCAM.  To mimic the effects of axonal NCAM binding to OPCs we used 
a small peptide from the FnIII domain of NCAM (FRM) and a full length soluble 
protein (NCAM-Fc).  FRM peptide and NCAM-Fc increased OPC survival, as detected 
by propidium iodide staining after four days in culture, to a level comparable to that 
obtained with the OPC survival factor insulin.  NCAM has previously been shown to 
increase neuronal survival and process outgrowth in vitro via the FGF receptor.  The 
FGF receptor inhibitor PD173074 specifically blocked the survival effects of FRM 
peptide and NCAM-Fc, leading to a return to control cell survival rates.  Selective 
inhibitors of MAP kinase, Fyn and PI3 kinase demonstrated the involvement of MAP 
kinase and Fyn in NCAM-mediated OPC survival.  This was supported with Western 
blotting using OPC cell lysates stimulated with FRM petide or NCAM-Fc, which 
detected phosphoERK1/2 but not phosphoAkt.  
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In addition, co-culture of OPCs on NCAM-expressing fibroblasts increased process 
outgrowth after one day in vitro, and this was dependent on signalling via Fyn.  
However, FRM peptide and NCAM-Fc were not able to replicate this effect, suggesting 
a requirement for NCAM to be presented in a cellular substratum to induce outgrowth.  
 
We have shown that NCAM mimetics increase OPC survival and that this is dependent 
on activation of the FGF receptor and downstream signalling. These results suggest that 
the binding of axonal NCAM may promote OPC survival and radial process outgrowth, 
enabling initiation of myelination. 
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Glial cells encompass several cell types, including astrocytes, oligodendrocytes and 
microglia, which together account for approximately 90% of the cells in the human 
brain.  Historically glia were dismissed as having a passive support role and being the 
‘glue’ that holds neurons together.  However, it has become increasingly apparent that 
they have a number of vital functions including roles in synaptic transmission and 
maintenance of the blood-brain barrier. Oligodendrocytes are specialised glial cells 
found in the central nervous system (CNS) that produce myelin, an extensive lipid-rich 
membrane that spirals around and insulates the axon, enabling rapid saltatory 
conduction of an action potential through the formation of nodes of Ranvier.  Myelin 
increases the resistance and decreases the capacitance of the axonal membrane.  In 
terms of nervous system evolution, myelination is a recent intervention and is only 
present in vertebrate species.  The generation of the correct number of oligodendrocytes 
for myelination is a complex and tightly controlled process, involving proliferation, 
migration and differentiation of oligodendrocyte precursor cells (OPCs) and intricate 
interactions with neurons, and is essential for correct functioning of the CNS.  As well 
as enabling rapid conduction of an action potential, myelination leads to the 
establishment of distinct axonal domains, maintains axon calibre and also inhibits 
axonal outgrowth. 
 
1.1 Gliogenesis 
OPCs are generated from neuroepithelial cells and arise towards the latter stages of 
embryogenesis from specific regions of the neural tube.  Studies have shown that 
neurons generally develop prior to glial cells, and that oligodendrocytes in particular are 
the last glial population to develop (reviewed by Rowitch 2004).  Examination of spinal 
cord patterning has revealed that OPCs arise at E12.5/E14 in the mouse or rat, 
respectively, and that they are spatially restricted along the dorso-ventral axis and 
dependent on signals released from the notochord.  The majority of OPCs originate in 
the ventral ventricular zone of the spinal cord (Hall et al. 1996; Warf et al. 1991) and 
have been identified by expression of platelet derived growth factor receptor alpha 
(PDGFR) (Pringle and Richardson 1993).  Distinct regions of the neural tube are 
organised by the concentration gradient of bone morphogenetic proteins (BMPs) 
released from the roof plate and sonic hedgehog (shh) released from the floor plate and 
notochord.  Shh is a long-range signalling molecule that regulates the expression of 
24 
 
transcription factors and is antagonised by BMPs.  Together these molecules establish a 
gradient of shh-BMP activity, which specifies different cell types.  OPCs of ventral 
origin arise in the pre-motor neuron (pMN) domain of the neural tube, after motor 
neuron precursors have formed, and respond to shh.  Experiments using notochord 
transplants in chick embryos have shown that early ventralising signals come from the 
notochord and that shh is necessary and sufficient for OPC generation (Orentas and 
Miller 1996; Orentas et al. 1999; Pringle et al. 1996).  Shh controls the expression of 
basic helix-loop-helix (bHLH) transcription factors olig1 and olig2 via the 
homeodomain proteins Nkx6.1 and Nkx6.2, which stimulate oligodendrocyte 
development.  In vitro studies have demonstrated the inhibitory effect of BMPs on 
oligodendrogenesis, causing neural stem cells to differentiate into astrocytes at the 
expense of neurons and oligodendrocytes (Grinspan et al. 2000; Gross et al. 1996; 
Mabie et al. 1997).   
 
Whilst the majority of OPCs are ventrally derived, a later population (E15.5 in the rat) 
arise in the dorsal spinal cord, which account for 5-15% of total OPCs and are not shh 
dependent (Cai et al. 2005; Fogarty et al. 2005).  In vitro, fibroblast growth factors 
(FGFs) may initiate oligodendrocyte development in the absence of shh (Chandran et al. 
2003), leading to the suggestion that they may be the shh-independent signal used in 
vivo.  However, the contribution of dorsally derived OPCs to the final oligodendrocyte 
population is unclear (Cai et al. 2005; Fogarty et al. 2005).  
 
Oligodendrocyte development in the rostral parts of the neural tube, in particular the 
forebrain, is less well understood.  It appears that at least two independent populations 
arise in the brain, one expressing PDGFRα and another that arises earlier (E9.5 in the 
mouse) expressing mRNA for the proteolipid protein (PLP) isoform PLP/DM20 
(Spassky 2000).  Another study describes three waves of oligodendrocyte development 
in the forebrain using Cre-loxP fate mapping in transgenic mice (Kessaris et al. 2006).   
The first wave (E12.5) arises from Nkx2.1 expressing precursors that appear in the 
medial ganglionic eminence (MGE) and the anterior entopeduncular areas (AEP).  
Although these cells are the only OPCs in the early forebrain, they are subsequently 
replaced to a large extent by Gsh2-positive cells arising from the lateral and caudal 
ganglionic eminences (LGE and CGE) and later Emx1-positive cortical precursors 
(Kessaris et al. 2006), arising at E15 and the time of birth, respectively.  There does not 
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appear to be any functional heterogeneity between the different populations as targeted 
ablation of any one population does not result in myelination deficits in the adult 
(Kessaris et al. 2006).  
 
1.1.1 Olig1 and 2 transcription factors 
Olig genes are initially expressed in the pMN region of the neural tube and lie 
downstream of shh signalling. The importance of olig1 and olig2 in oligodendrocyte 
production has been demonstrated by knock-out and gene inactivation studies 
(Takebayashi et al. 2002; Xin et al. 2005).  In the olig1/2 double knock-out very few 
motor neurones were produced and oligodendrocyte production was abolished, with 
progenitors producing interneurons and astrocytes instead (Zhou and Anderson 2002).  
The two genes appear to have differing but overlapping functions, as shown by the 
single transgenic animals. The olig2-null mouse lacks motor neurones and OPCs in the 
spinal cord, but does develop olig1 positive OPCs in the forebrain, suggesting some 
redundancy and also a differing role in the spinal cord compared to the brain, with olig2 
more important in the spinal cord and a greater role for olig1 in the brain (Lu et al. 
2002; Takebayashi et al. 2002).  Olig1-null mice develop OPCs but show an impaired 
maturation of oligodendrocytes, highlighting a role in the later stages of the lineage 
development (Lu et al. 2002; Xin et al. 2005).  Furthermore, these studies demonstrated 
that oligodendrocytes and astrocytes do not arise from a common glial cell precursor 
population and that their development are controlled by different factors, as loss of olig 
genes does not affect astrocyte production (Lu et al. 2002). 
 
1.1.2 Notch signalling 
The Notch pathway has been extensively conserved and was originally identified in 
Drosophila due to its role in neuroblast development.  It has been assigned a role in 
determining whether a cell has a neural or glial fate during vertebrate neurogenesis, 
where it mediates cell-cell signalling between adjacent cells.  Amongst a population of 
cells that have equal potential to become a neuroblast, the one that expresses the highest 
level of the membrane-associated ligands Delta or Serrate, inhibits surrounding cells 
from differentiating into neuroblasts by binding to their Notch receptors and activating a 
signalling pathway.  This pathway inhibits proneural genes, thus producing a glial cell.  
The cell that expressed Delta then becomes a neuroblast.  Several studies have been 
carried out using transgenic mice null for components of the Notch family, resulting in 
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lethality, widespread neuronal death or precocious neuronal differentiation, 
demonstrating their vital role in neurogenesis (as reviewed by Yoon and Gaiano 2005).  
Notch influences all stages of neural progenitor cells, and it appears to regulate several 
check points that determine a cells ultimate fate.  OPCs express Notch1, and its 
activation inhibits their differentiation (Wang et al. 1998).  Targeted ablation of Notch 
expression on OPCs using the Cre-loxP system resulted in premature myelination, 
indicating a role for Notch signalling the spatial and temporal control of OPC 
differentiation (Genoud et al. 2002).  
 
1.2 Migration, proliferation and survival of oligodendrocytes 
Following OPC origin in specific regions of the CNS, extensive proliferation and 
migration are required in order for OPCs to populate and then myelinate the entire CNS; 
by E17 PDGFRα+ cells are distributed throughout the rat brain and spinal cord and have 
a homogeneous morphology, suggestive of a homogeneous function (Nishiyama et al. 
1996; Pringle and Richardson 1993).  The differentiation of oligodendrocyte lineage 
cells has been well characterised in vitro, where they express a series of antigenic 
markers and exhibit well defined morphological characteristics as they progress from a 
bipolar progenitor to a multi-polar, myelin-membrane producing cell (Grinspan 2002, 
Figure 1.1).  Early progenitors are identified by their expression of PDGFRα (Pringle 
and Richardson 1993), followed by the chondroitin sulphate proteoglycan NG2 and at a 
slightly later stage the gangliosides recognised by the A2B5 antibody and the GD3 
ganglioside (Levi et al. 1987; Raff et al. 1983b).  The majority of cell migration occurs 
whilst OPCs are bipolar in morphology and dependent on a number of trophic factors 
for support, such as PDGF, FGF2 and neuregulin (NRG).  These cells are also described 
as oligodendrocyte-type 2 astrocyte (O2A) progenitors, due to their ability to 
differentiate into either oligodendrocytes in the absence of serum or astrocytes in the 
presence of serum in vitro (Raff et al. 1983a).  Furthermore, different in vitro treatments 
have enabled OPCs to revert to a more immature phenotype and subsequently 
differentiate into neurons well as astrocytes and oligodendrocytes (Kondo and Raff 
2000b). 
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Figure 1.1 Development of oligodendrocyte lineage cells (Grinspan 2002). 
The development of cells from the oligodendrocyte lineage has been well described in vitro, 
whereby they differentiate through a series of defined morphological stages and express 
specific cell surface markers and transcription factors. 
 
1.2.1 Migration 
The substrates required for OPC migration are not well understood.  Cellular substrates 
are thought to play a role, and in particular the migration of precursors along axon tracts 
has been described (Ono et al. 1997).  Adhesion molecules, such as netrins, 
semaphorins and extracellular matrix molecules (ECM) are likely to play a role 
(Kiernan and ffrench-Constant 1993; Payne and Lemmon 1993; Tsai et al. 2006).  
Different modes of migration are used at different stages of OPC development and 
location in the spinal cord, suggesting that migration is controlled by localised cues 
(Tsai et al. 2009).  Expression of GFP under the control of the PLP promoter has 
demonstrated an accumulation of OPCs in the ventricular spinal cord of netrin-1 mutant 
mice (Tsai et al. 2009).  The role of polysialated neural cell adhesion molecule (PSA-
NCAM) in OPC migration is elusive, it’s expression has been shown to enhance OPC 
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migration in vitro, but only in the presence of PDGF and FGF2 (Decker et al. 2000; 
Zhang et al. 2004), whereas in vivo experiments showed it was not required for 
migration in the chick optic nerve (Ono et al. 1997).  An in vitro chemotaxis assay 
showed that fibronectin and merosin increased OPC migration (Frost et al. 1996), 
whereas the ECM molecule tenascin-C was inhibitory to OPCs and may act as a 
migration stop signal (Bartsch et al. 1994).  OPCs migrate through ECM by expressing 
matrix metalloproteinases (MMPs) which degrade ECM components.  In vivo 
overexpression of MMPs increases the number of OPCs, and OPCs isolated from 
MMP-9 null mice elongate fewer processes (Uhm et al. 1998).   
 
1.2.2 Platelet derived growth factors 
PDGF is the most extensively characterised growth factor involved in OPC 
development.  It is released by neurons and astrocytes in the CNS (Fruttiger et al. 2000) 
and all PDGF isoforms are able to bind the PDGFR expressed by OPCs.  PDGF acts 
as a mitogen and stimulates migration, survival and differentiation of OPCs and is 
chemotactic (Armstrong et al. 1990; Frost et al. 2009; Milner et al. 1997a; Noble et al. 
1988).  As development progresses the receptors are down-regulated and the mitogenic 
effects of PDGF disappear, but the survival effect persists (Barres et al. 1992; Raff et al. 
1988).  In the CNS, OPCs compete for trophic support and PDGF is thought to be a 
rate-limiting growth factor for OPC development.  Over-expression or exogenous 
delivery of PDGF increased the number of progenitors in the rodent brain, but did not 
alter the final number of mature oligodendrocytes (Barres et al. 1992; Calver et al. 
1998; Fruttiger et al. 2000), suggesting that other factors regulate the final number of 
oligodendrocytes.  The PDGF-null mouse displayed hypomyelination and a tremor 
phenotype (Fruttiger et al. 1999).  It has been suggested that OPCs contain an intrinsic 
developmental clock, and that PDGF is important in controlling the number of divisions 
a cell undergoes prior to differentiation (Raff et al. 1988).  However, in vitro studies 
have demonstrated that OPCs can keep proliferating if PDGF levels are maintained, 
suggesting that in vivo, the levels fall, causing cells to cycle more slowly and then to 
exit the cell cycle (van Heyningen et al. 2001).  The levels of PDGF required to 
maintain OPC survival are approximately 200-fold lower than that needed for 
proliferation (Barres et al. 1993b).   
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1.2.3 Fibroblast growth factors 
The FGFs are a family of ligands, comprising 23 members that activate FGF receptors 
(FGFRs)  and constitute an elaborate signalling system involved in all aspects of neural 
development, such as neural patterning, survival, proliferation and differentiation, and 
many repair processes (as reviewed by Mason 2007; Reuss and von Bohlen und 
Halbach 2003).  At least 18 FGF ligands are expressed in the brain and act with 
differing affinity on five FGFRs.  The pleiotropic effects of FGFs are achieved through 
a combination of alternative splicing and post-translational modification, in conjunction 
with temporal and spatial restriction of ligand, receptor and co-receptor expression.  The 
FGFRs are receptor tyrosine kinases (RTK), which dimerise upon ligand binding and 
are able to activate a variety of downstream signalling cascades following interaction 
with FGF receptor substrate (FRS) and the docking protein Grb2.  Co-receptors include 
heparin sulphate proteoglycans (HSPG), which act as low affinity FGFRs, and cell 
adhesion molecules (CAMs), which will be discussed later. 
 
Several in vitro studies have highlighted a role for FGF in oligodendrocyte development 
and maintenance.  FGF acts as a mitogen for OPCs (Eccleston and Silberberg 1985), 
has a role in their migration (Milner et al. 1997a; Osterhout et al. 1997), inhibits 
differentiation and can modulate the expression of PDGFRα (McKinnon et al. 1990).  
In addition, FGF2 concentration peaks in the first two weeks of postnatal life in the rat 
spinal cord, corresponding to a peak in myelination (Murtie et al. 2005).  
Transplantation of OPCs expressing a dominant negative FGFR1, displayed impaired 
migration in vitro and in vivo (Osterhout et al. 1997).  The FGF2-null mouse has 
confirmed the role of FGF2 in blocking oligodendrocyte differentiation, as a greater 
number of mature oligodendrocytes are seen in this mutant (Murtie et al. 2005).  
However, no alterations in OPC survival or density were observed suggesting other 
growth factors or FGF family members are able to compensate in vivo (Murtie et al. 
2005).   Injections of FGF2 into the cerebrospinal fluid (CSF) also induced 
accumulation of OPCs in the postnatal rat brain, supporting its role in inhibiting 
differentiation (Butt and Dinsdale 2005).  
 
In vitro analysis has shown that cells of the oligodendrocyte lineage express three of the 
four FGFRs and that their expression differs during lineage progression (Bansal et al. 
1996).  FGFR1 is expressed at all stages of development, but its expression increases 
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with lineage progression.  FGFR2 is expressed primarily on mature oligodendrocytes 
and FGFR3 expression peaks on late progenitor cells (Bansal et al. 1996).  Additionally, 
alternative splice variants of the receptors are expressed and different FGF ligands have 
distinctive affinities for particular receptors (Bansal et al. 1996; Fortin et al. 2005).  
This leads to a wide repertoire of ligand-receptor signalling pairs, providing a 
mechanism for the variety of responses FGFs elicit on the oligodendrocyte lineage.   
 
1.2.4 Neuregulin 
The NRGs are a complex family of growth factors, related to epidermal growth factor 
(EGF), that act through the ErbB RTKs.  They have been assigned a multitude of 
functions, such as neuronal migration and differentiation, signalling at the 
neuromuscular junction and the development of both CNS and peripheral nervous 
system (PNS) glial cells (as reviewed by Adlkofer and Lai 2000; Buonanno and 
Fischbach 2001).  There are four genes encoding NRG ligands (NRG1-4) which 
activate four receptors (ErbB1-4).  NRGs contain an EGF like domain which is the 
region that activates the RTK.  NRG1, which has three isoforms, is the ligand with an 
assigned role in glial development acting via three receptors ErbB2, B3 and B4, which 
function as either homo- or heterodimers (Canoll et al. 1996).  NRG1 may associate 
with the cell membrane or it may be secreted by neurons (Adlkofer and Lai 2000).   
 
Transgenic knock-out mice have revealed the necessity of NRG signalling, as the lack 
of either NRG1, ErbB2 or ErbB4 are embryonically lethal, as a result of cardiac defects.  
Due to this early lethality, the role of NRG in the CNS could not be determined from 
straight-forward knock-out studies.  However, a loss of Schwann cell precursors could 
be detected and was also observed in the ErbB3 knock-out that survives until birth 
(Adlkofer and Lai 2000).  These results suggested an essential role of NRG in Schwann 
cell development and PNS myelination and this has subsequently been confirmed by in 
vivo and in vitro studies demonstrating that NRG1 type III is an essential and instructive 
signal, controlling several stages of their differentiation.  NRG1 was initially identified 
as being a soluble mitogen for Schwann cells, where it was named glial growth factor 
(GGF, also known as NRG1 type II) (Lemke and Brockes 1984).  Conditional ablation 
of ErbB2 in Schwann cells at the time of birth produced abnormally thin myelin sheaths 
(Garratt et al. 2000) and over-expression of axonal NRG1 resulted in increased myelin 
thickness, whilst under-expression resulted in thinner myelin (Michailov et al. 2004), 
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indicating that NRG1 controls myelin production in the PNS.  Taveggia et al (2005) 
have shown that the membrane-associated type III NRG1 controls the initiation as well 
as the extent of myelination in the PNS, using co-cultures of dorsal route ganglion 
(DRG) neurons and Schwann cells from wild-type and NRG1 type III deficient mice.   
 
In vitro studies have shown that NRG1 type II is also a mitogen for oligodendrocyte 
progenitors and it increases their survival (Canoll et al. 1996).  ErbB3 is the most 
abundantly expressed receptor by cells of the oligodendrocyte lineage and ErbB4 levels 
are high on early progenitors but decrease as cells progress along the lineage, whilst 
ErbB2 increases as cells differentiate.  The effect of a factor released from neurones, 
later identified as NRG, was demonstrated using medium conditioned from neuronal 
cultures, which increased GD3
+
 OPC proliferation and was not blocked with 
neutralising antibodies to PDGF or FGF (Hardy and Reynolds 1993b; Canoll et al. 
1996).  This effect was also observed on later stage progenitors that were O4
+
/O1
-
, 
where as well as inducing proliferation NRG1 type II reversibly blocked differentiation 
and induced dedifferentiation of later stage O1
+
 cells (Canoll et al. 1996).  Supporting 
the role of NRG in oligodendrocyte development, spinal cord explants from NRG 
knock-out mice failed to develop oligodendrocytes, but could be rescued by the addition 
of NRG to culture media (Vartanian et al. 1999).  However, more recent studies have 
shown that the effects of the membrane bound NRG1 type III are more complex in 
oligodendrocytes compared to Schwann cells (Brinkmann et al. 2008; Fernandez et al. 
2000; Taveggia et al. 2008).  Conditional null mutants that lack NRG1 at different 
stages of oligodendrocyte maturation, as well as double mutants lacking the ErbB3 and 
ErbB4 receptors displayed normal myelination (Brinkmann et al. 2008).  Conversely, 
hypomyelination without a decrease in the number of mature oligodendrocytes was 
observed in NRG1+/- mice (Taveggia et al. 2008) and hypermyelination is observed 
when NRG1 type I or type III is overexpressed (Brinkmann et al. 2008) or added to 
cultures cells (Wang et al. 2007).   In contrast to experiments described earlier with 
Schwann cells, culture of wild-type oligodendrocyte progenitors with NRG1 type III 
null DRG neurons resulted in myelination, although to a lesser extent than in wild-type 
cultures (Taveggia et al. 2008).  Together these reports show that NRG1 types I and II 
are important for the early development of oligodendrocyte lineage cells and that NRG1 
type III is an axonal signal that promotes myelination, but that it acts in conjunction 
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with other factors and that the control of myelination may be independent of 
oligodendrocyte differentiation.  
 
1.2.5 Insulin / Insulin-like growth factor 1 
Insulin and insulin-like growth factor (IGF-1) receptors are found on cells of the 
oligodendrocyte lineage.  IGF-1 is an important survival factor for oligodendrocytes 
(Barres et al. 1992) and insulin is frequently added to OPC media in vitro to activate 
IGF-1 receptors to increase survival and differentiation.  However, in vivo it is likely 
that the effects are mediated by IGF-1 as insulin is not produced in the CNS and is 
unable to cross the blood-brain barrier.  The broad dose-response curve for insulin-
mediated OPC survival suggests that IGF-1 actions are mediated by more than one 
receptor, presumably higher affinity insulin receptors and also IGF receptors (Barres et 
al. 1993b).  Furthermore, for long-term survival of maturing oligodendrocytes in vitro a 
combination of growth factors are required (Barres et al. 1993b).  IGF-1 is important for 
inducing precursors to commit to the oligodendrocyte lineage (McMorris and Dubois-
Dalcq 1988).  Animals over-expressing IGF-1 typically have enlarged brains whilst 
those lacking have smaller brains and a reduced proportion of myelin (Grinspan 2002).  
Several papers report that whilst insulin cannot induce proliferation of OPCs alone, it 
acts as a co-factor with FGF2 and neurotrophin-3 to increase their mitogenic activity 
(Barres et al. 1993b; Jiang et al. 2001) via the convergence of multiple signalling 
pathways on cyclin D (Frederick et al. 2007).  Conversely, other studies have shown 
that IGF1 induces early precursor cells to proliferate (Cui and Almazan 2007; McMorris 
and Dubois-Dalcq 1988). 
 
1.2.6 Neurotrophins 
Neurotrophins are a family of growth factors, comprised of nerve growth factor (NGF), 
brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and NT-4.  They act 
via high affinity Trk receptors with NGF preferentially binding to TrkA, BDNF and 
NT-4 to TrkB and NT-3 to TrkC (reviewed by Chao 2003).  In addition, all ligands can 
bind to the low affinity or co-receptor p75.  Since the discovery of NGF 50 years ago, 
numerous functions have been assigned to neurotrophins and they are essential for 
nervous system development.  They activate a variety of signalling cascades leading to 
survival, differentiation, proliferation and apoptosis.  Glial derived neurotrophic factor 
(GDNF) is from a similar family of molecules that acts via the Ret receptors.   
33 
 
NT-3 increases OPC survival to a level similar to that of insulin, and could increase 
OPC proliferation, but only in the presence of insulin (Barres et al. 1993b; Barres et al. 
1994b; Cohen et al. 1996; Kumar et al. 1998).  OPCs and mature oligodendrocytes 
express the TrkA and TrkC receptors, whereas a truncated form of the TrkB receptor, 
lacking the tyrosine kinase domain and the p75 receptor are upregulated on mature 
oligodendrocytes (Cohen et al. 1996; Kumar et al. 1998).   NGF has no effect on 
proliferation but did increase survival of mature oligodendrocytes (Cohen et al. 1996).  
However, NGF may exert opposing effects on mature oligodendrocytes when it acts via 
the p75 receptor, leading to apoptosis (Casaccia-Bonnefil et al. 1996).  Using a DRG 
neuron co-culture system, Chan et al (2004) demonstrated that NGF has alternative 
effects on Schwann cells compared to oligodendrocytes.  Addition of NGF promoted 
Schwann cell myelination but inhibited both oligodendrocyte maturation and 
myelination (Chan et al. 2004), once again highlighting the differences between PNS 
and CNS myelination.   
 
1.2.7 Other factors 
Ciliary neurotrophic factor (CNTF), leukaemia inhibitory factor (LIF) and interleukin 6 
(IL-6) are members of the cytokine family, all of which have been shown to increase 
OPC survival but not proliferation in vitro and a role for CNTF in vivo has been 
described (Barres et al. 1993b).  More recently a role for LIF in myelination has also 
been described, as myelination is delayed in the optic nerve of LIF-null mice (Ishibashi 
et al. 2009).  Transforming growth factor beta (TGFβ) is released by OPCs and acts to 
inhibit PDGF mediated precursor proliferation, leading to promotion of differentiation 
(McKinnon et al. 1993). 
 
1.3 OPCs in the mature CNS 
A quiescent population of immature cells reside within the adult CNS, which do not 
express markers of mature oligodendrocytes and are described as adult OPCs (Dawson 
et al. 2003; Polito and Reynolds 2005; Reynolds and Hardy 1997).  They are distributed 
throughout the white and grey matter, accounting for 3-8% of the total cell population 
(Dawson et al. 2003; Levine et al. 2001).  Their ability to differentiate into 
oligodendrocytes has been demonstrated in vitro, and in the presence of foetal calf 
serum they become type two astrocytes (Wolswijk and Noble 1989).  In vitro studies 
have shown that adult OPCs differ from their neonatal counterparts in several ways, 
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which may reflect the differing cellular environment that they are exposed to.  
Compared to neonatal OPCs, they migrate and differentiate more slowly (Wolswijk and 
Noble 1989).  Adult OPCs also display morphological differences, as neonatal OPCs 
are bipolar in culture whilst the majority of adult OPCs display a unipolar morphology 
(Wolswijk and Noble 1989).  The antigenic profiles of the two cell types are similar but 
not identical; upon isolation neonatal OPCs are A2B5
+
, vimentin
+
 and most are O4
-
, and 
only later gain O4 immunoreactivity, whereas adult OPCs are A2B5
+
 and O4
+
 but 
vimentin
-
, suggesting that adult OPCs
 
 may be more mature and that they do not express 
intermediate filaments (Wolswijk and Noble 1989).  Whereas neonatal OPCs proliferate 
in response to PDGF, FGF and NRG, adult OPCs only responded to PDGF (Shi et al. 
1998).  In vivo experiments have shown that during postnatal development, the majority 
of NG2
+
O4
+
 cells differentiate into mature oligodendrocytes.  However, a substantial 
proportion remain at this stage and go on to produce adult OPCs/NG2
+
 cells (Reynolds 
and Hardy 1997) and these do not express astrocytic or microglial markers (Dawson et 
al. 2000; Dawson et al. 2003).  Additionally, OPCs have been isolated from the adult 
human brain from biopsy and post-mortem tissue and whilst these cells did not 
proliferate in response to growth factors in vitro, they differentiated into 
oligodendrocytes (Armstrong et al. 1992; Kim 1990). 
 
Until recently the majority of data suggesting that adult OPCs could produce mature 
oligodendrocytes had come from in vitro studies.  NG2
+
 cells isolated from the adult 
mouse expressed mRNA for antigens specifically associated with cells of the 
oligodendrocyte lineage, such as PLP and 2’,3’ cyclic nucleotide 3’-phosphodiesterase 
(CNP), and not those for other CNS cells (Ye 2003) and transgenic mice expressing 
GFP under the NG2 promoter, showed co-localisation with OPC markers only (Karram 
et al. 2008).  The most convincing evidence for the progression of adult NG2
+
 cells into 
mature oligodendrocytes has come from recent fate-mapping studies.  Rivers et al 
(2008) generated transgenic mice expressing tamoxifen inducible Cre under the 
PDGFRα promoter and crossed these with Rosa26/YFP mice, which meant that YFP 
was permanently expressed in all the progeny of the PDGFRα+ cells following 
tamoxifen administration.  They showed that mature oligodendrocytes were generated 
in the adult CNS from adult PDGFRα expressing cells, as were a small number of 
glutamatergic projection neurons, but no astrocytes (Rivers et al. 2008).  A similar 
approach mapping NG2
+
 progeny showed that NG2
+
 cells predominantly became 
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oligodendrocytes, with a minority producing grey matter protoplasmic astrocytes (Zhu 
et al. 2008).  This indicates that PDGFRα and NG2 expressing cells in the adult CNS 
may represent different populations.  Similarly, cumulative BrdU incorporation in vivo 
showed that NG2
+
 cells continue to divide throughout adult life, although their rate of 
proliferation declines with age, and that they retain the capacity to produce mature 
oligodendrocytes (Psachoulia et al. 2009). 
 
The production of cells other than oligodendrocytes by adult NG2
+
 cells has led to the 
suggestion that they are multi-potent adult stem cells.  NG2
+
 cells are equally 
distributed between the white and grey matter, irrespective of axon density and this 
coupled with in vitro experiments describing the ability of OPCs to differentiate into 
type 2 astrocytes as well as oligodendrocytes, has led to speculation that they do not 
solely function as oligodendrocyte progenitors (Butt et al. 2002; Nishiyama 2007; 
Wolswijk and Noble 1989).  There is increasing evidence to suggest that NG2
+
 cells are 
involved in both glutamine neurotransmission and the glutamate-glutamine cycle, as 
they express glutamate receptors and glutamate transporters (as reviewed by Polito and 
Reynolds 2005).  NG2
+
 cell processes have been observed to contact nodes of Ranvier, 
indicating a possible neuromodulatory role (Butt et al. 2002; Butt et al. 1999).   It has 
been suggested that NG2
+
 cells may be involved in neurogenesis in the adult 
hippocampus and the piriform cortex (Belachew et al. 2003; Gaughwin et al. 2006; 
Karram et al. 2008; Rivers et al. 2008).  However, the majority of proliferating cells in 
the adult SVZ were not NG2
+
, suggesting NG2
+
 cells do not produce neural precursors, 
whereas proliferating cells of the olfactory bulb were NG2
+
 and produced mainly 
oligodendrocytes and a few astrocytes (Komitova et al. 2009).  Electrophysiological 
analysis has revealed that some populations of NG2
+
 cells can generate action potentials 
whilst others cannot (Karadottir et al. 2008), inferring that they represent a 
heterogeneous population. 
 
1.4 Oligodendrocyte Differentiation and Maturation 
Maturation to the pro-oligodendroblast stage is marked by binding of the O4 
monoclonal antibody (although this is expressed earlier on OPCs in the chick compared 
to the rodent, Ono et al. 1995), which recognises a sulphated lipid (Sommer and 
Schachner 1981).  Cells become increasingly complex, are less motile and the 
proliferative response to PDGF is lost (Hart et al. 1989) and they are classed as pre-
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oligodendrocytes, which settle alongside axons.  O4 expression is retained, but to a 
lesser extent on adult oligodendrocytes, whilst A2B5 and NG2 immunoreactivity are 
lost.  In vivo, a wave of differentiation of NG2
+
 cells into O4
+ 
cells occurs between 
postnatal days four and 20, spreading from the corpus callosum outwards to the pial 
surface (Reynolds and Hardy 1997).  Galactocerebroside (GalC) is recognised by the 
O1 antibody and marks differentiation into an immature post-mitotic oligodendrocyte.  
Following cell cycle exit the early myelin marker CNP is expressed.  Each structural 
myelin protein appears at a specific time point in development (Grinspan 2002).  CNP, 
which accounts for 4% of myelin, is followed by the more abundant proteins PLP and 
myelin basic protein (MBP), which each have several isoforms.  There are several other 
more minor myelin components, including myelin-associated glycoprotein (MAG) and 
myelin/oligodendrocyte glycoprotein (MOG).  The development of oligodendrocytes in 
vitro occurs in a similar manner to that in vivo, even in the absence of neurones (Temple 
and Raff 1986).  Therefore, it has been suggested that the ability to differentiate into an 
oligodendrocyte is an intrinsic property, as the expression of mature markers and the 
production of a myelin-like membrane occurs in the absence of axons (Temple and Raff 
1986).  Human OPCs have been isolated from foetal tissue and grown in culture, where 
they differentiate in response to insulin and proliferate in response to PDGF (Satoh and 
Kim 1994).  In common with rodent precursor cells they express GD3, O4 and GalC 
and myelin proteins once they have matured.   
 
1.4.1 Thyroid hormone and intrinsic factors 
Thyroid hormone (T3) increases oligodendrocyte differentiation and the degree of 
myelin synthesised (Almazan et al. 1985).  Moreover, the presence of thyroid hormone 
in culture medium leads to cells exiting the cell cycle and as a result this favours 
maturation (Barres et al. 1994a).  The effects of T3 are mediated by three functional 
isoforms of the thyroid receptor: α1, β1 and β2. Oligodendrocyte progenitors express α1 
and β2, whereas mature cells express α1 and β1 isoforms.  The thyroid receptors are 
ligand activated transcription factors, and along with other hormones such as 
corticosteroids and retinoic acid, are known to increase the synthesis of GalC and 
myelin proteins including MBP, PLP and CNP (Bhat et al. 1979; Bhat et al. 1981). 
Regulation of thyroid receptor expression is controlled by the bHLH proteins Hes1, 
which prevents expression on early progenitors, and Mash1, which increases expression 
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on more mature cells (Kondo and Raff 2000a).  Together they may operate as a cell-
intrinsic differentiation timer. 
 
Another factor that controls the number of oligodendrocytes is thought to be cell 
density, as when cells reach a certain density they cease to proliferate further and 
instead differentiate.  However, the signalling pathways involved in this process remain 
unknown.  Cessation of proliferation correlates with an increase in the expression of the 
cyclin dependent kinase inhibitors p21 and p27 kip and a decrease in cyclin expression 
(Durand et al. 1997; Durand et al. 1998).  This is supported by studies showing that 
fewer oligodendrocytes differentiate in the p27-null mouse (Casaccia-Bonnefil et al. 
1997) and the p21-null mouse is hypomyelinated in early life (Zezula et al. 2001).  
Zezula et al (2001) suggest that p27 is required for cell cycle withdrawal whereas p21 is 
involved in differentiation, independent of the cell cycle.  
 
1.4.2 Soluble growth factors 
As well as their role in development of oligodendrocyte progenitors, the soluble growth 
factors discussed earlier are also important for regulating the timing of differentiation.  
In vivo administration of IGF-1 increased the number of mature oligodendrocytes and 
promoted myelination, whereas FGF2 inhibited myelin production (Goddard et al. 
1999; Goddard et al. 2001).  This supports in vitro findings that FGFs inhibit the 
terminal differentiation of oligodendrocytes (Fortin et al. 2005; Grinspan et al. 1993) 
and induce mature cells to re-enter the cell cycle and down-regulate myelin-specific 
gene expression (Bansal and Pfeiffer 1997).  Conversely, FGF has been reported to 
increase the number of maturing cells in vitro, as detected by GalC immunoreactivity 
(Eccleston and Silberberg 1985).  Reducing levels of PDGF reduces proliferation and 
controls cell cycle exit, leading to differentiation (Raff et al. 1988).  An additional 
instructional role for PDGF in OPC differentiation has been described, involving 
signalling through MAP kinases and up-regulation of olig2 (Hu et al. 2008).   
 
The molecular mechanisms required to initiate OPC differentiation are ill-defined.  To 
address this several microarray studies have been performed to examine in more detail 
the genes that control oligodendrocyte differentiation.  Dugas et al (2006) showed that 
differentiation is a prolonged process, occurring in at least two stages, with some genes 
changing in expression levels immediately upon exposure to differentiation media, 
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whilst others were not altered until 24-48 hours later.  Genes up-regulated during 
oligodendrocyte differentiation included those involved in membrane trafficking, 
metabolism and cytoskeletal organisation and are likely to be involved in myelin sheath 
generation, whereas genes with roles in migration were down-regulated.  In addition, 
myelin genes and cell signalling genes were up-regulated (Dugas et al. 2006; Scarlato et 
al. 2000).  Another study measuring gene expression changes describes a role for IL-11 
in oligodendrocyte survival and myelin formation (Zhang et al. 2006).  It is suggested 
that IL-11 can be released by activated astrocytes and may contribute to remyelination 
during Multiple Sclerosis (MS) (Zhang et al. 2006).  One of the first detectable events 
during differentiation is the global deacetylation of histones, thought to be necessary for 
the activation of the transcriptional program leading to myelin gene expression (Shen et 
al. 2005; Ye et al. 2009).  Pharmacological inhibition of histone deacetyases (HDACs) 
prevents myelin gene expression (Shen et al. 2005).  The transcription factor Yin Yang 
1 has been identified as a critical regulator of oligodendrocyte differentiation (He et al. 
2007).  It functions by repressing transcriptional inhibitors of myelin gene expression 
and by recruiting HDACs to their promoters (He et al. 2007).     
 
Several other factors have been shown to perturb oligodendrocyte maturation including 
the wnt signalling pathway (Fancy et al. 2009; Feigenson et al. 2009) and oxidative 
stress (French et al. 2009).  Canonical wnt signalling through β-catenin inhibits 
oligodendrocyte maturation in vitro, independent of an effect on proliferation or 
survival (Feigenson et al. 2009).  Over-expression of β-catenin in CNP+ cells resulted in 
fewer mature oligodendrocytes and thinner myelin sheaths during development, 
although this recovers in the adult, suggesting a role for wnt in delaying myelination 
(Feigenson et al. 2009).  Furthermore, there is an interaction between HDACs and wnt 
signalling, which switches transcriptional activity from inhibiting differentiation to 
promoting it (Ye et al. 2009).  Oxidative stress causes alterations in gene expression and 
reduced histone deacetylation, preventing differentiation without an increase in cell 
death (French et al. 2009).  The transmembrane protein LINGO-1, which regulates 
RhoA signalling, is a negative regulator of myelination (Mi et al. 2005).  
 
1.4.3 Process outgrowth 
Oligodendrocytes extend a complex and elaborate network of processes and each 
individual cell may myelinate up to 40 axonal segments requiring a huge extension of 
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the plasma membrane (Pfeiffer et al. 1993).  The positioning of oligodendrocyte 
processes along axons appears to be a dynamic process.  Time-lapse imaging of the 
zebrafish has illustrated that processes continually extend and retract as they migrate 
and settle in their final positions (Kirby et al. 2006), which may aid uniform spacing of 
oligodendrocytes along axon tracts.  It is probable that oligodendrocytes produce an 
excess of processes and that only those that make the correct axonal contacts will be 
stabilised, whilst the rest will be pruned.  The morphology of oligodendrocytes is 
distinct from that of the other major glial subtype, the astrocyte, in that 
oligodendrocytes have a smaller cell body and nuclei, with dense chromatin and have 
many more processes.  The cytoplasm does not contain intermediate filaments, such as 
glial fibrillary acidic protein (GFAP), a common astrocytic marker; but have a high 
density of microtubules, which helps to increase the stability of processes.  
Considerable reorganisation of the cytoskeleton is required to extend processes over 
such a large area and actin filaments as well as microtubules are a major component of 
oligodendrocyte processes (Song et al. 2001).  Proteins that have a general role in actin 
filament organisation and lamellipodia formation are involved in oligodendrocyte 
outgrowth and myelination.  Kim et al (2006) have shown mice deficient in the actin 
binding protein WAVE1 are hypomyelinated and have fewer nodes of Ranvier.  They 
also found that cells isolated from these animals had fewer processes (Kim et al. 2006).  
Inhibition of the related protein, N-WASP, results in retraction of oligodendrocyte 
processes, reinforcing the idea that oligodendrocyte outgrowth is mediated by actin 
polymerisation driven protrusion (Bacon et al. 2007).  An actin binding protein, named 
Ermin, which is expressed exclusively in oligodendrocytes and appears at a late stage in 
myelination, has been assigned a role in myelin wrapping and compaction 
(Brockschnieder et al. 2006).  An elaborate network of microtubules helps to maintain 
the cytoarchitecture required for trafficking of organelles and translocation of myelin 
proteins (Richter-Landsberg 2008).  Oligodendrocytes exclusively express the 
microtubule-associated protein (MAP2c), which may help to initiate process extension 
(Vouyiouklis and Brophy 1995).   
  
The Src non-receptor tyrosine kinase Fyn has been implicated in oligodendrocyte 
differentiation and in particular the elaboration of processes.  Fyn expression peaks 
during early postnatal life, coincident with a peak in myelination (Sperber et al. 2001; 
Umemori et al. 1994).  Fyn knock-out animals display irreversible hypomyelination, 
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producing 50-60% of the myelin found in a wild-type brain, which was due to both a 
decrease in the number of oligodendrocytes and the amount of myelin produced per cell 
(Sperber et al. 2001; Umemori et al. 1994).  No significant reduction in myelin 
formation was found in other Src kinase mutants, suggesting that it is exclusively the 
Fyn member of the family that is important for myelination (Sperber et al. 2001).  
Interestingly, the role of Fyn appears to differ between CNS regions, as the cervical 
spinal cord exhibited no reduction in myelin content in the null mouse (Sperber et al. 
2001). 
 
In vitro studies investigating the role of Fyn have shown that following 24 hours in 
differentiation media, an increase in Fyn phosphorylation is detected and this occurs 
prior to morphological changes (Osterhout et al. 1999).  Process extension and myelin 
membrane formation were reduced by the Fyn inhibitors PP1 and PP2 and transfection 
with a dominant negative version of Fyn (Osterhout et al. 1999).  OPCs isolated from 
Fyn-null mice differentiate in vitro and can express mature antigenic markers and an 
elaborate network of processes.  However, fewer become mature oligodendrocytes 
compared with wild-type cultures (Sperber and McMorris 2001). 
 
Fyn is localised to lipid raft microdomains within the cell membrane and can interact 
with tau and tubulin, suggesting a mechanism by which it may control cytoskeletal 
rearrangement (Klein et al. 2002).  Fyn also associates with the CAMs NCAM, 
contactin/F3 and MAG in lipid rafts (Kramer et al. 1999; Umemori et al. 1994).  
 
1.5 Axon-oligodendrocyte interactions 
Although oligodendrocytes in vitro can mature and express myelin-like membranes, 
myelination per se cannot take place in the absence of axons.  In vivo, many more OPCs 
are produced during development than are required, suggesting that there is competition 
and that only those that receive the correct signals survive.  It is proposed that as an 
oligodendrocyte matures its trophic requirements alter, so it becomes less dependent on 
growth factors such as PDGF and that the non-myelinated axon provides a survival 
signal.  The pre-myelinating oligodendrocyte then has a short period in which it must 
make contact with an axon to avoid apoptosis (Barres and Raff 1999).  This degree of 
redundancy ensures that all the necessary axons are myelinated and indicates that the 
final numbers of oligodendrocytes produced are regulated by axon-oligodendrocyte 
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signalling (Barres and Raff 1999).  Axonal signals are likely to consist of a combination 
of soluble and contact-dependent signalling, both of which are poorly characterised.  
Axons have been shown to regulate oligodendrocyte proliferation (Barres and Raff 
1993; Hardy and Reynolds 1993a; Wood and Bunge 1986), survival (Barres and Raff 
1993; Fernandez et al. 2000; Frost et al. 1999) and the membrane trafficking of myelin 
components (Trajkovic et al. 2006).  Various molecules have been suggested as 
candidates to transduce signals between the axon and oligodendrocyte including CAMs, 
integrins and NRG.  This axo-glial interaction is mutually beneficial as the myelinating 
cell also triggers axonal signalling resulting in remodelling of neurofilaments and 
regulation of axonal diameter (Sanchez et al. 1996; Yin et al. 1998). 
 
1.5.1 Contact dependent signalling 
Several lines of evidence have suggested that axons provide a contact-dependent signal 
for oligodendrocytes.  Firstly, expression of myelin proteins is greatly up-regulated in 
the presence of neurons and oligodendrocytes will only myelinate axons and not 
dendrites (Lubetzki et al. 1993).  Secondly, conditioned medium taken from neuronal 
cultures and added to OPCs does not increase OPC survival as much as culture with 
neurons (Barres et al. 1993a).  Thirdly, antibodies directed against the axolemma 
blocked myelination in cerebellar slice cultures, although the exact antigens were 
unknown (Notterpek and Rome 1994).  Fourthly, transection of the optic nerve during 
development results in death of oligodendrocytes but not astrocytes (Barres et al. 
1993a).  Moreover, in transgenic optic nerves with increased numbers of axons, the 
number of oligodendrocytes generated increases proportionally (Burne et al. 1996).  
OPCs still proliferate, survive and differentiate in optic nerves following axon 
transection but do not proceed to myelinate (Ueda et al. 1999), supporting the notion 
that the contact-dependent signal from the axon may be the most important signal in 
initiating myelination and that earlier phases of development may be supported by 
signals from other cells, such as astrocytes.  However, it appears that adult 
oligodendrocytes may be less dependent on axonal signals, as transection of adult optic 
nerves does not lead to apoptosis of all oligodendrocytes (Ludwin 1992). 
 
1.5.2 Neuregulin 
NRG, as described above, is an important mitogen for OPCs and has additionally been 
proposed to be a contact-dependent mediator of axon-oligodendrocyte signalling, as all 
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NRG-1 isoforms can be membrane-bound as well as soluble.  Early in development 
NRG is an OPC survival signal and inhibits differentiation.  Its role changes later in 
development when axonal expression promotes survival and the inhibitory effect on 
differentiation is lost (Flores et al. 2000).  Neutralisation of the NRG signal using 
antibodies or recombinant receptors in spinal cord explants or DRG-OPC co-cultures 
reduced oligodendrocyte survival (Fernandez et al. 2000;  Vartanian et al. 1999).  NRG-
1 type III has been shown to be essential for myelination in the PNS and promotes 
oligodendrocyte myelination (Brinkmann et al. 2008; Taveggia et al. 2005; Taveggia et 
al. 2008).  The endopeptidase Bace1, which cleaves amyloid precursor protein at the β-
secretase site, has been shown to modulate myelination and cleave NRG, affecting its 
signalling (Hu et al. 2006).  Bace1-null mice display delayed myelination, reduced 
myelin thickness and decreased Akt phosphorylation, believed to be due to the altered 
NRG processing (Hu et al. 2006). 
 
1.5.3 Integrins 
Integrins are a family of molecules that mediate cell-ECM signalling.  They consist of α 
and β subunits, which function as heterodimers.  Cells of the oligodendrocyte lineage 
express a relatively limited repertoire of integrins consisting of the αv, which bind 
fibronectin and vitronectin, and α6 families, which bind to laminin (Milner and ffrench-
Constant 1994).  α6β1 integrins are expressed by precursors and mature cells, whereas 
αv may associate with either β1, β3, β5 or β8 (Milner and ffrench-Constant 1994; 
Milner et al. 1997b).  The predominant β subunit which associates with α5 varies as 
differentiation progresses, which may enable integrins to signal via different pathways 
at different stages (Milner et al. 1997b).  Laminin, which is expressed by neurons along 
myelinating tracts, can regulate oligodendrocyte survival via α6β1 integrins (Colognato 
et al. 2002; Frost et al. 1999).  A modest increase in survival was seen by plating 
oligodendrocytes on laminin but antibody mediated blockade of β1 greatly decreased 
survival (Frost et al. 1999).  Fewer oligodendrocytes were found in α6-null mice and 
OPCs isolated from these animals displayed higher levels of apoptosis (Colognato et al. 
2002) and laminin knock-out mice display myelin defects (Chun et al. 2003).  
Furthermore, laminin greatly potentiated the PDGF-mediated survival signal, 
suggesting cross-talk between contact-dependent and soluble signals to control 
oligodendrocyte survival (Frost et al. 1999).  Once the proliferative response to PDGF 
ceases, PDGFRα and integrins become sequestered in lipid raft domains, and this may 
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enable the amplification of PDGF signalling (Baron et al. 2003).  It is proposed that 
integrins may enable growth factors to initiate different responses at different stages of 
development, thus enabling soluble factors that originally caused proliferation and 
inhibited differentiation, such as PDGF and NRG, to promote survival and enable 
differentiation (Colognato et al. 2002).  Colognato et al (2002) also demonstrated that 
α6β1 integrins enhance NRG-mediated oligodendrocyte survival and that this is 
associated with a switch in signalling pathways from phosphatidyl inositol 3 phosphate 
(PI3K) to mitogen activated protein kinase (MAPK) dependent.  In addition, α6β1 
integrins associate with Fyn, which provides another mechanism to stimulate the 
oligodendrocyte differentiation program (Colognato et al. 2004).  Laminin/integrin 
interactions promote myelin membrane formation in a Ras-dependent manner (Buttery 
and ffrench-Constant 1999; Olsen and ffrench-Constant 2005).  Transgenic mice 
expressing a dominant negative version of β1 integrin under the MBP promoter failed to 
myelinate small axons, suggesting that integrins are involved in initiating myelination, 
and that in their absence the signal to oligodendrocytes may not be above the required 
threshold to stimulate myelination (Camara et al. 2009).  Therefore, association of 
growth factor receptors with integrins provides a contact-dependent mechanism for 
controlling oligodendrocyte development. 
 
1.5.4 Electrical activity 
Early experiments demonstrated the requirement for electrical activity in order to 
stimulate myelination.  Gyllesten et al (1966-cited in Baumann and Pham-Dinh 2001) 
showed in visually deprived rats, where there is no electrical stimulation of neurons in 
the optic nerve, there was reduced myelination and Tauber et al (1980-cited in  
Baumann and Pham-Dinh 2001) demonstrated that premature opening of the eye in the 
rabbit caused premature myelination of the optic nerve.  Oligodendrocyte proliferation 
is increased by electrical activity of retinal ganglion cells and tetrodotoxin prevents 
initiation of myelination (Barres and Raff 1993; Demerens et al. 1996).  Electrical 
activity causes the release of ATP from axons, which may be the signal that promotes 
myelination (Stevens, 2002).  The requirement for axonal activity to maintain 
proliferation can be overcome by artificially increasing the concentration of PDGF.  
However, the ability of axons to support oligodendrocyte survival has been shown to be 
independent of electrical activity, suggesting proliferation and survival are uncoupled 
(Barres et al. 1993a).  
44 
 
1.5.5 Inhibitory molecules 
Several molecules appear to behave as contact-dependent inhibitors of myelination, and 
their down-regulation is required in order for myelination to proceed.  Notch inhibits 
OPC differentiation, demonstrated by the addition of notch ligand Jagged1 to cultured 
OPCs, which blocked differentiation.  This is supported by the observation that Jagged1 
is down-regulated on retinal ganglion cells just before they are myelinated in vivo 
(Wang et al. 1998).   
 
1.6 Myelination 
Myelination proceeds caudrostrally in the brain and rostrocaudally in the spinal cord 
and its timing and localisation is very specific and reproducible within a species.  
Oligodendrocytes can myelinate segments of numerous axons and this is both space and 
energy saving in comparison to peripheral Schwann cells, which only myelinate a single 
internode.  Myelination is initiated after oligodendrocyte processes have attached to the 
axon and polarisation of the membrane has been triggered.  Mature oligodendrocytes 
are first observed in the rodent forebrain and optic nerve around the time of birth and 
increase over the first six weeks of postnatal life, peaking at day 18 (Barres and Raff 
1994; Hardy and Reynolds 1991).  Several groups have demonstrated that myelination 
occurs in much the same way in the developing human CNS beginning towards the end 
of foetal life, peaking during the first year after birth, but continuing until adulthood and 
remodelling may occur throughout life (as reviewed by Buchet and Baron-Van 2009; 
Jakovcevski et al. 2009).   
 
Many small axons are never myelinated, it is not known exactly why, but it is possible 
that this is because insulation would not offer any benefits to action potential 
conduction.  The precise thickness of the myelin sheath is in proportion with axonal 
diameter, referred to as the g ratio, suggesting that signalling occurs between the axon 
and the myelinating oligodendrocyte to control myelin production.  There is 
considerably morphological heterogeneity amongst mature oligodendrocytes, leading to 
classification into four categories based upon the cell size, the length of the myelin 
segments and the size of axons myelinated (Butt et al. 1995). 
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Figure 1.2 Organisation of the myelinated axon (Poliak and Peles 2003). 
This schematic diagram show the regions of a myelinated axon.  The unmyelinated central 
region is the node of Ranvier, where the action potential is propagated and a high concentration 
of sodium channels are present.  The rest of the axon is insulated by the myelin sheath.  Moving 
from the node is the paranode, where the end feet of the myelin make contact with the axon, 
followed by the juxtaparanode which is enriched in potassium channels.  The region surrounded 
by compacted myelin is the internode. 
 
1.6.1 Axonal domains 
A complex relationship exists between the axon and the oligodendrocyte that results in 
the formation of distinct domains within both cells (Figure 1.2).  Prior to myelination 
ion channels are dispersed evenly along the axon.  Following myelination, high 
concentrations of voltage gated sodium channels are clustered at the node of Ranvier, 
where the action potential is propagated, and other accessory proteins such as neuronal 
neurofascin (NFasc186),  ankyrin G  and neural-glial-related adhesion molecule 
(NrCAM) co-localise (Sherman and Brophy 2005).  The node of Ranvier is a gap of 
about 1 µm between each myelin segment, where the exposed axon is able to 
communicate with the extracellular environment.  The paranodal region is the area to 
either side of the node, where the myelin sheath ends and numerous loops (up to 40) 
contact the axon via septate-like junctions, which transmit axo-glial signals.  This 
adhesion complex comprises contactin/F3 and Caspr on the axon and the glial isoform 
of neurofascin (NFasc155) on the oligodendrocyte (Charles et al. 2002b; Tait et al. 
2000).  The paranodal loops of the myelin attach to the paranodal region of the axon.  
These junctions provide a physical barrier that prevents diffusion of sodium channels 
from the node and may be important for protein targeting (Sherman et al. 2005).  
Adjacent to the paranode is the juxtaparanode, a region with a high concentration of 
delayed rectifier potassium channels.  The clustering of these ion channels on the axonal 
membrane has been shown to be dependent on oligodendrocytes, suggesting that 
46 
 
signalling between them is bi-directional (Kaplan et al. 1997).  However, an intact 
paranodal junction is not essential for nodal formation and instead may help to maintain 
nodal clustering in the mature nerve (Sherman and Brophy 2005). 
 
1.6.2 Structure of myelin 
Myelin consists of an extension of the oligodendrocyte plasma membrane that spirals 
around the axon.  Compact myelin has very little cytoplasm between the layers and 
appears as dense bands by electron microscopy.  However, the end loops of myelin are 
less compact and are cytoplasm rich.  Pockets of un-compacted myelin exist within the 
internodes and are known as Schmidt-Lanterman incisures, although they are much less 
common in the CNS compared to the PNS.  Myelin dry weight is composed of 70% 
lipids and 30% proteins.  The lipid component of myelin is made up of cholesterol, 
phospholipids and glycolipids, whilst the major protein constituents are MBP and PLP 
(80% of total proteins) (Baumann and Pham-Dinh 2001).  The majority of myelin 
proteins, including PLP, are synthesised in the cell body and transported in vesicles to 
the plasma membrane.  Interestingly, MBP appears to be the only myelin protein which 
is not synthesised in the cell body.  Instead localised translation of mRNA takes place 
on free ribosomes and is directly incorporated into the extending processes (Colman et 
al. 1982).  Compared to the PNS which is relatively permissive to repair the CNS 
provides a hostile environment for axon regeneration, in part due to the inhibitory role 
of various myelin components, such as MAG.  Oligodendrocytes and myelin can cause 
growth cone collapse, preventing axon outgrowth (Bandtlow et al. 1990). 
  
1.7 Multiple Sclerosis 
The importance of myelination has been demonstrated by a number of human 
neurological disorders, such as MS, leukodystrophies and peripheral neuropathies, 
where myelin is compromised.  MS is a chronic inflammatory demyelinating disease 
affecting the CNS and is recognised as the most common neurological disease in young 
adults, affecting 2.5 million people worldwide, with an incidence of approximately one 
in 700 in northern Europe (Compston and Coles 2002).  The disease is twice as 
common in females as males, as is the case for all autoimmune diseases.  MS is usually 
first diagnosed at 20-40 years of age, following the identification of at least two lesions 
that affect two different sites and are separated in time (Compston and Coles 2002).  
Clinical symptoms vary considerably, depending on the areas of the CNS affected and 
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include a wide variety of motor, visual and sensory disturbances.  The disease typically 
follows a relapsing-remitting phase, which may last 10-15 years (Figure 1.4), during 
which unpredictable attacks (relapses) occur, that may be followed by months or even 
years with low disease activity (remission), where there may or may not be a persistent 
clinical deficit.  The second disease phase is progressive and chronic, whereby the 
number of lesions increases.  In a small number of cases the disease is progressive from 
the outset and there is no remission phase. 
 
MS is thought to be caused by a complex interplay between environmental factors and 
genetics, which are not fully understood.  There is a genetic component, highlighted by 
the concordance rate of 30% among monozygotic twins (Ebers et al. 1995).  MS is 
polygenic and several gene loci have been suggested to have a role in familial MS, 
including the class II major histocompatibility complex (MHC) (Hafler et al. 2007).  
MS is more common in temperate areas compared to equatorial regions, suggesting the 
role of environmental factors, such as viral infections, which double the risk of a 
relapse.  In particular, migration studies have suggested that the place of residence 
during childhood is a key factor (Compston and Coles 2008). 
 
Currently there is no cure for MS.  A number of disease modifying treatments are 
available which aim to decrease the relapse rate.  However they do not reverse fixed 
deficits, have questionable effects on long-term disease progression and their efficacy 
varies between patients (Compston and Coles 2008).  
 
 
Figure 1.3 The clinical course and pathogenesis of MS (Compston and Coles 2008). 
The top panals display clinical episodes, whereas the bottom panals display episodes of 
inflammation which may or may not result in clinical symptoms. Axonal loss begins early in the 
disease and increases with disease progression.  
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1.7.1 Demyelination 
MS is characterised by focal areas of inflammation accompanied by demyelination and 
a variable degree of axonal damage and loss.  Demyelination results in a loss of axonal 
insulation, of sodium channel clustering at the nodes of Ranvier and action potential 
conduction may be slowed down or prevented altogether.  Chronic demyelination leaves 
axons vulnerable and exposed to the inflammatory milieu, which can lead to irreversible 
damage (Papadopoulos et al. 2006).    
 
The gross pathology of MS lesions can be identified by Luxol fast blue histochemistry, 
where areas lacking myelin do not stain (Figure 1.3).  Evolution of the MS plaque can 
be divided into several stages, involving initial immune system activation, acute 
inflammatory injury to neurons and glia, repair and recovery, and finally a post 
inflammatory stage where gliosis and neurodegeneration occur (Compston and Coles 
2002).  Many of the earliest, and sometimes transient, clinical manifestations associated 
with MS can be attributed to the effects of the inflammatory milieu on axon conduction 
and disruption of the axon-oligodendrocyte complex at the node of Ranvier taking place 
prior to demyelination (England et al. 1990; Howell et al. 2006).  Accumulating axonal 
loss is believed to account for the permanent neurological disability in MS.  It was 
originally suggested that axonal damage and loss occurred at the later stages of MS and 
marked the transition to a progressive phase of the disease.  However, it has become 
apparent that axonal damage can occur early on in the disease and correlates with the 
degree of inflammation within lesions (Bjartmar et al. 2003).  Axonal damage may 
remain clinically silent for a number of years, and as it accumulates irreversible 
neurological damage presents in the clinical setting, suggesting that other neurones may 
compensate for a while or that a degree of reorganisation may occur. 
 
1.7.2 Remyelination 
The phenomenon of remyelination was first suggested by Marlburg in 1906 and 
extensive evidence now exists to support the idea that myelin can be replaced.  
Remyelination is thought to play an important role in the relapsing-remitting phase of 
MS and can result in functional recovery and may help prevent axonal loss, as 
demonstrated using animal models (Keirstead and Blakemore 1999).  Remyelination 
may be extensive, particularly in animal models of demyelinating disease (Dawson et 
al. 2003; Snyder et al. 1975), and is frequent at the edge of lesions in human MS (Bruck 
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et al. 2003; Patrikios et al. 2006; Prineas et al. 1993; Raine and Wu 1993) and can be 
extensive in some MS cases (Patani et al. 2007; Patrikios et al. 2006).  However, 
remyelination is frequently incomplete and the hallmark of MS pathology is the 
chronically demyelinated lesion, so whilst remyelination may provide some respite in 
the earlier stages of the disease it does not occur in all lesions and may become less 
effective as time progresses (Franklin 2002).  In many animal models of MS the 
remyelination process is robust and can continue even despite several episodes of 
demyelination, suggesting sufficient progenitors remain and axons retain myelination 
competence (Penderis et al. 2003; Reynolds et al, 2002; Setzu et al. 2004).  However, it 
is likely that these studies do not recapitulate the chronic conditions encountered in the 
human brain.  Progenitors are found in and adjacent to lesions and pre-myelinating 
oligodendrocytes (which are not found in the normal adult brain) in MS lesions appear 
to be contacting axons but are not engaged in myelin formation (Chang et al. 2002; 
Wolswijk 1998).  A block in the differentiation program of OPCs has been suggested as 
an explanation for the lack of remyelination in chronic MS lesions (Kuhlmann et al. 
2008; Wolswijk 2002).  Therefore, it has been suggested that a loss of signals from 
axons in the lesion, that would normally stimulate oligodendrocyte survival and initiate 
myelin formation, may be at least in part responsible for the chronic demyelination and 
the long term progression of the disease.  This is consistent with a disease model in 
which new oligodendrocytes can be repeatedly generated from a large pool of 
progenitors known to be present in the adult CNS and that repeated inflammation and 
demyelination will lead to not only axonal loss but also increasing levels of dysfunction 
in those axons that remain (Chang et al. 2002).  It would appear that for successful 
remyelination to occur, the events that take place during development need to be 
recapitulated (Miller and Mi 2007).  
 
The signals that may initiate differentiation and remyelination are poorly understood.  
Changes in the axon membrane as a result of repeated inflammation or altered electrical 
activity may inhibit remyelination by not allowing appropriate axon-oligodendrocyte 
interactions.  Re-expression of inhibitory molecules has been described in some lesions, 
such as Notch ligands, PSA-NCAM and LINGO-1 (Charles et al. 2002a; Mi et al. 2009; 
Wang et al. 1998).  Additionally, a dramatic reduction in the expression of NRG-1 has 
been observed in MS lesions, which could contribute to remyelination failure (Viehover 
et al. 2001).  Axonally derived oligodendrocyte trophic factors could be a future target 
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of therapies aimed at enhancing the endogenous repair process in MS.  Changes in 
CAMs on the axon have been described following demyelination (Howell et al. 2006) 
and this could also contribute to remyelination failure. 
 
 
 
Figure 1.4 MS Pathology (Dr Owain Howell, Imperial College London). 
Post-mortem tissue from an MS patient that has been stained with Luxol fast blue, depicting 
demyelinated lesions (white arrows) and an area of remyelination (yellow arrow) where thinner 
myelin sheaths are evident as shadow plaques. The higher magnification images show normal 
appearing white matter (nawm), an area of remyelination and a demyelinated lesion where no 
myelin staining is visible. 
 
1.7.3 Response of adult OPCs to damage 
Despite the limited capacity of the CNS for repair, endogenous remyelination of 
axons following a demyelinating insult is in many cases a rapid and successful 
process (Franklin 2002; Patani et al. 2007; Patrikios et al. 2006; Reynolds et al. 
2002).  Several reports have suggested that mature oligodendrocytes do not divide 
and remyelinate (Keirstead and Blakemore 1997; Hardy and Reynolds 1991), so it is 
largely believed that the remyelinating population comes from adult progenitor cells.  
In animal models of demyelinating disease NG2
+
 cells respond to injury by 
displaying a reactive morphology, increasing proliferation and migrating to the area 
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of damage, where they express markers associated with immature cells of the 
oligodendrocyte lineage, including CNP, olig2 and Nkx2.2 (Reynolds et al. 2002; 
Reynolds and Hardy 1997).  The signals that cause these cells to initiate myelination 
in the mature CNS are poorly understood but are thought to involve a combination of 
axonal and trophic signals.  Production of astrocytes as well as oligodendrocytes by 
NG2
+
 and NG2
-
Olig2
+
 cells may occur in response to injury (Hampton et al. 2007; 
Zhao et al. 2009). 
 
1.8 Neural Cell Adhesion Molecule 
CAMs mediate cell-cell and cell-ECM adhesion, are widely expressed and consist of a 
number of families of molecules including the immunoglobulin (Ig) superfamily, 
integrins and selectins.   The Ig superfamily all have one or more Ig domains, which are 
highly conserved.  They have a wide range of functions in the nervous system 
particularly during development where they have been assigned roles in cell 
recognition, migration, axon growth and guidance and synapse formation (as reviewed 
by Walsh and Doherty 1997).  CAMs can bind homophilically (e.g. NCAM to NCAM 
on adjacent cells) or heterophilically (to other CAMs, FGFRs or to collagens and 
proteoglycans in the ECM) and as well as mediating adhesion this binding can lead to 
the activation of intracellular signalling pathways.   
 
The neural cell adhesion molecule (NCAM) was first described in 1974 (Jorgensen and 
Bock 1974) and was originally isolated and purified from the embryonic chick brain, 
where antibodies against  it were shown to inhibit adhesion of retinal cells (Thiery et al. 
1977).  NCAM is the best characterised member of the Ig superfamily of CAMs and is 
particularly abundant in the nervous system.   
 
1.8.1 NCAM structure 
The NCAM gene, located on chromosome 11 in humans, consists of 25 exons and 
several isoforms are produced by alternative splicing.  The three major isoforms, 
NCAM-180, NCAM-140 and NCAM-120 are named according to their molecular 
weight and have the same extracellular N-terminal domain, consisting of five Ig 
domains plus two fibronectin type III (FnIII) modules proximal to the plasma 
membrane (Figure 1.5).  Ig domains consist of approximately 100 amino-acids with the 
most highly conserved regions surrounding a pair of cysteine residues separated by 50-
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60 amino-acids (Grumet 1991).  The FnIII domains are in general less conserved than 
the Ig domains and consist of 100 amino-acids including two aromatic residues.  
Variability in the extracellular domain may be introduced by the insertion of a variable 
alternatively spliced exon (VASE), which is 30 bp long, in the fourth Ig domain and is 
believed to be expressed by 50% of NCAM in the adult.  In addition, an AAG sequence 
can be added between the two FnIII modules.  NCAM-180 and NCAM-140 are class 1 
transmembrane glycoproteins with a small (140) or large (180) cytoplasmic domain, 
whereas NCAM-120 is attached to the cell membrane by a glycosylphosphatidylinositol 
(GPI) anchor and predominantly localises to lipid rafts.  The NCAM isoforms are 
differentially expressed in the nervous system; NCAM-180 is expressed exclusively on 
neurons, NCAM-120 is expressed on glia and myelin, whereas NCAM-140 is found on 
both neurons and glia.  NCAM interactions can be modulated by either N-linked or O-
linked glycosylation to consensus sequences (Figure 1.6, Nielsen et al. 2008).  In 
particular, NCAM is the only mammalian protein that can be posttranslationally 
modified by the addition of polysialic acid (PSA) residues.  PSA glycosylation consists 
of at least 30 chains of negatively charged sialic acid residues, which strongly influence 
the kinetics of binding, in many cases inhibiting homophilic interactions (Hoffman and 
Edelman 1983).   The amount of PSA decreases with development, whereas the 
expression of VASE increases, reflecting the changing roles of NCAM (Charles et al. 
2000; Saffell et al. 1994).  Palmitoylation of transmembrane forms of NCAM is 
common and thought to help anchor molecules to the membrane (Little et al. 1998).  
 
 
 
Figure 1.5 Structure of the extracellular domain of NCAM (Nielsen et al. 2008). 
Ig1-5 indicates the immunoglobulin homology domains whilst Fn3I-II indicates the fibronectin 
type 3 domains.  NCAM can be alternatively spliced at the positions indicated by the framed text 
and N-linked and O-linked glycosylation sites are indicated by arrowheads (black non-PSA 
sites, grey, PSA sites. VASE: variably alternative spliced exon, MSD1: muscle-specific domain 
1, SEC: exon expressed by secreted NCAM, AAG: AAG exon, HBD: heparin binding domain, 
LHD: lectin homology domain.  
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1.8.2 NCAM binding 
CAMs were originally identified based on their ability to mediate homophilic binding 
interactions with molecules on adjacent cells, involving a trans interaction of the Ig 
domains.  Several mechanisms of homophilic binding have been proposed, whereby all 
of the Ig domains or just Ig domains 1-3 are involved with Ig domain three being of 
particular importance (Johnson et al. 2004; Kiselyov et al. 1997; Ranheim et al. 1996; 
Rao et al. 1993; Soroka et al. 2003).  It is possible that different Ig domains are 
involved depending on the particular isoform and glycosylation status of the molecule 
(Johnson et al. 2004).  Heterophilic interactions of NCAM have also been described, 
and this may create opportunities for fine-tuning CAM-mediated cellular responses 
(Nielsen et al. 2008).  Heterophilic interactions between NCAM and other adhesion 
molecules such as L1, FGFR, the prion protein, with ECM proteins, for example HSPG, 
chondroitin sulphate proteoglycans (CSPG) and collagen and also the rabies virus have 
been described (as reviewed by Nielsen et al. 2008).  Heterophilic interactions involve 
the FnIII modules as well as Ig domains and may involve cis as well as trans binding.   
 
 
 
Figure 1.6 Relative expression of NCAM isoforms in the human brain (Cox et al. 2009). 
The graph shows the abundance of the three major membrane-bound isoforms of NCAM, 
NCAM-120, NCAM-140 and NCAM-180, as well as polysialated NCAM (PSA-NCAM), and 
proteolytic fragments NCAM-EC (secreted form) and NCAM-IC (small fragment of the 
cytoplasmic domain of NCAM-140). 
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In addition to the commonly studied membrane bound NCAM, soluble NCAM has been 
described (Bock et al. 1987) and is thought to arise due to active secretion as well as 
shedding of membrane-bound forms.  It has been detected in the normal blood and CSF 
of humans, rising as age increases (Massaro 1998) and its function is so far unclear. 
Soluble NCAM forms only a minor proportion of the total NCAM in the neonatal rat 
brain (0.8%) and has been detected in neuronal cell culture medium. 
 
1.8.3 NCAM expression 
NCAM is widely but not ubiquitously expressed and expression is thought to be 
regulated by homeobox genes.  It is first observed at E8-8.5 in the mouse brain, at 
which point it is not polysialated (Probstmeier et al. 1994).  Shortly afterwards NCAM 
becomes predominantly polysialated and its level peaks perinatally.  During embryonic 
development the 140 and 180 isoforms are detected but not NCAM-120 (Probstmeier et 
al. 1994).  PSA-NCAM remains the predominant form during the first three weeks of 
postnatal life, whilst extensive migration continues, whereas in the adult brain PSA-
NCAM is only found in areas of plasticity and ongoing neurogenesis, such as the 
olfactory bulb and subventricular zone (Chuong and Edelman 1984; Seki and Arai 
1993).  After 21 days of age NCAM expression declines and then remains at a similar 
level throughout adult life, where it is observed in the white and grey matter and along 
axonal tracts.  Immunohistochemical analysis of the developing optic nerve has shown 
NCAM expression on fasiculating axons, growth cones and at both axo-glial and glial-
glial contact sites (Bartsch et al. 1989).  Furthermore, NCAM was expressed on 
myelinated axons and on compact myelin, suggesting a role in maintaining contact 
between the axon and oligodendrocyte (Bartsch et al. 1989).  NCAM was not expressed 
at contacts with the basement membrane or on astrocyte end-feet (Bartsch et al. 1989).  
The expression of NCAM in human post-mortem tissue has been described and shows 
that the isoforms and relative abundance of PSA-NCAM and soluble NCAM change 
through development to adulthood in the pre-frontal cortex (Figure 1.6, Cox et al. 
2009).  In agreement with rodent studies they showed that the highest levels of NCAM-
140 and 180 are seen in the foetus and that NCAM-120 peaks during postnatal life (Cox 
et al. 2009). 
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1.8.4 NCAM function 
NCAM has been assigned important roles in neurodevelopment, particularly in axon 
guidance and cell migration (Walsh and Doherty 1997).  NCAM knock-out mice are 
viable and fertile, but do display a number of abnormalities, as summarised in Table 
1.1, including reduced brain weight, reduced size of the olfactory bulb, deficits in 
spatial learning and increased anxiety (Cremer et al. 1994; Tomasiewicz et al. 1993).  It 
is thought that many of the defects are a result of the lack of polysialation that exhibits 
anti-adhesive properties and therefore promotes cell migration (Ono et al. 1994).  A 
limitation of NCAM knock-out studies has been that it also results in loss of PSA and it 
is difficult to ascertain which defects are due to abscence of PSA and which are due to 
NCAM.  The lack of NCAM or PSA-NCAM does not result in a complete block in cell 
migration in the adult rostral migratory stream, where it is normally highly expressed 
(Chazal et al. 2000).  It may be that the roles of NCAM are underestimated by knock-
out studies, owing to some degree of redundancy amongst CAMs and because the 
animals are chronically devoid of NCAM.  Conditional ablation of NCAM in postnatal 
hippocampal neurons reduced spatial learning and memory formation, supporting the 
role of NCAM in the adult as well as developing brain (Bukalo et al. 2004).  More 
recently, a double knock-out for the two polysialyltransferase enzymes that add PSA to 
NCAM was created, and it recapitulated most of the defects associated with the NCAM 
knock-out (Weinhold et al. 2005).  However, the phenotype was more severe with 80% 
dying at four weeks of age, but could be rescued by a simultaneous deletion of the 
NCAM gene, showing that defects in the double polysialyltransferase knock-out were a 
result of the gain of function of NCAM (Weinhold et al. 2005).  This suggests that one 
of the major functions of PSA may be to mask the effects of NCAM and its down-
regulation as development progresses ensures that NCAM-mediated cell-cell adhesion 
is temporally and spatially organised (Hildebrandt et al. 2007; Muhlenhoff et al. 2009).  
Aberrant NCAM expression has been implicated in mental retardation, schizophrenia, 
bipolar disorder, depression and memory deficits and an increase in CSF NCAM is 
found in patients with schizophrenia, bipolar and depression NCAM (as reviewed by 
Cox et al. 2009; Vawter et al. 2000).   
 
NCAM-VASE is not found in brain areas where plasticity is apparent and it is 
inhibitory to neurite outgrowth, indicating it may have a role in stabilising cell 
interactions (Doherty and Walsh 1994).  In vitro adhesive assays have shown that 
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expression of NCAM-VASE decreases adhesion compared to NCAM and that cells 
expressing VASE will preferentially bind to other cells expressing VASE (Chen et al. 
1994).  An elevation in secreted NCAM-VASE is observed in schizophrenia, where 
dysregulated NCAM expression is postulated to have a role in synaptic plasticity and so 
influence cognitive ability (Vawter et al. 2000).   
 
Mouse 
NCAM deficiency 
 
 
 
 
 
 
 
 
 
 
 
 
NCAM conditional deficiency 
 
 
Deficiency in polysialation 
 
 
NCAM extracellular domain secreting 
 
Decreased body weight 
Small olfactory bulb 
Decreased spatial learning 
Abnormal mossy-fibre projections in the 
hippocampus 
Corticospinal tract hypoplasia 
Increased inter-male aggression 
Decreased contextual and cued fear learning 
Increased anxiety 
Decreased pre-pulse inhibition 
Abnormal synaptic vesicle release at the 
neuromuscular junction 
Abnormal circadian clock 
Decreased spatial learning; long-term 
potentiation and depression in the 
hippocampus 
Alterations of some but not all NCAM functions 
e.g. decreased migration of precursors from 
subventricular zone, increased adhesion 
Decreased GABAergic synapses in frontal 
cortex pre-pulse inhibition, fear conditioning, 
hyperlocamotion and sterotypy 
Human 
Diseases linked to 11q23 
 
Schizophrenia, depression, Alzheimer’s 
disease, defects in neural tube closure 
 
Table 1.1 Phenotypes of NCAM mutations (Maness and Schachner 2007). 
 
1.8.5 NCAM stimulates neurite outgrowth and neuronal survival 
There is a considerable body of evidence showing that NCAM increases neurite 
outgrowth and survival of rat pheochromocytoma cells (PC12) and primary neurones in 
vitro.  Co-culture of neuronal cells on a confluent monolayer of NCAM-expressing 
fibroblasts increased outgrowth compared to that on untransfected cells (Doherty et al. 
1989; Doherty et al. 1990b; Saffell et al. 1992; Williams et al. 1994a).  Alternatively, 
recombinant proteins (Meiri et al. 1998) or small peptide mimetics (Anderson et al. 
2005; Neiiendam et al. 2004) have been added to cultured cells to simulate the effects 
of NCAM binding in trans.  An interaction between the FnIII domains of NCAM and a 
region of the FGFR has been said to mediate the survival and outgrowth responses 
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(Anderson et al. 2005; Carafoli et al. 2008; Saffell et al. 1997; Williams et al. 1994a).  
NCAM peptides are neuroprotective both in vivo and in vitro against ischaemic insult 
and amyloid beta toxicity and enhance synaptic plasticity, so are currently being 
investigated as therapeutic agents (Berezin and Bock 2008; Klementiev et al. 2007; 
Klementiev et al. 2008; Skibo et al. 2005).  PSA-NCAM is permissive to neurite 
outgrowth and its removal resulted in inhibition of outgrowth (Doherty et al. 1990a).  
The presence of VASE in neurons results in a reduced outgrowth response to NCAM in 
vitro, which may explain why neurons lose their ability to extend processes in the adult 
(Doherty et al. 1992a; Saffell et al. 1994).  A peptide containing the VASE motif 
prevented NCAM from stimulating outgrowth, and it is suggested that this may be 
because it prevents NCAM interacting with the FGFR (Saffell et al. 1994).  NCAM is 
able to interact in trans with L1, and it has been shown that NCAM-VASE also 
interacts with L1, and this does result in neurite outgrowth and may offer a mechanism 
stimulating outgrowth in developmentally mature cells where responsiveness to NCAM 
is reduced (Lahrtz et al. 1997).   
 
1.8.6 Intracellular Signalling via NCAM 
CAMs themselves do not have intrinsic enzymatic activity so activation of signalling 
cascades occurs through interaction with RTKs such as the FGFR or the non-RTK Fyn.  
Several intracellular pathways have been implicated in NCAM-mediated signalling 
including activation of PI3K, MAPK, protein kinases A and C (PKA and PKC), 
increased in intracellular calcium and an interaction with the cytoskeletal protein 
spectrin (Crossin and Krushel 2000; Povlsen et al. 2003).  The existence of lipid raft 
microdomains within the plasma membrane provides a platform for NCAM-mediated 
signalling as it allows clustering of certain molecules together and may help regulate 
NCAM-mediated signalling.  All three major NCAM isoforms can localise to lipid rafts, 
but the 120 kDa isoform is predominantly located there (as reviewed by Povlsen and 
Ditlevsen 2008).  It has been suggested that NCAM-FGFR signalling predominantly 
occurs outside of lipid rafts whereas Fyn is found mainly is rafts (Kramer et al. 1999; 
Niethammer et al. 2002). 
 
1.8.7 Role of NCAM in oligodendrocyte development 
NCAM is expressed on rat OPCs and oligodendrocytes in vitro and in vivo (Bhat and 
Silberberg 1986; Bhat and Silberberg 1988a; Trotter et al. 1989).  PSA-NCAM is 
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expressed on OPCs and as they mature the PSA is removed (Bartsch et al. 1990; Trotter 
et al. 1989) and NCAM-120 becomes the predominant isoform on oligodendrocytes, 
appearing in the rat brain at approximately postnatal day seven, and coinciding with 
oligodendrocyte maturation (Bhat and Silberberg 1988a).  The expression of NCAM 
within the brain and spinal cord peaks in the first week of postnatal life (Chuong and 
Edelman 1984), coincident with the time when pre-myelinating oligodendrocytes are 
contacting axons and NCAM expression has been reported at points of axon-glial 
contact (Bartsch et al. 1989). 
 
PSA-NCAM appears to be a negative regulator of myelination.  The extent of 
myelination has been shown to correspond with a decrease in PSA-NCAM expression 
and it appears that removal of PSA is a requirement for myelination to proceed in the 
rodent and human brain (Charles et al. 2000; Fewou et al. 2007; Jakovcevski et al. 
2009).  Removal of the PSA moiety, either enzymatically or with blocking antibodies, 
resulted in premature and increased levels of myelination (Charles et al. 2000).  Re-
expression of PSA-NCAM following demyelination may serve to increase migration of 
OPCs into the lesion and therefore aid remyelination (Nait-Oumesmar et al. 1995).  
Conversely, re-expression of PSA-NCAM has been found in demyelinated MS lesions, 
and may inhibit remyelination (Charles et al. 2002a).  The role of non-polysialated 
NCAM has been little studied in oligodendrocytes.  As PSA appears to inhibit axon-
oligodendrocyte interactions, it is likely that following PSA removal NCAM-mediated 
cell-cell interactions may occur.  NCAM presented on glass coverslips has been shown 
to promote the survival and process outgrowth of oligodendrocytes (Gard et al. 1996; 
Payne and Lemmon 1993).  NCAM-VASE expression has been described on 
oligodendrocytes in the adult brain, but its function is not known (Reyes et al. 1993; Dr. 
Jane Saffell, Imperial College London, personal communication). 
 
 
A role for NCAM in myelination has been supported by studies in the dysmyelinating 
mutants jimpy and shiverer, which have mutations to the PLP and MBP genes, 
respectively.  As these mutants have decreased myelin it was not a surprise to observe 
reduced levels of NCAM-120, however, NCAM-180 was also reduced suggesting that 
changes to the axon are also taking place in these mutants (Bhat and Silberberg 1988b; 
Bhat and Silberberg 1990). 
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Figure 1.7 Structure of CAMs. 
 
1.9 Role of other adhesion molecules in myelination 
1.9.1 Contactin 
Contactin/F3 belongs to a subgroup of CAMs which contain six Ig domains and four 
FnIII repeats. It is expressed by neurons and oligodendrocyte lineage cells at the O4
+
, 
GalC
+
 and MAG
+
 stage in vitro and in myelin (Koch et al. 1997).  Contactin/F3 is a GPI 
linked molecule and thus localises to lipid rafts, where it is found in close proximity to 
NCAM-120 and can interact with signalling molecules such as Fyn (Kramer et al. 1999; 
White et al. 2008).  Both contactin/F3 expression and Fyn activation are maximal 
during the first weeks of postnatal life coincident with peak myelination (Kramer et al. 
1999).  The proposed axonal binding partner of contactin/F3 on the oligodendrocyte is 
L1 (discussed in more detail below).  White et al (2008) show that binding of L1 to 
oligodendrocytes results in Fyn activation, leading to increased MBP translation.  An 
interaction between contactin/F3 and α6β1 integrins is reported to converge at the level 
of Fyn phosphorylation, resulting in oligodendrocyte adhesion and cell spreading 
(Laursen et al. 2009).  Contactin/F3 is reported to interact in cis with the Notch 
receptor, enabling the Notch receptor to signal in the absence of a ligand and changing 
the response from inhibiting differentiation to promoting it (Hu et al. 2004). 
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1.9.2 L1 
The adhesion molecule L1 is related to the chicken neuron-glia CAM (NgCAM), 
sharing 40% homology (Grumet 1991).  Structurally it consists of six Ig domains and 
five FnIII domains.  Immunohistochemistry has demonstrated that the expression of L1 
is more spatially restricted than that of NCAM.  It is found on unmyelinated axons in 
the retina and the PNS, but axons that are myelinated become L1 negative (Bartsch et 
al. 1989; Haney et al. 1999).  L1 may participate in homophilic interactions with other 
neurons or heterophilic interactions with other binding partners, for example 
contactin/F3 or integrins.  L1 mRNA has been detected in oligodendrocytes but protein 
expression has not been visualised using immunohistochemistry (Barbin et al. 2004).  
This is in contrast to Schwann cells, which do express L1 and L1 homophilic 
interactions are important for axon-Schwann cell adhesion and axonal survival (Haney 
et al. 1999).  Furthermore, antibodies to L1 inhibit in vitro myelination (Seilheimer et 
al. 1989).   The role of L1 in CNS myelination is not clear as two studies have added L1 
blocking antibodies or L1-Fc fusion protein to myelinating co-cultures and one showed 
reduced myelination (Barbin et al. 2004), whilst the other observed enhanced 
myelination (Laursen et al. 2009).  As discussed above, the binding partner for axonal 
L1 may be oligodendrocyte contactin/F3 (White et al. 2008) or integrins (Laursen et al. 
2009; Oleszewski et al. 1999).  Down-regulation of L1 may be required in order for 
myelination to proceed or it may provide an early signal to initiate myelination perhaps 
functioning in the initial stabilisation of contacts between the axon and glial cells 
(Bartsch et al. 1989).  The previously described fibroblast co-culture system has shown 
that neurons extend longer neurites when grown over L1-expressing cells than 
untransfected cells and that this is dependent on the FGFR (Kulahin et al. 2008; 
Williams et al. 1994a), and L1-Fc increases neuronal survival (Nishimune et al. 2005), 
suggesting it behaves in a similar way to NCAM.   
 
1.9.3 MAG 
MAG is a CAM that contains five Ig domains and a transmembrane domain but no 
FnIII domain and is expressed by oligodendrocytes and Schwann cells (Grumet 1991).  
MAG constitutes a minor component of myelin and localises to the axo-glial interface, 
so is a candidate to transduce signals between the axon and the oligodendrocyte.  MAG 
can interact with two families of receptors; Nogo receptors and sialoglycans including 
the gangliosides GD1a and GD1b, which signal to maintain axon stability (Schnaar and 
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Lopez 2009).  MAG is expressed prior to and during the initial ensheathment of axons 
and its expression continues in compact myelin (Bartsch et al. 1989).  MAG-null mice 
appear to myelinate normally but exhibit defects in periaxonal organisation and in some 
cases produce an incorrect amount of myelin (Li et al. 1994; Li et al. 1998).  
Interestingly, NCAM over-expression has been observed in MAG deficient mice in the 
PNS suggesting it might compensate as the two molecules have a very similar structure 
(Carenini et al. 1997).  A double knock-out for MAG and NCAM had a more severe 
phenotype than either of the single mutants and showed that NCAM could compensate 
for the effect of MAG on myelin maintenance but not myelin formation (Carenini et al. 
1997).  In the PNS MAG over-expression is associated with hypermyelination whilst its 
under-expression produces hypomyelination (Baumann and Pham-Dinh 2001).  In vitro 
studies have shown that MAG can increase oligodendrocyte survival and outgrowth 
(Gard et al. 1996) but MAG inhibits neurite outgrowth and may inhibit axon 
regeneration following nerve injury (Filbin 2003).  It is unknown what signalling may 
be activated in the oligodendrocyte following MAG binding to the axon.   
 
1.9.4 N-cadherin 
Cadherins are a family of molecules distinct from the Ig superfamily.  Neural or N-
cadherin is a calcium-dependent CAM that binds homophilically.  During development 
N-cadherin is expressed by neurons, oligodendrocytes and astrocytes (Hatta et al. 
1985).  It appears early during embryonic development, around E16 where expression is 
strong and ubiquitous, then becomes restricted to particular neuronal cell layers and in 
the adult N-cadherin expression is only described on Purkinje cells of the cerebellum 
and in the olfactory bulb (Redies and Takeichi 1993).  Its expression on OPCs and 
oligodendrocytes has been demonstrated in vitro and culture of cells on N-cadherin 
leads to adhesion and extension of a myelin-like membrane, suggesting it increases 
process outgrowth (Payne and Lemmon 1993; Payne et al. 1996).  Soluble N-cadherin 
can induce OPC proliferation but decreased migration and antibody or peptide-mediated 
blocking of N-cadherin promoted cell migration (Schnadelbach et al. 2000).  N-
cadherin expression is down-regulated following myelination, although it may play a 
role in initial axo-glial contact (Schnadelbach et al. 2001).  Blocking peptides reduced 
myelination in a cerebellar slice culture system where oligodendrocytes failed to 
elaborate complex processes and align with axons (Schnadelbach et al. 2001).  N-
cadherin has also been shown to increase neurite outgrowth and survival via the FGFR 
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(Doherty et al. 1991; Skaper et al. 2004; Williams et al. 1994a; Williams et al. 2001).  
In addition, whereas neuronal responsiveness to NCAM decreases developmentally as 
VASE is up-regulated, there is no loss of outgrowth associated with N-cadherin 
(Doherty et al. 1992b).   
 
1.9.5 Neurofascin 
Neurofascin is another member of the L1/NgCAM subgroup of Ig CAMs and was first 
identified in the chick nervous system, consisting of six Ig domains and four FnIII 
domains (Volkmer et al. 1992).  In the mammalian nervous system there are two 
isoforms created by alternative splicing; the Nfasc186 is expressed on axons and the 
Nfasc155 is expressed by oligodendrocytes and Schwann cells (Tait et al. 2000).  
NFasc155 expression is transiently upregulated during myelination, suggesting it may 
have a role in regulating axo-glial interactions (Collinson et al. 1998).  NFasc186 is 
required for the clustering of sodium channels at the node of Ranvier, where it 
associates with ankyrin G and βIV-spectrin.  NFasc155 is expressed at the paranodal 
junctions and binds to the Caspr-contactin complex on the axon (Charles et al. 2002b; 
Sherman et al. 2005).  The importance of NFasc in the establishment of axonal domains 
has been demonstrated by the NFasc-null mice, which die at postnatal day seven due to 
aberrant myelination (Sherman et al. 2005).  In the absence of NFasc other proteins are 
not recruited to the node and paranode, suggesting a role for NFasc in formation of axo-
glial junctions (Sherman et al. 2005).  Expression of a NFasc155 construct in NFasc-
null mice resulted in recruitment of Caspr-contactin and formation of paranodal 
junctions but did not rescue the node of Ranvier in the PNS, suggesting a requirement 
for NFasc186 to cluster sodium channels (Sherman et al. 2005; Koticha et al. 2006).  In 
the CNS, expression of NFasc155 in the knock-out, rescued both nodal and paranodal 
components, whereas expression of NFasc186 rescued the node but not the paranodal 
complex, suggesting they have distinct functions (Zonta et al. 2008).  Disruption of 
NFasc155 expression at the paranodes occurs in inflammatory lesions and precedes 
demyelination in MS (Howell et al. 2006).  This disruption can severely reduce axon 
conduction velocities producing clinical symptoms.  Re-organisation of nodal regions 
can occur following remyelination, leading to recovery of function (Howell et al. 2006). 
 
Experiments in the chick embryo have shown a role for Nfasc in neurite outgrowth 
during development, where it is believed to interact with chick isoforms of L1 
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(NrCAM) and contactin/F3 (axonin) (Pruss et al. 2006; Rathjen et al. 1987; Volkmer et 
al. 1996).  Over-expression of the embryonic chick isoform NFasc166 and over-
expression of the FGFR1 showed that the two proteins associate and that NFasc166 
leads to FGFR1 activation in vitro (Kirschbaum et al. 2009), suggesting that NFasc may 
signal in a similar way to NCAM and L1.  NFasc155 and NFasc186 fusion proteins and 
stable cell lines expressing NFasc produced opposing effects on neurite outgrowth of rat 
neurons (Koticha et al. 2005).  NFasc186 inhibited neuronal adhesion and outgrowth, 
whereas NFasc155 promoted it (Koticha et al. 2005).  It is suggested that the presence 
of the mucin-like domain in NFasc186 is responsible for its inhibitory actions (Koticha 
et al. 2005).  However, whether the effects of the two splice variants are the same on 
oligodendrocytes is unknown.  The expression of NFasc by oligodendrocytes peaks at 
the onset of myelination, this suggests a role for NFasc in establishment of axo-glial 
contact and it may help initiate myelination (Collinson et al. 1998).  Addition of NFasc-
Fc to in vitro co-cultures inhibits myelination, indicating it may prevent axo-glial 
contact (Charles et al. 2002b).   
 
1.9.6 Nectins 
Nectins are members of the Ig superfamily and bind homophilically to one another or 
heterophilically to nectin-like molecules (Necls), integrins and growth factor receptors 
(as reviewed by Sakisaka et al. 2007).  In particular, a role for Necls has been described 
in PNS myelination, whereby Necl4 on the Schwann cell interacts with Necl1 on the 
neuron.  Interruption of this interaction with dominant negative constructs or soluble 
proteins inhibited myelination (Maurel et al. 2007; Spiegel et al. 2007).  Furthermore, a 
role for Necls in the CNS has been suggested by in vivo studies where Necl1 was 
inactivated resulting in delayed myelination (Park et al. 2008).  Necl3 is expressed on 
CNS axons where is localises along the internode and is said to bind to 
oligodendrocytes, to an unknown binding partner is unknown (Pellissier et al. 2007). 
 
1.9.7 Netrins 
Netrins are a family of proteins that display homology to laminins and have a role in 
axon guidance and cell migration.  They function as either secreted molecules or as 
GPI-anchored membrane proteins.  OPCs do not express netrin and their expression by 
other cells in the CNS is thought to act as a repellent and increase migration (Jarjour et 
al. 2003; Tsai et al. 2006).  Netrin-1 is expressed on oligodendrocytes and it is said to 
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interact with the deleted in colorectal carcinoma (Dcc) protein, both of which localise to 
paranodal junctions (Jarjour et al. 2008; Manitt et al. 2001).  In vitro netrin-1 induces 
Dcc-dependent increase in process outgrowth and myelin-membrane formation 
(Rajasekharan et al. 2009).  Netrin-1 and Dcc are not required for paranodal formation 
but in their abscence paranodes become disorganised (Jarjour et al. 2008). 
 
1.10 Aims of this study 
Axon-oligodendrocyte signalling provides initial adhesion and maintains 
oligodendrocyte survival so that myelin formation can proceed.  The molecular nature 
of the contact dependent events that control the later stages of myelination involves a 
number of molecules but their interactions are poorly understood.   In order to 
understand the possible mechanisms whereby changes to the axonal membrane could 
modulate oligodendrocyte survival and differentiation, we have investigated the role of 
NCAM, as it is known to be involved in neuronal survival and process outgrowth.  
PSA-NCAM, L1 and N-cadherin are down regulated prior to myelination, whereas 
NCAM and neurofascin are upregulated, thus providing possible signals to the axon-
oligodendrocyte unit.  
 
1.10.1 Hypothesis 
The cell adhesion molecule NCAM can provide the oligodendrocyte-axon signalling 
required to promote the survival and differentiation of oligodendrocytes. 
 
1.10.2 Specific Aims 
1. To characterise NCAM expression on cultured oligodendrocytes 
2. To investigate whether a peptide corresponding to the FG loop in the first FnIII 
domain of NCAM can increase the survival and differentiation of pre-
myelinating oligodendrocytes 
3.  To investigate whether a soluble NCAM protein can increase the survival and 
differentiation of pre-myelinating oligodendrocytes 
4. To examine the interaction between NCAM and the FGFR in oligodendrocytes 
5. To identify the downstream intracellular signalling pathways employed by 
oligodendrocytes following NCAM interactions 
6. To investigate the effects of interrupting NCAM signalling on oligodendrocyte 
survival and differentiation. 
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Chapter 2 
 
 
 
 
 
Effect of soluble NCAM on the survival and proliferation pre-
myelinating oligodendrocytes 
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2.1 Introduction  
 
2.1.1 Oligodendrocyte precursor cell culture 
Following their initial isolation from the rodent optic nerve, dissociated cell culture 
studies have been widely used to study the development of oligodendrocytes (Raff et al. 
1983a).  The discovery that OPCs have bipotential, generating oligodendrocytes and 
type-2 astrocytes, and that a significant proportion remain in the adult CNS has 
significantly enhanced our understanding of brain development and led to them being 
categorised as a fourth major glial type (Nishiyama 2007).  In vitro OPCs differentiate 
via a series of well defined morphological stages and sequentially express specific cell 
surface antigens (Grinspan 2002, Figure 1.1).  The pre-progenitor is highly proliferative, 
displays many features of a neural stem cell and is characterised by the expression of 
PSA-NCAM, nestin and vimentin (Hardy and Reynolds 1991; Grinspan 2002).  The 
OPC (or O-2A progenitor) can be identified by expression of NG2, A2B5 and 
PDGFRα, and cells at this stage proliferate and migrate throughout the CNS and are 
highly dependent on soluble growth factors.  The late progenitor or pro-
oligodendroblast is increasingly committed to the oligodendrocyte lineage, has a 
multipolar morphology and expresses the O4 antigen.  These cells cycle more slowly 
and are less migratory.  The fourth stage is the immature oligodendrocyte, which is a 
post-mitotic cell that expresses GalC and myelin proteins and has a complex 
morphology.  Finally cells mature into a myelinating oligodendrocyte with an elaborate 
myelin membrane.  The stages that are observed in vitro have been shown to translate 
well to the developing brain in vivo (Hardy and Reynolds 1991; Reynolds and Hardy 
1997).   
 
As well as providing a mechanism to study oligodendrocyte development, OPCs have 
been used to study cell lineage and differentiation in general.  Whilst the major function 
of the OPC is to produce mature oligodendrocytes, several studies have suggested that 
they are multipotent and can produce astrocytes and neurons in the normal and injured 
brain (Karram et al. 2008; Leoni et al. 2009; Matthias et al. 2003; Rivers et al. 2008; 
Zhu et al. 2008). 
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Several methods of isolating OPCs have been described (Armstrong 1998).  Mixed glial 
cell cultures can be isolated from postnatal day (P) 1-2 rat brains by plating dissociated 
brain cortices onto poly-D-lysine (PDL) coated flasks and allowing them to proliferate 
in serum for approximately 10 days.  OPCs and microglia can be seen growing on a 
layer of astrocytes; and can be removed by gentle agitation and plating the released cells 
onto glass coverslips (McCarthy and de Vellis, 1980; Armstrong et al. 1990).  However, 
as oligodendrocytes differentiate asynchronously in the CNS it is difficult to obtain a 
population of cells that are homogeneous and will respond in the same way in culture.  
One solution is to use immunopanning to selectively capture cells that express specific 
cell surface markers, such as A2B5, O4 or GalC using monoclonal antibodies (Barres et 
al, 1992; Gard and Pfeiffer 1993; Wu et al. 2001).  This enables sampling of a more 
homogeneous cell population, thereby reducing the potential for artefact and allows 
characterisation of the properties of cells at a specific point in the lineage.  We have 
used the O4 antibody, which recognises the sulphatide antigen, to isolate cells at the late 
progenitor phase.  Expression of the O4 antigen is observed from birth in the rat brain 
and increases over the first two weeks of postnatal life (Reynolds and Hardy 1997).  
The recovery of cells declines with postnatal age due to difficulty in dissociating the 
tissue.  Therefore, to obtain an optimal yield of O4
+
 cells, P4-5 rat brain is used (Gard 
and Pfeiffer 1993).  At this stage there are few mature GalC
+
 oligodendrocytes, which 
retain their O4 expression, and due to their morphological complexity few survive the 
dissociation process (Gard and Pfeiffer 1993).  
 
2.1.2 Regulation of oligodendrocyte survival 
A fine balance between proliferation, survival and cell death ensures that the correct 
numbers of myelinating oligodendrocytes are produced.  Approximately 50% of newly 
formed oligodendrocytes normally die in the optic nerve during development, as a result 
of competition for limited survival factors (Barres et al. 1992), suggesting an over-
production to ensure all the necessary axons become myelinated.  An understanding of 
the cellular and molecular mechanisms that modulate OPC and pre-myelinating 
oligodendrocyte survival would aid our understanding of myelinogenesis. The 
regulation of oligodendrocyte survival is a complex process and the trophic factors they 
require varies as they progress through the lineage.  It is suggested that the process of 
remyelination recapitulates the process of myelination that occurs during development 
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(Franklin 2002).  Therefore, a knowledge of the signals modulating oligodendrocyte 
survival is essential to our understanding of repair processes in MS. 
 
2.1.2.1 Growth factors 
Soluble growth factors are the best characterised OPC survival factors and include 
PDGF and insulin (Figure 1.1, as described in Chapter 1.2).  As well as mediating OPC 
survival they also act as mitogens and influence both cell migration and differentiation 
(Frost et al. 2009; Milner et al. 1997a; Noble et al. 1988).  PDGF increases proliferation 
and survival and is believed to be the rate limiting growth factor which determines how 
many cell cycles OPCs go through before they differentiate (Barres et al. 1992; Noble et 
al. 1988; Raff et al. 1988).  Far lower concentrations are required to stimulate survival 
(half-maximal survival at 8 pg/ml) than proliferation (half maximal proliferation at 1850 
pg/ml) (Barres et al. 1993b).  FGF2 increases OPC proliferation and inhibits 
differentiation (10 ng/ml) (McKinnon et al. 1990).  Insulin increases OPC survival and 
promotes differentiation (Barres et al. 1992; Barres et al. 1993b).  
 
2.1.2.2 Contact-dependent signalling 
Considerably less is known about the target-dependent signals that control the later 
stages of OPC maturation and lead to the initiation of myelination.  It is recognised that 
an excess of oligodendrocytes are produced during development and that the final 
number of myelinating oligodendrocytes is controlled by signalling from the axon 
(Barres et al. 1993a).  Several molecules have been shown to be involved in the axon-
oligodendrocyte signalling (reviewed by Bozzali and Wrabetz 2004).  Adhesion 
molecules expressed on the axon may bind by homophilic or heterophilic interactions to 
those on the oligodendrocyte and this can influence oligodendrocyte survival.  In vitro 
experiments showed that NCAM and MAG increased oligodendrocyte survival and this 
effect appeared to be specific as growth on other substrates such as L1, fibronectin, 
laminin, tenascin-C and tenascin-R did not have an effect (Gard et al. 1996).  The 
mechanisms underlying these effects are yet to be characterised and it is unknown 
whether NCAM can activate intracellular signalling in oligodendrocytes as it can in 
neurons.  Conversely, other studies have shown that binding of neuronally-secreted 
laminin to integrins on oligodendrocytes also increased oligodendrocyte survival 
(Colognato et al. 2002; Frost et al. 1999).  Furthermore, NRG is an axonally derived 
factor that increases survival of maturing oligodendrocytes (Colognato et al. 2002; 
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Fernandez et al. 2000).  Therefore, it is likely that oligodendrocyte survival is not 
determined by a single molecular interaction. 
 
2.1.3 NCAM and cell survival 
It is now well recognised that as well as mediating cell-cell adhesion CAMs are able to 
activate intracellular signalling pathways to modulate a number of cell responses.  The 
Ig domains of NCAM are required for homophilic binding although the precise 
mechanism is disputed and there may be multiple modes of homophilic interaction 
(Johnson et al. 2005; Kiselyov et al. 1997; Soroka et al. 2003).  Following NCAM-
NCAM binding in trans in neurons, a cis interaction between the FnIII domains of 
NCAM and the FGFR has been described that is said to lead to activation of the FGFR 
and downstream signalling pathways (Figure 2.1).   
 
 
 
Figure 2.1 Hypothetical interaction between NCAM and the FGF receptor (Anderson et al. 
2005). 
The extracellular domain of NCAM consists of five immunoglobulin (Ig) domains, involved in 
homophilic and heterophilic interactions in cis, and two fibronectin type three (FnIII) domains, 
which can interact in trans with the FGF receptor Ig domains (D2 and D3), with sequences 
within the CAM homology domains (CHD). Within the FnIII domains, are the FRM and FGL 
motifs, believed to contain the sequences important for activating the FGF receptor. 
 
A number of small peptides derived from the NCAM sequence have been shown to 
mimic the effects of the whole protein and increase neuronal survival (Anderson et al. 
2005; Ditlevsen et al. 2003; Ditlevsen et al. 2007; Neiiendam et al. 2004; Pedersen et 
al. 2004).  In particular, peptides derived from the FnIII domains, such as the FGL 
peptide derived from the second FnIII domain (Neiiendam et al. 2004) and the FRM 
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peptide derived from the first FnIII domain (Anderson et al. 2005) are postulated to 
interact directly with the FGFR, bypassing the need for NCAM-NCAM binding 
(Anderson et al. 2005; Saffell et al. 1997; Williams et al. 1994a; Kiselyov et al. 2005).  
Determination of the structure of the FnIII domains of NCAM has led to the production 
of numerous other peptide motifs, which may also activate the FGFR, indicating the 
presence of multiple FGFR binding sites in NCAM (Carafoli et al. 2008; Jacobsen et al. 
2008; Figure 2.2).  Interestingly other NCAM peptides derived from the FnIII domains, 
such as BCL, can bind to the FGFR and elicit neurite outgrowth but not neuronal 
survival (Jacobsen et al. 2008; Li et al. 2008).  The different peptide motifs may be 
regarded as regions of the NCAM-FGFR binding interface and it is suggested that the 
binding kinetics may be different for each peptide, varying the tyrosine residues that are 
phosphorylated and therefore the signalling proteins that are recruited (Jacobsen et al. 
2008).  In addition, peptides derived from sequences in the Ig domains, such as P2 and 
C3, have been used, and these are predicted to mimic homophilic NCAM binding, and 
subsequently lead to FGFR activation and neuronal survival (Ditlevsen et al. 2003; 
Pedersen et al. 2004).  NCAM peptide mimetics have proven to be neuroprotective in 
both in vitro and in vivo studies (Klementiev et al. 2007; Klementiev et al. 2008; Skibo 
et al. 2005). NCAM peptides also enhanced memory formation in rodents (Cambon et 
al. 2004; Secher et al. 2006), reduced depression in the NCAM-null mouse (Aonurm-
Helm et al. 2008) and are being evaluated in clinical trials for Alzheimer’s disease 
(Anand et al. 2007).  
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Figure 2.2 Model of the first and second FnIII domains of NCAM (Jacobsen et al. 2008). 
The model is based on data obtained from NMR and X-ray crystallography studies and depicts 
six strand-loop-strand regions in each FnIII domain, with motifs synthesised as peptides 
labelled.  The FRM motif is highlighted in blue and lies within the first FnIII domain.  
 
2.1.4 Hypothesis 
This chapter addressed the hypotheses that:  
1. OPCs can be isolated from the neonatal rat brain and differentiated in vitro 
2. OPCs and pre-myelinating oligodendrocytes express NCAM 
3. NCAM mimetics will increase the survival of OPCs 
4. NCAM mimetics will not affect OPC proliferation. 
 
2.1.5 Aims 
The aims of this study were to characterise an in vitro system for culturing OPCs 
isolated from the neonatal rat brain and to characterise them antigenically and 
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morphologically as they differentiate and confirm that they produce mature 
oligodendrocytes.  The expression of adhesion molecules on these cells was examined.  
Additionally, the expression of NCAM on the CG4 OPC cell line was investigated.  
Previous studies have demonstrated that NCAM is expressed by neurons, OPCs and 
oligodendrocytes and its expression is up-regulated prior to the onset of myelination 
(Bhat and Silberberg 1986; Bhat and Silberberg 1988a; Trotter et al. 1989).  Therefore, 
it is ideally placed to transduce signals between the axon and the oligodendrocyte.  It 
has been shown that NCAM can activate intracellular signalling in neurons and this is 
important for their survival (Anderson et al. 2005; Ditlevsen et al. 2003; Ditlevsen et al. 
2007; Neiiendam et al. 2004; Pedersen et al. 2004).  Preliminary evidence has shown 
that an NCAM peptide and a full-length recombinant protein can increase the survival 
of pre-myelinating oligodendrocytes (Anderson et al. 2005; Gard et al. 1996).  To 
investigate whether NCAM could affect the survival or proliferation of pre-myelinating 
oligodendrocytes a soluble chimeric protein, NCAM-Fc, and a small peptide (FRM) 
corresponding to the FG loop of the first FnIII domain of NCAM were added to the 
culture system.  
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2.2 Methods 
 
2.2.1 Neonatal OPC isolation and culture 
All reagents were purchased from Sigma-Aldrich (Poole, UK), unless otherwise 
indicated.  An immunopanning protocol was used to isolate OPCs from the neonatal rat 
brain, as described previously (Wu et al. 2001), in order to isolate a pure population of 
OPCs that were at the late progenitor stage.  Cortices were removed from four day old 
Sprague Dawley (SD; Harlan, UK) rat pups, chopped coarsely and dissociated with 
trypsin EDTA (0.25%).  The tissue was transferred to a T75 tissue culture flask with an 
additional 20 ml trypsin EDTA and placed in a shaking incubator at 37C for 20 
minutes. 1 ml of trypsin inhibitor (containing 6.25 mg/ml trypsin inhibitor, 2 mg/ml 
DNase and 0.74 mg/ml magnesium sulphate) was added and the flask incubated for a 
further five minutes.  The tissue homogenate was centrifuged for ten minutes at 1200 
rotations per minute (RPM) at 4C, supernatant aspirated and the tissue was dissociated 
to a single cell suspension using a flame narrowed Pasteur pipette in minimum essential 
eagles media with HEPES buffer modification (MEM-HEPES), 2 mM L-glutamine, 100 
units/ml penicillin-streptomycin and 5% heat inactivated foetal calf serum (HI FCS – 
PAA, Yeovil, UK).  The cell suspension was spun through MEM-HEPES with 4% 
bovine serum albumin (BSA) at 1000 RPM, 4C for ten minutes, without brake.  The 
supernatant was aspirated and cells resuspended in MEM-HEPES 5% HI FCS and 
added to a T75 flask and incubated at 37C for 25 minutes to remove microglia, 
macrophages and other adherent cells.   
 
The day before the tissue was collected, two 10 cm Petri dishes (Falcon, BD 
Biosciences, Oxford, UK) were coated overnight with anti-IgM Fab2 (Cambridge 
Bioscience, Cambridge, UK) diluted to 5 µg/ml in Tris-HCl, pH 7.4.  Plates were next 
washed twice with phosphate buffered saline (PBS), incubated with anti-O4 antibody 
(hybridoma supernatant, ECACC, 1:5 dilution) for 1-2 hours at 37C and washed with 
PBS and Dulbecco’s modified Eagle’s medium (DMEM).  Cells that did not bind to the 
T75 flask were removed and centrifuged at 1200 RPM for 10 minutes, re-suspended in 
MEM-HEPES containing 5% HI FCS and 5 µg/ml insulin, added to the O4-coated 
immunopanning plates and incubated for 30 minutes at 37°C.  Unbound cells were 
removed and the plates were washed five times with DMEM containing 5 µg/ml insulin.  
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Trypsin EDTA (0.125%) solution was added to the panning plates and a flame 
narrowed Pasteur pipette used to remove cells, followed by centrifugation.  Cells were 
plated onto poly-D-lysine (PDL)-coated 13 mm glass coverslips in DMEM containing 
10% HI FCS and 5 µg/ml insulin  (3X10
4
 cells per well of a 24 well plate).  After 1-2 
hours incubation medium was changed to chemically defined serum free 
oligodendrocyte progenitor media (OLP) (Hardy and Reynolds 1993b) composed of 
DMEM containing 100 units/ml penicillin-streptomycin, 2 mM L-glutamine, 1 mM 
sodium pyruvate, 63 µg/ml N-acetyl-L-cysteine, 0.5 mg/ml BSA, 30 nM sodium 
selenite, 10 µm transferrin, 100 µM putrescine, 1.5 nM triiodothyronine, 20 nM 
progesterone and 10 nM hydrocortisone. Cells were grown in culture for 2-6 days at 
37C, 5% CO2 and 100% humidity. 
 
2.2.2 Addition of growth factors and peptides 
All growth factors, peptides and inhibitors were diluted into OLP media and added 
when the media was changed on the day of isolation. As a positive control insulin (5 
µg/ml), recombinant human basic FGF (FGF2, 0.1-10 ng/ml, R and D Systems Ltd, 
Minneapolis, USA) or porcine PDGF-AA (1 ng/ml, Sigma-Aldrich) were added to 
media.  To mimic the effect of axonal NCAM binding to OPCs a soluble peptide and 
protein were used.  All peptides were purchased from Mimotopes (Melbourne, 
Australia).  The FRM peptide (FGF receptor activation motif) consisted of a ten amino 
acid sequence, DRVEPYSSTA, corresponding to a region within the first FnIII domain 
of NCAM.  The sequence was cyclised and joined together by two cysteine residues and 
used at 0.5-50 µg/ml (0.36-36 µM).  A scrambled peptide (the same amino acids as 
FRM but in a random order) was also used as a control at 5 µg/ml or 50 µg/ml.  An 
NCAM-Fc fusion protein consisting of the full extracellular domain of NCAM fused to 
the Fc region of human IgG1 was produced using a mammalian expression system (see 
below) and was used at 5 µg/ml or 50 µg/ml (33.8 or 338 µM).  For experiments 
measuring cell survival FRM peptide and NCAM-Fc were added to media in the 
absence of insulin, and control cells were cells with no insulin or peptides added.   
 
2.2.3 CG4 cell culture 
Central glia-4 (CG4) cells are an OPC cell line that can be maintained in an 
undifferentiated state using B104 neuroblastoma cell conditioned media (B104-CM) 
(Louis et al. 1992). B104 cells were cultured in DMEM, 2 mM L-glutamine, 100 
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units/ml penicillin-streptomycin and 10% HI FCS until confluent.  For conditioned 
media production, cells were washed with Hanks Balanced Salt Solution (HBSS) and 
incubated with 15 ml DMEM, 1% N1 supplement, 2 mM L-glutamine and 100 units/ml 
penicillin-streptomycin per T75 flask for four days.  Media was filtered and frozen in 
aliquots until required.  CG4 media consisted of DMEM, 30% B104-CM, 1% N1 
supplement, 2 mM L-glutamine, 100 units/ml penicillin-streptomycin, 5 ng/ml FGF2, 1 
ng/ml PDGF and 10 ng/ml biotin.  CG4 cells were grown on PDL-coated flasks and 
passaged twice a week.  To differentiate CG4 cells media was switched from CG4 
media to OLP media.  
 
2.2.4 Double immunofluorescence of OPCs and CG4 cells 
Coverslips were removed from the 24 well plate, placed on parafilm on ice and 
incubated for 20 minutes with anti-O4, anti-A2B5 or anti-O1 antibodies diluted in 
MEM-HEPES containing 0.3% BSA.  Cells were washed three times with MEM-
HEPES + 0.3% BSA and incubated for 15 minutes with anti-IgM γ chain FITC 
conjugate (Sigma-Aldrich).  Cells were washed and fixed for 15 minutes at room 
temperature (RT) in 4% paraformaldehyde (PFA) and permeabilised with PBS 
containing 0.1% Triton X-100.  Following a wash with MEM-HEPES and 0.3% BSA, 
cells were incubated with a second primary antibody for 45 minutes (Table 2.1), washed 
with MEM-HEPES + 0.3% BSA and incubated for 30 minutes with secondary antibody.  
Cells were washed again and incubated for five minutes with the nuclear stain 4’, 6-
diamidino-2-phenylindole (DAPI, diluted 1:5000 in PBS).  Cells were briefly washed 
with PBS and distilled water before mounting with Vectorshield hardset mounting 
medium (Vector Laboratories, Peterborough, UK). To prevent misinterpretation of 
results, negative controls were performed with each antibody, whereby wash buffer was 
added instead of the primary antibody and the secondary antibody was incubated as 
normal.   
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Primary Antibody Secondary 
Antibody 
Primary Antibody Secondary Antibody 
Mouse anti O4 
(hybridoma 
supernatant, 
ECACC) 1:5 
Goat anti mouse IgM 
 chain FITC (Sigma-
Aldrich) 1:100 
Rabbit anti olig1 
(Millipore, UK) 
1:200 
Goat anti rabbit cy3 
(Jackson 
Immunoresearch) 1:500 
Mouse anti O4 1:5 Goat anti mouse IgM 
 chain FITC 1:100 
Rabbit anti MBP (in 
house, RR) 1:500 
Goat anti rabbit cy3 
1:500 
Mouse anti O4 1:5 Goat anti mouse IgM 
 chain FITC 1:100 
Rabbit anti NCAM 
(Millipore, UK) 
1:200 
Goat anti rabbit cy3 
1:500 
Mouse anti O4 1:5 Goat anti mouse IgM 
 chain FITC 1:100 
Rabbit anti 
neurofascin (gift 
from P Brophy) 
1:1000 
Goat anti rabbit cy3 
1:500 
Mouse anti O1 
(hybridoma 
supernatant, 
ECACC) 1:5 
Goat anti mouse IgM 
 chain FITC 1:100 
Rabbit anti MBP 
1:500 
Goat anti rabbit cy3 
1:500 
Mouse anti A2B5 
(hybridoma 
supernatant, 
ECACC) 1:5 
Goat anti mouse IgM 
 chain FITC 1:100 
Rabbit anti NG2 
(Millipore, UK) 1: 
200 
Goat anti rabbit cy3 
1:500 
Mouse anti O4 1:5 Goat anti mouse IgM 
 chain FITC 1:100 
Mouse anti 
neurofilament 
(RT97- Millipore) 
1:500 
Goat anti mouse IgG1 
Texas Red (Cambridge 
Bioscience) 1:100 
Mouse anti O4 1:5 Goat anti mouse IgM 
 chain FITC 1:100 
Mouse anti-MOG 
(hybridoma 
supernatant, Dr S 
Piddlesden, Cardiff) 
1:500 
Goat anti-mouse IgG2A 
Alexa 594 (Invitrogen) 
1:500 
Mouse anti O4 1:5 Goat anti mouse IgM 
 chain FITC 1:100 
Mouse anti-
CNPase (Millipore) 
1:200 
Goat anti mouse IgG1 
Texas Red 1:100 
Mouse anti-PSA 
NCAM (Millipore) 
1:200 
Goat anti mouse IgM 
 chain FITC 1:100 
Rabbit anti NCAM 
1:200 
Goat anti rabbit cy3 
1:500 
Mouse anti O4 1:5 Goat anti mouse IgM 
 chain FITC 1:100 
Rabbit anti-NCAM 
VASE (gift Dr Jane 
Saffell) 1:40 
Goat anti rabbit cy3 
1:500 
 
Table 2.1 Antibodies used for immunocytochemistry 
 
2.2.5 Propidium iodide survival assay 
Cell survival was assessed after four days in culture.  Coverslips were placed on 
parafilm on a bed of ice and incubated for five minutes with propidium iodide (PI, 30 
M, Invitrogen) in MEM-HEPES containing 0.3% BSA and washed three times with 
MEM-HEPES containing 0.3% BSA.  PI was used to identify the dead or dying cells, 
which have permeable membranes allowing PI uptake into the nucleus where it binds to 
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DNA.  Cells were then stained with O4 antibody, as described earlier and fixed with 4% 
PFA before mounting with Vectorshield. 
 
2.2.6 MTS survival assay 
The CellTiter 96® AQueous one solution cell proliferation assay (Promega, 
Southampton, UK) is a colorimetric alternative to radioactive cytotoxicity assays.  This 
assay measures the conversion of MTS to soluble formazan, that is accomplished by 
metabolically active cells. Cells were cultured on PDL-coated 96-well plates (plating 
density of 1.2X10
4
 cells per well) and incubated in OLP with growth factors or peptides 
for four days.  On the day of the assay 20 µl CellTiter 96® AQueous one solution was 
added per well, as per kit instructions.  Plates were incubated at 37ºC for two hours 
before reading the absorbance at 490 nm.  Absorbance is directly proportional to the 
number of viable cells.  Each condition was carried out in quadruplicate.  Background 
(absorbance of wells without addition of MTS reagent) was subtracted from all values 
and the values of treated cells were converted to a percentage of the control (untreated 
cell).  The data was converted to express survival as a percentage relative to control 
cells, with control cells being 100%. 
 
2.2.7 BrdU proliferation assay 
5-Bromo-2’-deoxyuridine (BrdU, Sigma-Aldrich, 50 µM in OLP medium) was added to 
cultures 24 hours after plating and immunocytochemistry for O4 and BrdU carried out 
16 hours later. Cells were labelled with O4-FITC and fixed with 4% PFA as described 
above. Coverslips were permeabilised for five minutes with 0.25% Triton X-100 and 
incubated with 2 M hydrochloric acid for ten minutes to denature DNA, washed once 
with MEM-HEPES and neutralised with 0.1 M sodium tetraborate, pH 8.5. Cultures 
were then incubated for 45 minutes with monoclonal anti-BrdU antibody (1:200, 
Millipore) followed by goat anti-mouse IgG1-Texas Red secondary antibody (1:100, 
Cambridge Bioscience) for 30 minutes and mounted as above. 
 
2.2.8 Cell counting and image analysis 
Cells were visualised using epifluorescence illumination on a Nikon Eclipse 1000 
microscope and digital images were captured using a QICAM Fast 1394 camera 
(QImaging, Media Cybernetics, Marlow, UK).  Image ProPlus version 5.1 software 
(Media Cybernetics) was used to create composite images. 
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For the PI survival assay cells were counted using a X20 objective.  Ten fields were 
randomly selected per coverslip and counted manually and three coverslips per 
condition were used in each experiment.  Data presented graphically is from a minimum 
of three independent experiments.  Graphs were produced using Graphpad Prism 
version 4 software (GraphPad Software Inc, San Diego, USA) and statistics were also 
carried out using this package.  To compare groups an unpaired Student’s t-test or a one 
way ANOVA, with Bonferroni post-hoc test were used. 
  
2.2.9 Production of NCAM-Fc 
Escherichia Coli (E.coli) bacteria of the strain MC1061/P3 transformed with the pIG-1 
vector (Wright et al. 1997) containing the NCAM-Fc gene were a gift from David L 
Simmons (Figure 2.3, as described in Fawcett et al. 1992).  Bacteria were grown in 
liquid broth (LB, consisting of 10 g/L tryptone, 5 g/L yeast extract and 10 g/L sodium 
chloride, pH 7.4) with 15 g/ml ampicillin and 10 g/ml tetracycline for selection, in a 
shaking incubator at 37C.  Bacteria were then pelleted by centrifugation at 6000 RPM 
and a Maxiprep Kit used to extract the DNA (Qiagen Ltd, Crawley UK).  The Plasmid 
Maxi Kit can be used to isolate plasmids from E. coli using alkaline lysis and anion-
exchange resin to bind plasmid DNA (up to 500µg), and was used as per kit 
instructions. DNA concentration was determined spectrophotometrically by measuring 
absorbance at 260 nm NanoDrop ND1000 (NanoDrop Technologies, Delaware, USA).  
Samples were digested using HindIII and BamH1 restriction enzymes (New England 
Biolabs, Hitchin, UK) for two hours at 37C.  The digested DNA was diluted with 5X 
sample buffer and run on a 1% agarose gel containing ethidium bromide for 90 minutes 
at 80 volts to confirm the presence of the NCAM insert in the plasmid DNA. 
 
Cos-7 cells were used as a mammalian expression system for producing NCAM-Fc 
protein.  Cos-7 cells were cultured in DMEM with Glutamax II (Invitrogen), 100 
units/ml penicillin-streptomycin and 10% HI FCS and routinely passaged twice a week 
1:4.  The day prior to transfection cells were plated onto 10 cm plates (2X10
6 
cells per 
plate) and incubated overnight. 
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Cells were transfected using Lipofectamine LTX and Plus reagent (Invitrogen), used 
according to the manufacturer’s instructions for Cos-7 cells.  Briefly, 10 µg of plasmid 
DNA was diluted with 10 µl Plus reagent and 15.6 µl LTX per dish, diluted in DMEM 
containing 10% HI FCS without antibiotics and incubated with cells overnight.  The 
following day media was changed to DMEM with Glutamax II, 100 units/ml penicillin-
streptomycin and 1% ultra low gamma globulin HI FCS (Invitrogen). NCAM-Fc was 
produced and excreted by the cells and harvested after six days.   
 
Media was collected from the plates and filtered (0.2 m) to remove debris and 375 mg 
Protein A sepharose beads (GE Healthcare, Amersham, UK) added which bind to the Fc 
region of NCAM-Fc.  Media and beads were incubated on a shaker overnight at 4C 
and then passed through 10 ml columns with a porous plug that catches the beads.  The 
columns were washed with 20 ml PBS and protein eluted from the beads using 100 mM 
glycine-HCl, pH 2.7.  The pH was neutralised using 1 M Tris-HCl pH 9.  The protein 
was dialysed into PBS and concentrated by centrifugation in a Vivaspin column 
(Millipore) at 4C.  NCAM-Fc protein concentration was determined by absorbance at 
280 nm using the NanoDrop and was aliquoted and stored at -20C until required. 
 
Figure 2.3 Structure of the pIG1 plasmid (courtesy of Prof. D. Simmons) 
A diagram of the structure of the PIG1 vector for the production of soluble, secreted Fc chimeric 
proteins.  cDNA for NCAM-Fc was inserted between the HindIII and BamH1 restriction sites. 
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2.2.10 Sodium dodecyl polyacrylamide gel electrophoresis (SDS-PAGE) and 
Western blotting 
SDS-PAGE was used to separate proteins according to their molecular mass and was 
used for purified protein samples as well as whole cell lysates.  Cell lysates were 
prepared from cells cultured in 6 well plates or 6 cm dishes.  Cells were washed twice 
with cold PBS before the addition of 70-400 l RIPA lysis buffer (Sigma Aldrich, 50 
mM Tris-HCl, pH 8.0, 150 mM sodium chloride, 1% NP-40, 0.5% sodium 
deoxycholate and 0.1% sodium dodecyl sulphate) with the addition of protease inhibitor 
cocktail, (Roche, Welwyn, UK) and phosphatase inhibitors 1 and 2 (Sigma-Aldrich) for 
15 minutes on ice.  Cells were scraped into the lysis buffer and centrifuged at 13000 
RPM for ten minutes at 4C to remove cell debris.  Supernatant was removed, aliquoted 
and stored at -80C until required.  Protein concentration was determined using the 
Bradford protein assay (Bio-Rad, Hemel Hempstead, UK), using BSA as a standard, 
and reading plates on a spectrophotometer at 595 nm.  20 g of protein per well was 
diluted with four times sample buffer (Invitrogen), heated to 70C for five minutes and 
loaded onto a Nupage 4-12% bis tris gel (Invitrogen) for SDS-PAGE separation.  The 
gels were run using Nupage MES running buffer (Invitrogen) for 1.5 hours at 100-150 
volts.   
 
As a control samples were run in duplicate so that one gel could be stained using 
coomassie blue dye (Sigma-Aldrich) to identify whether samples had run correctly and 
to confirm the presence of protein on the gel.  The gel was covered with the dye and 
placed on a shaker for one hour and then destained to reveal protein bands using 40% 
methanol / 40% acetic acid.   
 
Following SDS-PAGE separation, proteins were transferred onto a nitrocellulose 
membrane (Invitrogen) using the Invitrogen
™ 
Xcell II blot module.  Samples were 
transferred for 90 minutes at 135 mamps constant current using Nupage transfer buffer 
(Invitrogen).  The nitrocellulose membrane was blocked with 5% w/v fat free milk in 
Tris Buffered Saline (100 mM NaCl,  10 mM Tris-HCl, pH 7.4 at RT) containing 0.1% 
Tween-TBST) for one hour prior to an overnight incubation with primary antibody (as 
detailed in Table 2.2) at 4ºC with gentle agitation.  Following overnight incubation blots 
were washed three times with TBST and HRP-conjugated secondary antibodies (Dako, 
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Cytomaton, Ely, UK) added for one hour at RT.  After washing, the membrane was 
incubated with advanced ECL reagent (GE Healthcare) for five minutes and film 
developed.  This depends on the combined peroxidase and peroxide catalysed oxidation 
of the Lumigen PS-3 acridin substrate to generate a chemiluminescent signal.  Bands 
were quantified according to their pixel density using Image J software (National 
Institute of Health, USA).  Bands were outlined and mean grey area calculated.  
 
Antibody Diluent Secondary Antibody 
Anti-NCAM (Santa Cruz 
Biotechnology, CA, USA,  
H300 clone) 1:200 
4% milk 1% BSA TBS 0.1% 
Tween 20 
Anti-rabbit HRP (Dako) 
1:2000 
Anti-pan neurofascin (gift from 
P.J. Brophy) 1:1000 
5% milk TBS 0.1% Tween 20 Anti-rabbit HRP 1:2000 
Anti-MBP (in house, RR) 
1:2000 
5% milk TBS 0.1% Tween 20 Anti-mouse HRP (Dako) 
1:2000 
Anti-CNPase (Millipore) 1:2000 5% milk TBS 0.1% Tween 20 Anti-mouse HRP 1:2000 
Anti-MOG (Z12 hybridoma, a 
gift from Sarah Piddleston) 
1:2000 
5% milk TBS 0.1% Tween 20 Anti-mouse HRP 1:2000 
 
Table 2.2 Antibodies used for Western blotting 
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2.3 Results 
 
2.3.1 Characterisation of OPC and CG4 cell differentiation in culture 
To investigate the role that NCAM might have on oligodendrocyte survival we isolated 
O4
+
 OPCs from the postnatal day four rat cerebral cortex and further differentiated them 
in vitro using serum free defined media, to the point where they were pre-myelinating 
oligodendrocytes and would be making axonal contact in vivo.  The differentiation of 
these cells was followed, where they underwent a series of morphological changes and 
expressed well-characterised markers of the oligodendrocyte lineage (Figure 2.4).  
Following isolation cells extended several processes (Figure 2.4a) and a small 
proportion expressed the early progenitor markers A2B5 and NG2 (Figure 2.4b).  A 
minority of the cells were not O4
+
 (approximately 5%) and immunocytochemistry for 
GFAP revealed that they were contaminating astrocytes.  After three days in vitro, cells 
became increasingly complex and many expressed the mature oligodendrocyte marker 
GalC/O1 (Figure 2.4c) and transcription factor olig2 (Figure 2.4d).  
Immunocytochemistry demonstrated the sequential expression of myelin proteins CNP 
(appearing after 1-2 days in culture, Figure 2.4e), MBP (appearing after three days and 
being present in virtually all cells by five days in vitro, Figure 2.4f) and MOG 
(appearing after five days, Figure 2.4g).  This was supported by Western blotting with 
anti-CNP and anti-MBP antibodies on OPC lysates from different time points, whereby 
CNP protein was detected on progenitor cells and MBP appeared after three days 
differentiation (Figure 2.4h-i).  After five days in vitro, many cells had lost the defined 
processes of immature oligodendrocytes and started to produce rafts of myelin-like 
membrane (Figure 2.4g), suggesting that they were equivalent to pre-myelinating 
oligodendrocytes identified in vivo (Hardy and Fredrich, 1996).  Although the OLP 
media promoted the differentiation of OPCs, it did not support prolonged cell survival 
and after more than 5-6 days in culture the number of viable cells decreased radically. 
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Figure 2.4 Morphology and antigen expression of O4
+
 oligodendrocytes 
OPCs were isolated by O4 immunopanning and differentiated in vitro in OLP.  Morphology and 
myelin protein expression were monitored using immunocytochemistry.  After one day in vitro 
cells displayed an immature phenotype with few processes (A) and many expressed the early 
OPC marker A2B5 (green) and a small proportion expressed NG2 (red, B). After three days in 
culture most cells displayed a complex network of processes and expressed the more mature 
marker galactocerebroside (O1, green, C), transcription factor olig2 (red, D) and the early 
myelin protein CNP (red, E). After 3-5 days differentiation, MBP expression was observed (red, 
F), followed by the late myelin marker MOG, in cells which had lost their defined processes and 
instead displayed myelin-like membranes (red, G). Western blotting also confirmed the 
increasing expression of CNP (H) and MBP (I) as cells differentiate.  Blue: DAPI nuclei. Scale 
bars: 50 µm. 
  
85 
 
CG4 cells are a popular oligodendrocyte model owing to their potentially unlimited 
capacity for renewal in the presence of mitogenic growth factors that maintain them as 
early progenitors (Louis et al. 1992).  The differentiation of the CG4 OPC cell line was 
also followed in vitro.  In B104-CM CG4 cells proliferated rapidly, had a bipolar 
morphology and expressed the progenitor markers A2B5 and NG2 but not O4 (Figure 
2.5a-b).  When the media was switched to OLP, which promotes their differentiation, 
cells acquired a multi-processed morphology, lost NG2 immunoreactivity and expressed 
the O4 antigen (Figure 2.5c).  After three days differentiation MBP expression was seen 
in the cell body and some processes, but the morphology of CG4 cells was less complex 
than that of primary OPCs and the expression of myelin proteins less extensive (Figure 
2.5d). 
 
2.3.2 Characterisation of adhesion molecule expression by OPCs and CG4 cells 
Immunocytochemistry and Western blotting demonstrated that NCAM was expressed 
by OPCs and pre-myelinating oligodendrocytes at all time points investigated.  NCAM 
was present on bipolar precursor cells (Figure 2.6a) and then increased after three days 
in culture, where it was expressed on the cell body and processes (Figure 2.6b-c).  As 
cells matured, NCAM was detected in the large processes and the myelin-like 
membrane (Figure 2.6d).  Similarly, NCAM was also expressed by CG4 cells.  It was 
seen on bipolar progenitors (Figure 2.5e) and on differentiated cells (Figure 2.5f).  
Western blotting showed two isoforms of NCAM were expressed by primary 
oligodendrocyte lineage cells and CG4 cells, the 140 kDa transmembrane form and the 
120 kDa GPI-linked isoform, which was expressed at higher levels (Figure 2.6e, Figure 
2.5g).  Upon isolation OPCs expressed the embryonic polysialated form of NCAM, but 
as they matured PSA-NCAM was no longer detected (Figure 2.7a-b).  Additionally, the 
VASE isoform of NCAM was detected on the cell body after five days in vitro, as was 
the adhesion molecule contactin/F3 (Figure 2.7c-d).  The glial isoform of neurofascin 
(NFasc155) was present on OPCs, peaking after approximately three days in vitro 
(Figure 2.7e).   
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2.3.3 Effect of FRM peptide and NCAM-Fc on cell survival 
To investigate the effect of soluble NCAM on OPC survival a small peptide and a full 
length protein were used.  A ten amino-acid cyclised peptide (sequence 
DRVEPYSSTA) corresponding to a region in the first FnIII domain of NCAM 
identified as a potential FGFR activation motif (FRM, Doherty et al. 1996) was used.  
NCAM-Fc consisted of the full extracellular domain of NCAM fused to human 
antibody Fc and was produced using a mammalian expression system (Figure 2.8).  The 
addition of the Fc tag ensures that NCAM does not become incorporated into the 
plasma membrane of the cells that produce it and is instead targeted for excretion 
(Fawcett et al. 1992).  To prepare the NCAM-Fc chimera plasmid DNA was purified 
from transformed E.coli (Figure 2.8a) and to confirm the presence of the NCAM insert 
digested with BamH1 and HindIII restriction endonucleases (Figure 2.8b).  Cos-7 cells 
were transiently transfected with the plasmid DNA and NCAM-Fc was harvested from 
the culture media by binding to protein A beads.  Purified protein was separated by 
SDS-PAGE gel electrophoresis, for coomassie staining or Western blotting with anti-
NCAM, both of which showed a prominent band at approximately 296 kDa 
corresponding to the NCAM-Fc dimer (Figure 2.8c-d).  Additional samples were 
collected throughout the purification process and showed weaker bands corresponding 
to NCAM-Fc and also smaller protein fragments.  
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Insulin is a well characterised OPC survival factor and was used as a positive control when 
measuring cell survival.  As a negative control insulin was removed from the media.  All 
proteins and peptides were added to media without insulin.  Cell survival was measured 
using PI labelling of pyknotic nuclei in conjunction with O4 immunocytochemistry after 4 
days in culture (Figure 2.9).  PI is a dye that is excluded by intact cell membranes so it is 
unable to enter live cells.  Dead cells were identified by intensely stained, shrunken nuclei 
and many had degenerating processes, characteristic of cells undergoing apoptosis (Figure 
2.9b).  To quantify cell survival, the number of O4
+
PI
+
 cells were counted and expressed as 
a proportion of the total number of O4
+
 cells per field.  Therefore, a decrease in O4
+
PI
+
 
cells equates to an increase in cell survival.  Without the addition of growth factors 
(control, Figure 2.9a) 27 ± 7% of O4
+
 cells were PI
+
 after 4 days in culture and this was 
decreased to 16 ± 6% in the presence of insulin (Figure 2.9c, 2.10).  The FRM peptide (5 
µg/ml) produced a significant increase in OPC survival, whereas the scrambled peptide 
which was the same amino-acids as FRM but in a random order had no effect on cell 
survival, suggesting that the effect is not non-specific.  NCAM-Fc (5 and 50 µg/ml, Figure 
2.9e) also significantly increased OPC survival, comparable to that seen with insulin.  The 
effect of insulin, FRM peptide (5 µg/ml) and NCAM-Fc (5 and 50 µg/ml) on survival was 
statistically significant compared to control cells, as assessed by a one way ANOVA 
(Figure 2.10).  In addition the combined effect of either insulin and FRM peptide or insulin 
and NCAM-Fc was greater than any of them singly, with just 10% cell death after four 
days with insulin and NCAM-Fc (Figure 2.11).   
 
As an alternative method of assessing cell survival, the MTS assay was used.  Raw counts 
(Figure 2.12a,c) were converted to express survival as a percentage relative to control cells, 
with control cells being 100% (Figure 2.12b.d).  Exposure to FRM peptide, NCAM-Fc 
(both 5 µg/ml) and FGF2 (0.1 ng/ml) moderately increased OPC survival; however the 
extent of survival was far greater with insulin, where it reached significance (Figure 
2.12a,b).  The level of survival achieved by FRM peptide and NCAM-Fc was similar to 
that observed with FGF2 (Figure 2.12a,b).  The MTS four day survival assay was also 
performed using CG4 cells.  Insulin approximately doubled the level of survival, but FRM 
peptide, NCAM-Fc and FGF2 did not significantly affect CG4 survival compared to 
control cells (Figure 2.12). 
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2.3.4 Effect of FRM peptide and NCAM-Fc on cell proliferation 
To identify whether the increase in survival observed with FRM peptide and NCAM-Fc 
was due to survival per se and not to proliferation, the incorporation of the thymidine 
analogue BrdU was measured.  BrdU was added to cultures after one day in vitro and 
immunocytochemistry for O4 and BrdU carried out the following day.  The proportion 
of proliferating or O4
+
BrdU
+
 cells were expressed as a percentage of the total number of 
O4
+
 cells per field.   Very few proliferating cells (less than 5%) were observed when 
cells were treated with insulin (5 µg/ml), FRM peptide (5 and 50 µg/ml) or NCAM-Fc 
(5 and 50 µg/ml, Figure 2.13a-c, 2.14).  In contrast, addition of FGF2 (0.1-10 ng/ml) 
significantly increased OPC proliferation, to 21 ± 5% with 10 ng/ml FGF2, as assessed 
by a Student’s unpaired t test (Figure 2.14).  The two higher concentrations of FGF2 (1 
and 10 ng/ml) also influenced cell phenotype, with cells displaying a less complex 
morphology, suggesting that differentiation was inhibited (Figure 2.13d-f). 
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2.4 Discussion 
 
2.4.1 Expression of NCAM by cells of the oligodendrocyte lineage 
NCAM expression has previously been demonstrated on cells of the oligodendrocyte 
lineage, both in vivo and in vitro (Bartsch et al. 1989; Bhat and Silberberg 1986; Bhat 
and Silberberg 1988a; Martini and Schachner 1986; Trotter et al. 1989).  In vitro 
immunocytochemistry revealed that A2B5
+
 and O4
+
 cells were almost all NCAM
+
, 
expression being highest on late progenitors but decreased on more mature 
oligodendrocytes, consistent with earlier studies (Bhat and Silberberg 1986; Trotter et 
al. 1989).  The antibodies used in this study bind to all NCAM isoforms so conclusions 
cannot be drawn about the relative abundance of each isoform from 
immunocytochemistry.  In agreement with other studies, we showed via Western 
blotting that two NCAM isoforms (120 kDa and 140 kDa) were expressed, with 
NCAM-120 being the predominant isoform.  However, the antibodies could bind with 
higher affinity to one isoform over the others.  It is possible that the abundance of 
NCAM may have been underestimated in these experiments, as on more mature cells 
NCAM frequently localises to lipid raft microdomains and the method of extracting cell 
lysates used here may not have fully disrupted detergent insoluble fractions of the 
plasma membrane.  In particular, NCAM-120 is known to localise to lipid rafts in 
mature oligodendrocytes (Kramer et al. 1999; Niethammer et al. 2002).  A previous 
study has shown that less than 30% of the total NCAM-120 and about 70% of NCAM-
140 are extracted using Nonidet P-40 containing lysis buffer, as this does not disrupt 
lipid rafts (Bhat and Silberberg 1988a).  Earlier studies only detected NCAM-120 on 
oligodendrocytes and myelin (Bhat and Silberberg 1986).  This may be due to down-
regulation of NCAM-140 on mature cells and at the longest time point we investigated 
(six days in vitro) the cells were immature rather than mature myelinating 
oligodendrocytes.   
 
Early work suggested that the NCAM expressed on oligodendrocytes may differ to that 
of neurons in that it is involved in calcium dependent adhesion (Bhat and Silberberg 
1986).  However, there has been no further evidence to suggest that NCAM mediates 
calcium dependent adhesion and it may be that the effects of other oligodendrocyte 
expressed CAMs were also being observed, such as N-cadherin (Payne and Lemmon 
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1993).  NCAM expression has previously been described on CG4 cells and at levels 
comparable to that of OPCs (Hughson et al. 1998) and our study also confirmed their 
expression of NCAM, suggesting that they may provide a useful model to investigate 
the effects of CAMs on oligodendrocytes.  
 
The peak of NCAM expression at the onset of myelination and its localisation to the 
non-compacted lamellae of the periaxonal collar on the oligodendrocyte and along the 
axolemma of the neuron (Bartsch et al. 1989; Martini and Schachner 1986), makes it an 
ideal candidate to transduce signals between the axon and oligodendrocyte during 
myelination.  The expression of the neuronal isoform of NCAM, NCAM-180, increased 
until postnatal day 14 and declined thereafter, but was maintained at low levels on 
axons in the adult (Bhat and Silberberg 1988a).  Therefore, NCAM-180 on the axon 
may interact with NCAM-120 on the oligodendrocyte to mediate axon-oligodendrocyte 
recognition, leading to myelin wrapping.  This is supported by studies on the quaking 
mouse, a dysmyelinating mutant that has a defect in myelin compaction and reduced 
expression of NCAM-180, suggesting that NCAM-180 may be involved in myelin-
sheath formation (Bhat and Silberberg 1988b).  Moreover, although its expression 
declines with postnatal development, NCAM expression remains in the adult, 
particularly the 120 kDa isoform found in myelin (Bartsch et al. 1989; Bhat and 
Silberberg 1988a; Cox et al. 2009) indicating that it may provide a signal to maintain 
oligodendrocyte survival.  Changes in the relative abundance of NCAM isoforms on 
cells of the oligodendrocyte lineage during development may help control subsequent 
signalling events and be biologically relevant to controlling myelination.   
 
2.4.2 FRM peptide and NCAM-Fc increase cell survival 
We have demonstrated that a soluble protein and a small peptide that can mimic the 
effects of NCAM-NCAM binding increased OPC survival to a similar degree to the 
soluble growth factors insulin and FGF2.  A cyclised version of the FRM peptide was 
used because this had proved more efficacious in earlier studies using neurons and 
fibroblasts compared to monomeric peptides (Anderson et al. 2005).  The increase in 
OPC survival is consistent with a previous study by our group using FRM peptide 
(Anderson et al. 2005) and by another group that coated coverslips with purified 
NCAM (Gard et al. 1996).  NCAM is an abundant molecule and its concentration on the 
surface of neurones has been calculated to approximate 50 µM (Kiselyov et al. 2003).  
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Therefore, the concentrations of the peptide and protein used here are comparable to 
those that would be encountered in vivo.  The dose-response curve for the FGL peptide 
varied between neuronal cell types and for dopaminergic neurons concentrations over 1 
µg/ml were inhibitory (Neiiendam et al. 2004).  However, no inhibitory effect on OPC 
survival was observed at high concentrations of the FRM peptide (50 µg/ml).  A greater 
effect on cell survival was seen using the PI assay compared to the MTS assay.  In the 
PI assay, FRM peptide and NCAM-Fc caused an increase in survival comparable to that 
with insulin, whereas the effect was much lower and did not reach significance in the 
MTS assay.  This may be due to the differing cell densities between assays.  Cells were 
cultured at a much higher density in the MTS assay, in order to detect a signal, whereas 
the PI assay was counted manually so cells were seeded at a low density.  Therefore, 
there would be a greater amount of cell-cell contact in the MTS assay, which may mean 
that NCAM-NCAM binding between cells already operated and could explain why 
FRM peptide and NCAM-Fc were unable to have an additional effect.  
 
FRM peptide proved as efficacious as NCAM-Fc, suggesting that the region conferring 
bioactivity lies with the first FnIII domain of NCAM.  Sequence homology between the 
FnIII regions of NCAM and the FGFR1, led to the hypothesis that they would interact 
with the second Ig domain of the FGFR.  This region is also important for FGF and 
heparin sulphate binding to the FGFR (Doherty and Walsh 1996; Pellegrini et al. 2000; 
Plotnikov et al. 1999).  However, this region has subsequently been shown to be 
dispensable and a region called the ‘acid box’ of the FGFR appears to be important for 
interactions with CAMs.  The acid box is located between Ig domains one and two and, 
whilst it is not required for FGF2 binding, it is essential for the interaction with NCAM 
and N-cadherin (Sanchez-Heras et al. 2006).  Interestingly, whilst NCAM interaction 
has only been demonstrated with FGFR1 and FGFR2 (Christensen et al. 2006), all 
FGFR isoforms can contain the acid box.  Alternative splicing can result in removal of 
this region from all FGFR subtypes, suggesting a possible mechanism for control of 
CAM-FGFR interactions (Sanchez-Heras et al. 2006).  The FnIII domains of NCAM 
and the second Ig domain of the FGFR are located at a similar distance from the plasma 
membrane, enabling an in cis interaction (Anderson et al. 2005).   
 
The functional importance of the first FnIII domain of NCAM was demonstrated using 
an antibody directed against this motif, which was able to inhibit NCAM-stimulated 
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neurite outgrowth (Anderson et al. 2005).  Previously, the FRM peptide has been shown 
to promote both neurite outgrowth and the survival of neurons, oligodendrocytes and to 
a lesser extent fibroblasts.  Such differences in sensitivity may reflect variations in 
receptor expression or signalling microenvironments in these cell types (Anderson et al. 
2005).  The FRM region of NCAM is highly conserved between species and structural 
studies have shown it maps to an exposed descending loop (Figure 2.2, Anderson et al. 
2005).  A similar region in the second FnIII domain of NCAM, designated FGL (FGF 
loop) peptide has been shown to increase neurite outgrowth and survival (Neiiendam et 
al. 2004).  NMR and surface plasmon resonance binding studies demonstrated that FGL 
interacted directly with the FGFR (Kiselyov et al. 2003).  The amino-acid sequence of 
FGL shows no homology with that of FRM, but maps to an ascending loop that has 
structural similarities to FRM, and it is hypothesised that these two loops together 
comprise the FGFR binding domain (Figure 2.2, Anderson et al. 2005; Kiselyov et al. 
2003).  Given that both peptides are able to stimulate a response individually, it 
suggests that it is not necessary for both FGFR binding sites to be occupied, or that the 
peptides may be able to bind to both regions and lead to activation.  The specific amino-
acids involved in the FRM response have been further narrowed down using a 
combination of amino-acid substitutions and various truncated peptides (Anderson et al. 
2005).  The DRVE amino-acids were shown to be important for the stimulatory effects 
of FRM peptide (Anderson et al. 2005).  The FRM region of NCAM is also present in 
other adhesion molecules, such as L1 and N-cadherin (Williams et al. 1994a).  
However, peptides corresponding to this sequence in N-cadherin inhibited outgrowth 
(Williams et al. 2001). 
 
CG4 cells are frequently used as a model of oligodendrocytes to overcome the limited 
supply of primary oligodendrocytes, because oligodendrocytes are post-mitotic and 
their precursors will not divide indefinitely in culture.  CG4 cells arose as a result of a 
spontaneous mutation in primary rat OPCs (Louis et al. 1992).  FRM peptide and 
NCAM-Fc did not stimulate an increase in CG4 cell survival, whereas insulin did.  This 
suggests that CG4 cells do not respond in the same way as primary OPCs, which limits 
their usefulness for future experiments.  We have observed that CG4 cells do not 
differentiate as well as OPCs and it is likely that the effects of NCAM are greater on 
more mature cells, when it would be encountered as a contact-dependent signal in vivo.  
In less mature cells the signalling components may differ to prevent cells from 
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differentiating too soon.  Previously, it has also been shown that CG4 cells do not 
respond in the same way as OPCs to PDGF (Barres et al. 1993b).  Far lower 
concentrations of PDGF were required to stimulate OPC survival compared to 
proliferation, whereas high concentrations were needed to elicit survival and 
proliferation of CG4 cells, raising the possibility that they do not express the same 
PDGF receptors (Barres et al. 1993b).  A higher concentration of FRM peptide and 
NCAM-Fc may be required to stimulate CG4 cells survival.  Differences in the 
signalling pathways activated in CG4s and primary OPCs and in their expression of 
antigenic markers have also been reported (Stariha and Kim 2001).   
 
2.4.3 FRM peptide and NCAM-Fc do not increase cell proliferation 
Neuronal signals are known to be important for OPC proliferation, such as NRG (Hardy 
and Reynolds 1993b; Canoll et al. 1996).  Previous studies investigating the effects of 
NCAM on neurons and fibroblasts have demonstrated that NCAM and NCAM peptides 
do not increase proliferation (Anderson et al. 2005).  However, as neurons are post-
mitotic in contrast to OPCs, we investigated whether FRM peptide or NCAM-Fc could 
induce OPC proliferation.  Neither the peptide nor full length protein significantly 
affected proliferation compared to that produced by insulin, a growth factor that 
promotes the survival and maturation of OPCs (Barres et al. 1992; Barres et al. 1993b).  
This agrees with the study by Gard et al (1996) that demonstrated an increase in 
oligodendrocyte survival when cells were cultured on substrate bound NCAM in the 
absence of proliferation.  This is interesting because FGF2 does stimulate OPC 
proliferation and as the FRM peptide is reported to act by interacting with the FGFR, it 
suggests that the two are able to elicit distinct responses whilst binding to the same 
receptor.  Following treatment with high concentrations of FGF2 (10 ng/ml), OPCs 
retain a more immature phenotype and differentiation is inhibited, which is consistent 
with previous studies (McKinnon et al. 1990).  FRM peptide and NCAM-Fc do not 
appear to inhibit differentiation, as cells treated with them differentiated in the same 
manner as those treated with insulin.  However, lower concentrations of FGF2 (0.01-0.1 
ng/ml) stimulated OPC survival in the absence of a mitogenic effect, which is 
comparable with results observed in fibroblasts (Garcia-Maya et al. 2006).  It appears 
that FRM peptide may mimic the effects of low level FGF2 in fibroblasts, which 
express FGFRs but not endogenous NCAM, in that it stimulates survival and inhibits 
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proliferation (Anderson et al. 2005).  Our results suggest that FRM peptide may behave 
in a similar way to low concentrations of FGF2 on OPCs. 
 
2.4.4 Conclusions 
This study has demonstrated that OPCs can be isolated from the neonatal rat brain at the 
late progenitor stage and differentiated in vitro.  We have confirmed the expression of 
the 120 kDa and 140 kDa isoforms of NCAM on OPCs and pre-myelinating 
oligodendrocytes.  Mimicking the effects of axonal NCAM using the FRM peptide and 
NCAM-Fc increased cell survival.  FRM peptide was able to increase survival to the 
same extent as NCAM-Fc, which suggests that the region important for inducing cell 
survival is contained within the FnIII domain and that the other regions of the molecule 
are not required.  However, other regions of the molecule are likely to be involved in 
mediating homophilic binding. The survival effect of FRM peptide and NCAM-Fc was 
independent of an effect on proliferation.  These results suggest that an interaction 
between axonal NCAM and NCAM on pre-myelinating oligodendrocytes might be a 
vital signal for matching oligodendrocyte number to the number of axons requiring 
myelination. 
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Chapter 3 
 
 
 
 
 
Mechanism of soluble NCAM-mediated oligodendrocyte survival 
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3.1 Introduction 
 
3.1.1 Signalling pathways involved in oligodendrocyte survival 
Despite the recognition that several soluble growth factors, such as insulin, PDGF, 
FGF2 and NRG, are required to maintain oligodendrocyte survival, the intracellular 
mechanisms regulating these processes are less well understood.   
 
3.1.1.1 Insulin 
Insulin/IGF-1 has been assigned a role in maintaining oligodendrocyte survival (Barres 
et al. 1992; Barres et al. 1993b) and in supporting differentiation via regulation of 
myelin gene expression (Carson et al. 1993; Bibollet-Bahena and Almazan 2009).  
Some studies have shown that IGF1 increased OPC proliferation (Cui et al. 2007; 
McMorris and Dubois-Dalque 1988), although this study and others found no increase 
in proliferation in response to insulin (Barres et al. 1993b).  Insulin acts via the IGF-1 
receptor, a heterotetramer with intrinsic tyrosine kinase activity that phosphorylates the 
scaffolding adapter proteins insulin receptor substrates 1 and 2 (IRS1/2).  Insulin can 
activate two main downstream signalling pathways, the PI3K/serine threonine kinase 
Akt pathway and the Ras-Raf-MAPK pathway, with crosstalk between the two 
pathways reported in some studies but not in others (Cui et al. 2005; Cui et al. 2007; 
Palacios et al, 2005).  Inhibitors of PI3K, MEK and Fyn have been shown to prevent 
IGF1 mediated OPC proliferation (Cui et al. 2007; Frederick et al. 2007).  PI3K can be 
activated directly by IRS and subsequently phosphorylates phosphatidlyinositol-2-
phosphate (PIP2) to become PIP3, which is able to phosphorylate Akt.  Downstream 
targets of PI3K/Akt include inhibition of glycogen synthase kinase-3β (GSK3β), which 
leads to stabilisation of cyclin D and therefore increased proliferation, and the inhibition 
of pro-apoptotic proteins caspase-3 and Bad, thereby promoting survival. 
 
The MAPK cascade consists of a set of highly conserved molecules, involved in 
numerous cell processes, for example proliferation, survival, differentiation and 
migration, as illustrated in Figure 3.1.  MAPK signalling may be activated by growth 
factors or cell stress and include extracellular signal-regulated kinases 1 and 2 
(ERK1/2), which are the classical MAPKs, and p38 and c-Jun-amino-terminal kinase 
(JNK), typically considered stress kinases.  ERK, p38 and JNK are activated by two 
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levels of serine threonine kinases, such as Raf and then MEK, which phosphorylate 
ERK on threonine and tyrosine residues.  The targets of MAPK include transcription 
factors and also cytosolic proteins that regulate cellular function. 
 
Figure 3.1 MAPK signalling, adapted from www.cellsignal.com 
An illustration of the different proteins involved in the three levels of MAPK signalling. MAPK 
(mitogen activated protein kinase), ERK (extracellular signal-regulated kinase) MEK 
(MAPK/ERK kinase), JNK (c-Jun-amino-terminal kinase), BMK (big MAP kinase), SAPK (stress-
activated protein kinase), MLK3 (mixed lineage kinase), ASK1 (apoptosis signal-regulating 
kinase). 
  
3.1.1.2 FGF2 and PDGF 
FGF2 and PDGF increase OPC survival and proliferation via specific growth factor 
receptors (Barres et al. 1992; Barres et al. 1993b; McKinnon et al. 1990).  Activation of 
the FGFR enables interaction with the adapter proteins FGF receptor substrate 2 (FRS2) 
and Shc, which provide docking sites for Src homology 2 (SH2) domain proteins, such 
as Grb2 (Kouhara et al. 1997).  Induction of OPC proliferation by PDGF and FGF2 is 
said to involve ERK, p38 and pp70 S6 kinase signalling (Baron et al. 2000; Bansal et al. 
2003).  Activation of PKC by PDGF and FGF2, leads to reorganisation of the actin 
cytoskeleton and may inhibit differentiation (Baron et al. 2000).  Inhibition of PI3K 
resulted in a partial reduction in PDGF-induced proliferation but did not affect that of 
FGF2 (Baron et al. 2000), consistent with reports that activation of the FGFR does not 
lead to signalling via PI3K (Bansal 2002; Mohammadi et al. 1996).  However, other 
studies have demonstrated Akt phosphorylation in response to FGF2 in neurons 
108 
 
(Ditlevsen et al. 2008a).  The mitogenic response to FGF2 in OPCs signals via MAPK 
(Baron et al. 2000; Frederick et al. 2007).   
 
Different FGFR subtypes are expressed depending on the stage of differentiation.  
FGFR3 is expressed maximally at the late progenitor stage when cells enter terminal 
differentiation and then is down-regulated; FGFR1 is expressed at relatively low levels 
but at all stages of maturation, whereas FGFR2 is upregulated on mature 
oligodendrocytes (Bansal et al. 1996).  FGFR3 has been suggested to be the important 
FGFR subtype for controlling differentiation, as illustrated by FGFR3-null mice, where 
oligodendrocyte differentiation was delayed (Oh et al. 2003).  In this study proliferation 
was not affected, suggesting that proliferation and differentiation are controlled 
independently and that cessation of proliferation was not sufficient to induce 
differentiation, indicating that an alternative positive signal is required to promote 
maturation (Oh et al. 2003).   
 
In addition to regulation via the expression of different receptor subtypes, FGF2 itself 
can elicit pleiotropic effects via FGFRs depending on its concentration, leading to 
activation of different signalling components (Garcia-Maya et al. 2006).  In NIH3T3 
mouse fibroblasts low (0.1 ng/ml) and high (100 ng/ml) levels of FGF2 stimulated 
survival and differentiation but inhibited proliferation, whereas intermediate 
concentrations (1-10 ng/ml) caused proliferation in the presence of serum but apoptosis 
in its absence (Garcia-Maya et al. 2006).  Evaluation of the signalling proteins activated 
showed that p38 activation increased as FGF2 concentration rose, whereas ERK 
phosphorylation required a threshold of 10 ng/ml FGF2.  Pharmacological inhibitors 
showed that fibroblast apoptosis was dependent on ERK, whereas proliferation was 
dependent on FRS2 and p38 (Garcia-Maya et al. 2006).  This suggests that, in the 
absence of other survival pathways, ERK activation leads to apoptosis, highlighting the 
complexity in signalling activated by a single ligand and also differences in pathways 
activated in different cell types.   
 
3.1.2 Signalling pathways involved in NCAM-mediated survival 
A role for NCAM and NCAM peptides in cell survival has been described in a number 
of studies (Anderson et al. 2005; Ditlevsen et al. 2003; Ditlevsen et al. 2007a; 
Neiiendam et al. 2004; Pedersen et al. 2004).  Whilst the activation of several signalling 
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pathways in response to NCAM have been described in neurones (Ditlevsen et al. 2003; 
Ditlevsen et al. 2007a; Neiiendam et al. 2004; Pedersen et al. 2004), the stimulation of 
intracellular signalling by NCAM in oligodendrocytes has not previously been explored.  
NCAM does not have intrinsic enzymatic activity.  Therefore, interaction with other 
signalling proteins is required to stimulate signal transduction. 
    
3.1.2.1 Interaction with the FGFR and Fyn 
A major way in which NCAM can activate intracellular signalling is through an 
interaction with the FGFR.  Early experiments used a number of approaches to 
demonstrate the NCAM/FGFR interaction and link it to functional responses, for 
example, antibodies to the FGFR (Williams et al. 1994a), tyrosine kinase inhibitors 
(Williams et al. 1994b) and dominant negative FGFR constructs (Saffell et al. 1997), all 
of which inhibited neurite outgrowth in primary neurones or PC12 cells grown over 
monolayers of NCAM-expressing fibroblasts.  However, these data only provided 
indirect evidence that the FGFR was involved in NCAM signalling.  More recently 
direct binding of NCAM and the FGL peptide to the FGFR have been demonstrated 
using binding studies (Kiselyov et al. 2003).  Furthermore, NCAM peptide-induced 
phosphorylation of the FGFR has been detected following immunoprecipitation and 
Western blotting in both wildtype PC12 and fibroblast cells (Anderson et al. 2005; 
Saffell et al. 1997) and in HEK293 cells over-expressing the FGFR (Kiselyov et al. 
2003).  The mechanism of FGFR activation by NCAM is not well understood, but it is 
thought that interaction of NCAM with the FGFR induces receptor dimerisation, 
leading to autophosphorylation of tyrosine residues, in a similar way to activation with 
FGF.   
 
NCAM binding also leads to activation of Fyn and focal adhesion kinase (FAK), which 
sequentially activates MAPK signalling (Beggs et al. 1994; Beggs et al. 1997; Ditlevsen 
et al. 2007a; Schmid et al. 1999).  This is thought to occur independently of FGFR 
activation.  Clustering of NCAM induces autophosphorylation of the closely associated 
Fyn molecules at the cell surface, leading to recruitment of FAK via its SH2 domain 
(Beggs et al. 1997).  FAK interacts with the adapter proteins Grb2 or Cas, leading to 
activation of Ras and subsequent MAPK activation (Kolkova et al. 2000a; Schmid et al. 
1999).  The possible activation of Fyn by NCAM in oligodendrocytes is of particular 
interest because Fyn has been shown to have an important role in myelination, but its 
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upstream activators are not known.  Fyn is activated by growth factors in a number of 
other cell types, but interestingly was not activated by FGF2 or PDGF in 
oligodendrocytes (Osterhout et al. 1999). 
 
3.1.2.2 Downstream signalling 
Fewer studies have addressed the mechanisms involved in the neuroprotective effects of 
NCAM compared to its role in neurite outgrowth, although it appears that many 
signalling proteins are involved in both responses.  However, signalling pathways 
involved in neuronal survival are not identical to those required for neurite outgrowth.  
The use of pharmacological agents to inhibit the effects of the C3 and FGL peptide have 
shown that FGFR, Fyn, MAPK, PI3K, cyclic GMP, PKA and PKC are involved in both 
responses, whereas phospholipase C (PLC) and calcium-calmodulin-dependent kinase II 
are only necessary for neurite outgrowth (Ditlevsen et al. 2007a; Ditlevsen et al. 2007b; 
Neiiendam et al. 2004, Figure 3.2).  Examination of the levels of phosphorylated ERK, 
Akt and CREB in neurons treated with a variety of inhibitors enabled the identification 
of their upstream activators in response to FGF2 and the C3 peptide, which showed 
some differences between pathways activated by FGF2 and C3 (Ditlevsen and Kolkova 
2008, Figure 3.2).  In addition, different signalling pathways have been shown to be 
important for neuroprotection versus neurite outgrowth in response to L1, and these 
pathways are different again to those activated by NCAM (Loers et al. 2005).  
 
 
Figure 3.2 NCAM versus FGF2 signalling (Ditlevsen and Kolkova 2008) 
A schematic and simplified version of signalling pathways required for activation of ERK (A), Akt 
(B) and CREB (C) by C3 peptide (blue arrows) and FGF2 (red arrows) in cerebellar granular 
neurons. 
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3.1.3 Hypothesis 
This chapter addressed the hypotheses that:  
1.  NCAM mimetics FRM peptide and NCAM-Fc can activate intracellular 
signalling in oligodendrocytes  
2. the FGFR participates in NCAM-mediated signalling.   
 
3.1.4 Aims 
It was the aim of this chapter to test the above hypotheses using an oligodendrocyte cell 
model.  Having established in the previous chapter that soluble versions of NCAM 
could increase the survival of pre-myelinating oligodendrocytes, we sought to elucidate 
the mechanism of action.  An interaction between NCAM and the FGFR has been 
shown to be important in neuronal survival and neurite outgrowth, but this has not been 
explored in oligodendrocyte lineage cells.  This study aimed to establish whether the 
NCAM mimetics, FRM peptide and NCAM-Fc, can activate intracellular signalling in 
oligodendrocytes, and if this was dependent on the FGFR.  Signalling proteins that had 
defined roles in NCAM-mediated neuronal survival or in oligodendrocyte formation 
were investigated.  This was carried out using several small molecule pharmacological 
inhibitors in the O4/PI survival assay and by assessing the activation status of 
intracellular signalling proteins via Western blotting.    
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3.2 Methods 
 
3.2.1 Cell culture 
OPCs were isolated by O4
+
 immunopanning as described in Chapter 2.2.1, further 
differentiated in vitro and cell survival measured using PI labelling of pyknotic nuclei.  
To investigate the signalling pathways underlying the NCAM-mediated response, 
several small molecule inhibitors were utilised, as detailed in Table 3.1 (all purchased 
from Calbiochem, via Merke Chemicals Ltd, Nottingham, UK).  These inhibitors were 
added to the OLP medium with or without insulin, FRM peptide or NCAM-Fc on the 
day of cell isolation.  They were solubilised in DMSO and added to culture medium so 
that final DMSO concentration was 0.1% when media was changed to defined OLP.  
0.1% DMSO was also added to media without inhibitors to ensure the DMSO did not 
affect cell viability.   
Compound Target Working Concentration Catalogue number 
PD173074 FGF receptor 50 nM 341607 
LY294002 PI3 kinase 2 and 10 µM 440204 
PD98059 
MEK1/2 kinase 
 
2 and 50 µM 513000 
PP2 Src kinase 1 µM 529573 
SB203580 P38 kinase 1 and 5 µM 559389 
 
Table 3.1 Small molecule inhibitors used in OPC survival assay 
 
CG4 cells were cultured as described in Chapter 2.2.3. They were maintained in an 
undifferentiated state using B104-CM and differentiated using OLP.  NIH3T3 mouse 
fibroblasts (a generous gift from Dr Jane Saffell) were maintained in DMEM containing 
2 mM L-glutamine, 100 units/ml penicillin-streptomycin and 10% HI FCS and routinely 
passaged using 0.25% Trypsin EDTA twice a week. 
 
3.2.2 FGF receptor immunoprecipitation 
Following O4 immunopanning, primary OPCs were expanded using B104-CM.  OPCs 
or CG4 cells were then plated onto PDL coated 6 cm dishes at a density of 1X10
6
 cells 
per plate and 3T3 cells at 2X10
6
 per plate.  Cells were starved of growth factors (CG4 
and OPCs) or serum (3T3s) for five hours using OLP or DMEM, respectively and then 
stimulated with FGF2 (1-10 ng/ml), FRM peptide (5 µg/ml) or NCAM-Fc (5 µg/ml) for 
ten minutes at 37°C.  Cells were then rinsed with cold PBS on ice and lysed in 400 µl 
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RIPA buffer containing protease and phosphatase inhibitor cocktails for 15 minutes on 
ice, before vortexing, scraping and transferring to an eppendorf tube.  Insoluble material 
was cleared by centrifugation for ten minutes at 1000 RPM and 4°C.  The cleared 
lysates were incubated with primary antibody (Table 3.2) overnight at 4°C on a rotating 
wheel.  Protein A sepharose beads (GE Healthcare) were rehydrated with PBS and 20 µl 
of beads added to the tubes containing lysates and antibody.  Immune complexes were 
incubated for a further two hours at 4°C on a rotating wheel.  To remove unbound 
protein, lysates were centrifuged at 8000 RPM, supernatant removed and the beads 
washed in 1 ml RIPA buffer. Three wash steps were performed, and then beads were 
resuspended in 4X protein sample buffer and boiled for ten minutes to disrupt protein 
binding.  Samples were briefly centrifuged so that beads settled at the bottom of the 
tube and the supernatant resolved by SDS-PAGE gel electrophoresis and Western 
blotting as described in Chapter 2.2.10.  
 
Antibody Dilution 
Immunoprecipitation 
Dilution Western Blotting 
Rabbit anti-FGFR1 (Santa 
Cruz) 
20 µl (4 µg) per lysate 1:200 in 5% milk TBS 0.1% 
Tween 20 
Rabbit anti-Bek (FGFR2, 
Santa Cruz) 
20 µl (4 µg) per lysate 1:200 in 5% milk TBS 0.1% 
Tween 20 
Rabbit anti-FGFR3 (Santa 
Cruz) 
20 µl (4 µg) per lysate 1:200 in 5% milk TBS 0.1% 
Tween 20 
Mouse anti-phosphotyrosine 
(4G10, Millipore) 
4 µl (4 µg) per lysate 1:500 in 5% BSA TBS 0.1% 
Tween 20 
Anti-phospho FGFR (Cell 
Signaling Technology) 
 1:500 in 5% BSA TBS 0.1% 
Tween 20 
 
Table 3.2 Antibodies used for FGFR immunoprecipitation and Western blotting. 
 
3.2.3 Western blotting 
To investigate the activation status of a variety of intracellular signalling proteins, 
Western blotting on whole cell lysates was carried out.  Samples were prepared and run 
as described in Chapter 2.2.10, using the antibodies listed in Table 3.3.  
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Antibody Diluent Secondary Antibody 
Anti-AKT (Cell Signaling 
Technology, Boston, MA, USA) 
1:1000 
5% BSA TBS 0.1% Tween 20 Anti-rabbit HRP 1:2000 
Anti-phosphoAKT (Ser473) 
(Cell Signaling Technology) 
1:500 
5% BSA TBS 0.1% Tween 20 Anti-rabbit HRP 1:2000 
Anti-ERK1/2 (Cell Signaling 
Technology) 1:1000 
5% BSA TBS 0.1% Tween 20 Anti-rabbit HRP 1:2000 
Anti-phosphoERK1/2 
(Thr202/Tyr204) (Cell 
Signaling Technology) 1:1000 
5% BSA TBS 0.1% Tween 20 Anti-rabbit HRP 1:2000 
Anti-p38 (Cell Signaling 
Technology) 1:1000 
5% BSA TBS 0.1% Tween 20 Anti-rabbit HRP 1:2000 
Anti-phospho p38 
(Thr180/Tyr182) (Cell 
Signaling Technology) 1:500 
5% BSA TBS 0.1% Tween 20 Anti-rabbit HRP 1:2000 
Anti-Fyn (Santa Cruz) 1:200 5% milk TBS 0.1% Tween 20 Anti-rabbit HRP 1:2000 
Anti-phospho Src (Invitrogen) 
1:1000 
5% BSA TBS 0.1% Tween 20 Anti-rabbit HRP 1:2000 
 
Table 3.3 Antibodies used for Western blotting. 
 
3.2.4 Real-time quantitative polymerase chain reaction (RT-qPCR) 
To prepare cells for RNA extraction they were removed from the tissue culture plate 
using trypsin-EDTA, centrifuged and the media aspirated.  RNA was extracted using an 
RNeasy mini kit (Qiagen), as per kit instructions.  RNA concentration was determined 
by spectrophotometry.   
 
Reverse transcription to obtain first stand cDNA from extracted mRNA was carried out 
using QuantiTect® reverse transcription kit (Qiagen), as per manufacturer’s 
instructions.  Briefly, 1 µg RNA was diluted to 14 µl in RNAse-free water and 2 µl 
genomic DNA wipeout was added and incubated at 42°C for two minutes to remove 
any contaminating DNA.  6 µl of reverse transcription master mix was then added, 
consisting of 1 µl Quantiscript reverse transcriptase, 4 µl Quantiscript 5X buffer and 1 
µl primer mix.  This was incubated at 42°C for 15 minutes and inactivated at 95°C for 
three minutes. 
 
The QuantiTect® SYBR green kit and QuantiTect® primer assays, consisting of a 
mixture of forward and reverse primers (both Qiagen), were used for real-time, two-step 
RT-PCR, according to the manufacturer’s instructions and reactions were performed 
using a Strategene MX3000p™ system with software version 4.01 (Strategene, La Jolla, 
USA).  The sequences of the QuantiTect® primers (listed in Table 3.4) used are 
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proprietary information of Qiagen.  For each sample 25 µl reactions were set up in 
duplicate, consisting of 1 µl template cDNA, 9 µl RNAse-free water, 2.5 µl primer and 
12.5 µl SYBR green reagent.  Internal controls consisting of reverse transcription 
reactions set up without the reverse transcriptase enzyme and also PCR reactions 
without cDNA were included on all plates.  The thermal cycling conditions for all 
samples and controls consisted of an initial activation step of 15 minutes at 95°C, to 
activate the hotstar Taq DNA polymerase, followed by 40 cycles of denaturation (15 
seconds at 94°C), annealing (30 seconds at 55°C) and extension (30 seconds at 72°C) 
and finally a melting curve with a ramp from 55°C to 95°C, as illustrated in Figure 3.5.  
Fluorescent data was collected during the annealing step.  To control for variation 
across different cDNA samples the same cDNA was used to investigate the expression 
of a reference gene (GAPDH) and the expression level of target genes was normalised 
to the expression of the reference gene in that particular sample using the provided 
software.  Each experimental condition was carried out in duplicate and experiments 
were repeated three times.  Subsequent statistical analysis was performed using 
GraphPad Prism software version 4.1. 
 
Gene symbol Official gene name Entrez 
gene ID 
Accession 
no. 
Amplicon 
length 
Catalogue 
no. 
Fgfr1 Fibroblast growth factor 
receptor 1 
79114 NM_024146 72 bp QT00180992 
Fgfr2 Fibroblast growth factor 
receptor 2 
25022 NM_0127121 94 bp QT01600893 
Fgfr3 Fibroblast growth factor 
receptor 3 
84489 NM_053429 109 bp QT00188944 
Gapdh Glyceraldehyde-3-
phosphate 
dehydrogenase 
24383 NM_017008 149 bp QT00199633 
 
Table 3.4 Primers used for RT-qPCR 
 
 
3.2.5 Protein Array 
In order to investigate the activation of a number of intracellular signalling proteins a 
human phospho-MAP kinase protein array kit (R and D Systems Ltd, #ARY002) was 
used, as this enables multiple antibodies to be used at once.  Following immunopanning, 
OPCs were expanded using B104-CM and then plated onto four 6 cm PDL-coated 
dishes.  Media was then switched to OLP with no growth factors overnight.  The 
following day plates were stimulated for 15 minutes with either no growth factors 
(control), insulin (5 μg/ml), FRM peptide (5 μg/ml) or NCAM-Fc (5 μg/ml).  Cells were 
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lysed using the buffer provided, as per kit instructions, and protein samples were 
incubated with the nitrocellulose membrane that has the antibodies to signalling proteins 
spotted onto it overnight at 4ºC on a shaker.  Both phosphorylated and 
unphosphorylated proteins bind to the membrane.  The membrane was washed and the 
detection antibody cocktail, which contains biotinylated phospho-site specific 
antibodies, was added for two hours at RT on a shaker.  After washing, streptavidin-
HRP was added for 30 minutes, followed by detection with ECL.  Film was exposed to 
the membrane for different lengths of time in order to get the optimal exposure for the 
different antibodies.  All reagents were part of the kit except the ECL (GE Healthcare). 
In total, 21 antibodies were spotted onto each membrane, in duplicate, plus a number of 
secondary antibody and PBS negative controls. 
 
The protein array was analysed using Image J (NIH, USA) and Excel.  Films were 
scanned and a circle was drawn around the antibody spots on the film and pixel density 
measured using Image J.  Results were exported to Excel, where PBS control 
background was removed and an average for the duplicate spots calculated for each 
antibody.  Data was presented as a bar chart to allow comparison of each antibody 
between the different cell treatments.  The fold difference relative to the control was 
also calculated.    
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3.3 Results 
 
3.3.1 Involvement of FGFR activation in NCAM-mediated survival 
To investigate whether the survival effect of FRM peptide and NCAM-Fc were 
dependent on the FGFR, we used the small molecule inhibitor PD173074 at 50 nM.  
PD173074 is an ATP-competitive reversible inhibitor of all FGFRs with an IC50 of 21.5 
nM.  It has been shown to be selective up to 1 µM, having no effect on IGF1 or PDGF 
responses and to be active in culture for prolonged periods (Bansal et al. 2003; Skaper 
et al. 2000).  Its specificity was confirmed in our assay by the lack of an effect on 
control and insulin treated cells (Figure 3.3).  PD173074 significantly inhibited the 
survival response to FGF2 (0.1 ng/ml), FRM peptide (5 µg/ml) and NCAM-Fc (5 
µg/ml), increasing the number of O4
+
PI
+
 cells and leading to a return to approximately 
control levels of survival, suggesting that signalling via the FGFR was exclusively 
responsible for mediating the increase in OPC survival (Figure 3.3).  
 
To confirm the involvement of the FGFR in the NCAM-mediated survival response we 
sought to detect an increase in phosphorylated FGFR following treatment with FRM 
peptide and NCAM-Fc.  Immunoprecipitation followed by Western blotting was carried 
out on cell lysates from 3T3 fibroblasts, CG4 cells and primary OPCs.  The expression 
of FGFRs are typically low, making detection of protein levels difficult.  Therefore, we 
first confirmed if we could detect the activated receptors in fibroblast cells (as phospho-
FGFR has previously been detected in these cells, Anderson et al. 2005) and CG4 cells.  
Following a ten minute stimulation with FGF2 and immunoprecipitation of FGFR1, 
phospho-FGFR was detected in fibroblast cells (Figure 3.4a).  The doublet band is 
present because fibroblasts express both α and β subtypes of FGFR1, containing two or 
three Ig domains, respectively.  However, phospho-FGFR was detected both in the 
absence and presence of FGF2 in CG4 cell lysates (Figure 3.4a).   We then repeated this 
using OPC cell lysates (Figure 3.4b).  Immunoprecipitation of the FGFR1 followed by 
immunoblotting for phospho-FGFR did not detect FGFR in the OPCs (Figure 3.4bi-iii).  
We also carried out immunoblotting on whole cell lysates from OPCs without 
immunoprecipitation (Figure 3.4biv-vi).  No difference in the level of phospho-FGFR 
was observed between control and FRM peptide and FGF2 treatments.  In addition, 
immunoprecipitation of the FGFR1 (Figure 3.4c), FGFR2 and FGFR3 from OPC 
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lysates, followed by immunoblotting with anti-phosphotyrosine detected no phospho-
FGFR. 
 
As the level of FGFR protein expressed by OPCs was too low to detect by Western 
blotting, we investigated the expression of different FGFR subtypes at the mRNA 
levels, using quantitative RT-PCR.  RT-PCR was carried out using primers to FGFR1, 
FGFR2 and FGFR3, optimised by Qiagen and a Stratagene MX3000p™ system 
compared to GAPDH (Figure 3.5).  All three FGFR subtypes were detected in our 
OPCs (Figure 3.6).  The levels of FGFR1 increased moderately in more mature cells 
(six days differentiated) compared to undifferentiated cells (Figure 3.6a).  FGFR2 levels 
were increased more than ten fold in differentiated cells compared to undifferentiated 
and late progenitors (Figure 3.6b).  FGFR3 levels were higher in late progenitors and 
mature cells than undifferentiated cells, peaking after three days differentiation (Figure 
3.6c).  
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3.3.2 Downstream signalling pathways 
To examine the pathways that may be involved in NCAM-mediated OPC survival we 
first used a protein array kit, which allowed multiple intracellular protein targets that are 
commonly involved in cell signalling to be investigated simultaneously. The kit 
specifically detects phosphorylated or active proteins that are part of the MAPK 
signalling cascade (Figure 3.7).  After exposing film to the membrane for ten minutes, 
the greatest increase in signal was observed in insulin-treated cells binding to the Akt 
antibodies, where the signal was up to 30 fold higher than in control cells (Figure 3.7a).  
A higher signal was also seen for HSP27, GSK3β, RSK2 and P70 S6K, particularly 
following insulin treatment (Figure 3.7a). Changes in ERK1/2 phosphorylation after a 
five minute exposure showed that, whilst ERK2 was phosphorylated in treated and 
untreated cells, a greater increase in phosphorylation relative to control cells was seen 
for ERK1 (Figure 3.7b).  Levels of phospho-Akt 1, 2 and 3 were increased following 
insulin, FRM peptide and NCAM-Fc treatment (Figure 3.7c).  The increase was much 
greater with insulin stimulation and highest with the Akt2 and pan Akt antibodies 
(Figure 3.7c).  The levels of all isoforms of p38 did not vary between treatments, 
suggesting insulin, FRM peptide and NCAM-Fc do not increase p38 phosphorylation 
(Figure 3.7d). Similarly, there was only a small increase in phosphorylation of JNK 
proteins 1, 2 and 3 compared to control cells (Figure 3.7e).   
  
A.) 10 minute exposure
B.) ERK
AA 
BB
A=ERK1  Control   Insulin  FRM peptide NCAM-Fc
B=ERK2  
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C.) Akt
AA BB
CC DD
A=Akt1    Control    Insulin   FRM peptide NCAM-Fc
B=Akt2  
C=Akt3
D=panAkt
D.) p38
AA BB
CC DD
A=p38δ   Control    Insulin   FRM peptide NCAM-Fc 
B=p38γ   
C=p38β 
D=p38a
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E.) JNK
AA BB
   CC
   DD
         Control Insulin FRM peptide NCAM-Fc
A=panJNK
B=JNK1
C=JNK2
D=JNK3
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3.3.2.1 MAP kinase signalling 
To investigate whether the MAPK signalling pathway was a downstream mediator in 
the FRM peptide or NCAM-Fc-stimulated OPC survival response, the MEK inhibitor 
PD98059, which has an IC50 of 2 µM, was used in the O4/PI survival assay at 2 and 50 
µM.  PD98059 has been reported to be selective for MEK and acts via an allosteric 
mechanism (Dudley et al. 1995).  PD98059 did not affect control cells, but significantly 
inhibited the insulin, FRM peptide and NCAM-Fc-induced responses at 50 µM and the 
insulin and FRM peptide responses at 2 µM (Figure 3.8a).  The involvement of MAPKs 
was confirmed by Western blotting for phospho-ERK 1 and 2, where a 20-30% increase 
in phosphorylated ERK 1 and 2 compared to total ERK 1/2 or actin was detected 
following a 15 stimulation with insulin, FRM peptide and NCAM-Fc (5 µg/ml, Figure 
3.8b-c).  A time course investigating the levels of ERK 1 and 2 after a five minute to 24 
hour stimulation showed that the levels were higher after a short stimulation and had 
returned to approximately control levels after four hours (Figure 3.8d).  
 
3.3.2.2 PI3 kinase signalling 
A pharmacological inhibitor of PI3K was used to investigate if this well-described 
survival pathway was involved in FRM peptide and NCAM-Fc mediated OPC survival.  
LY294002 is a selective for PI3K that blocks all subtypes and has an IC50 of 1.4 µM.  
LY294002 was used at 2 and 10 µM in the O4/PI survival assay, where it significantly 
inhibited the survival effect of insulin (5 µg/ml) and PDGF (1 ng/ml) at both 
concentrations, and that of FGF2 (0.1 ng/ml) at 10 µM (Figure 3.9a).  The higher 
concentration had a slight effect on FRM peptide and NCAM-Fc responses, but this did 
not reach significance (Figure 3.9a).  Western blotting to detect the activated form of 
Akt, which lies downstream of PI3K, demonstrated an increase in phospho-Akt 
following a 15 minute stimulation with insulin but not FRM peptide or NCAM-Fc 
(Figure 3.9b-c), suggesting that the PI3K pathway is not involved in NCAM-mediated 
OPC survival. 
 
  
128
129 
 
Figure 3.8 FRM peptide and NCAM-Fc mediated OPC survival are MAPK dependent. 
OPCs were incubated with insulin (5 µg/ml), FRM peptide (5 µg/ml), NCAM-Fc (5 µg/ml) or 
FGF2 (0.1 ng/ml) in the presence or absence of the MEK inhibitor PD98059 (2 and 50 µM), and 
oligodendrocyte survival measured using propidium iodide (PI) uptake 4 days later. PD98059 
significantly inhibited the survival effect of insulin, FRM peptide and NCAM-Fc (A). Control cells 
were grown in medium without insulin. Results are shown as mean ± SEM of at least 3 
independent experiments, with each experiment analysed in triplicate assessed by a one way 
ANOVA and Bonferroni post-hoc test. Asterisks indicate a significant difference between groups 
(*p<0.05, **p<0.01, ***p<0.001). NS none significant. 
 
B-D. Immunoblot analysis of OPC cell lysates from untreated (i), insulin (ii), FRM peptide (iii) or 
NCAM-Fc (iv) treated cells revealed an increase in phosphorylated ERK1/2 in OPCs stimulated 
by insulin, FRM peptide and NCAM-Fc compared to control cells. B.) representative blot from 15 
minute stimulation, C.) densitometry for a 15 minute stimulation. D.) ERK1 and 2 
phosphorylation were greatest during the first 30 minutes following stimulation and then 
returned to approximately control levels. Images show representative blots of experiments 
repeated at least three times. 
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3.3.2.3 Confirmation of specificity of pharmacological inhibitors 
To confirm that the various inhibitors used in the O4/PI survival assay were blocking 
the activity of the enzymes they are directed against, we carried out Western blotting on 
lysates from OPCs that had been pre-incubated with the inhibitors for 15 minutes and 
then stimulated with the growth factors/peptides plus inhibitors for a further 15 minutes.  
PD173074 (50 nM) reduced ERK1/2 phosphorylation induced by FRM peptide and 
NCAM-Fc, to a level below that of cells treated with the inhibitor alone, but did not 
affect the insulin induced response (Figure 3.10a).  This suggests that ERK/MAPK 
signalling lies downstream of FGFR activation in the NCAM-mediated survival 
response, which is in agreement with data obtained from neurons (Ditlevsen et al. 
2008a).  PD173074 did not affect Akt phosphorylation (Figure 3.11a), as would be 
expected as only insulin increased phospho-Akt and the insulin response was not 
affected by the FGFR inhibitor. 
 
The MEK inhibitor PD98059 (50 µM) reduced ERK1/2 phosphorylation of insulin, 
FRM peptide and NCAM-Fc treated cells, as expected (Figure 3.10b) but did not affect 
Akt phosphorylation (Figure 3.11b).  The PI3K inhibitor LY294002 (10 µM) did not 
affect insulin-mediated phosphorylation of ERK1/2 (Figure 3.10c) but did prevent the 
phosphorylation of Akt (Figure 3.11c), confirming its specificity.  This suggests that 
there was no crosstalk between the PI3K and MAPK in this system. 
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3.3.2.4 Fyn Signalling 
Several lines of evidence have suggested that signalling via Fyn may lie downstream of 
NCAM binding, so we investigated the effect of a Fyn inhibitor in the O4/PI survival 
assay and examined levels of phospho-Fyn in OPCs.  PP2 is a Src kinase inhibitor, with 
a reported IC50 of 5 nM.  We used PP2 at 1 µM, which is much higher than the IC50, but 
several other papers have used it at this concentration on oligodendrocytes (Osterhout et 
al. 1999).  When a lower concentration of 0.5 µM was investigated, no effect was 
observed, whereas the higher concentration of 5 µM proved cytotoxic to cells (data not 
shown).  PP2 (1 µM) did not affect control cells but significantly decreased the survival 
of insulin, FRM peptide and NCAM-Fc (all 5 µg/ml) treated cells (Figure 3.12a).  
However, the levels of cell death did not quite reach those of control cells, suggesting 
that either the inhibitor did not completely block Fyn activity or that there are 
alternative pathways that increase OPC survival independent of Fyn (such as FGFR, 
IGF-1 receptor).  Immunoblotting for phospho-Fyn (Y420) revealed that Fyn was active 
in both control and treated cells, and only NCAM-Fc induced a significant increase in 
Fyn phosphorylation compared to total Fyn or actin (Figure 3.12b-c).  A time course 
investigating Fyn phosphorylation revealed that NCAM-Fc increased phosphorylation 
up to an hour after stimulation and then returned to control levels (Figure 3.12d).  
Activation of Fyn in the brain was highest at postnatal day four, as measured by 
phosphorylation of Tyr 531 (Umemori et al. 1994). 
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Figure 3.12 Role of Fyn signalling in OPC survival. 
OPCs were incubated with insulin (5 µg/ml), FRM peptide (5 µg/ml) or NCAM-Fc (5 µg/ml), in 
the presence or absence of the Fyn/Src kinase inhibitor PP2 (1 µM) (A). Oligodendrocyte 
survival was measured using propidium iodide (PI) uptake four days later. PP2 significantly 
inhibited the survival effect of insulin, FRM peptide and NCAM-Fc, but did not cause a complete 
return to control (untreated) survival levels.  Results are shown as mean ± SEM of at least four 
independent experiments, assessed by unpaired Student’s t-test.  Asterisk indicates a 
significant difference between groups (*p<0.05, NS not significant).  
B-D Immunoblot analysis of OPC cell lysates from untreated (i), insulin (ii), FRM peptide (iii) or 
NCAM-Fc (iv) treated cells (all 5 µg/ml), revealed that Fyn is phosphorylated in both treated and 
untreated cells (B).  Images show representative blots of experiments repeated at least three 
times.  Band densometric analysis to examine changes in phospho-Fyn compared to total 
protein showed that there was a slight increase in phosphorylated Fyn in NCAM-Fc treated cells 
following a 15 minute stimulation (B-C). Cells stimulated for longer time points displayed no 
significant difference in Fyn phosphorylation over time, as compared to untreated cells (D). The 
percentage change was calculated based on the ratio of P-Fyn:Actin, whereby activation in 
control cells was considered 100%. 
  
137 
 
3.3.2.5 P38 Signalling 
The p38 MAPK can be activated by a number of signals including GPCRs, growth 
factors, stress and inflammatory cytokines (Haines et al. 2008).  It is phosphorylated by 
the upstream kinases MKK3 or MKK6.  An important role for p38 in myelination has 
been described (as reviewed by Haines et al. 2008).  Therefore, the possible role of p38 
in FRM peptide and NCAM-Fc stimulated OPC survival was investigated.  SB203580 
is a specific p38 inhibitor with an IC50 of 600 nM, which was used at 1 and 5 µM in the 
O4/PI survival assay.  It inhibits α and β p38 isoforms, but OPCs express just two 
isoforms α and γ (Fragoso et al. 2007).  Therefore, we would expect that this compound 
acted to block the activity of p38 α in this system.  At 1 µM, SB203580 did not 
significantly affect OPC survival, whereas at 5 µM, it appeared to have cytotoxic effects 
on the cells, as survival of both treated and untreated cells was decreased (Figure 3.13a).  
Cell morphology was altered in the presence of SB203580 with cells appearing smaller, 
suggesting that it may affect process outgrowth and differentiation.  Activated p38 
could not be detected via Western blotting in untreated or insulin, FRM peptide or 
NCAM-Fc treated cells, but was detected following exposure of cells to UV irradiation, 
which activates p38 as part of a stress pathway (Figure 3.13b). 
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3.4 Discussion 
 
3.4.1 FRM peptide and NCAM-Fc survival is dependent on the FGFR 
Several studies have shown that the FGFR is important for NCAM signalling in neurons 
(Anderson et al. 2005; Carafoli et al. 2008; Kiselyov et al. 2003; Neiiendam et al. 
2004), but very little is known concerning the role of NCAM/FGFR in oligodendrocyte 
development.  Whilst there is data confirming the expression of NCAM on OPCs and 
oligodendrocytes (Bhat and Silberberg 1986; Trotter et al. 1989) and there is 
preliminary evidence that NCAM protein and FRM peptide can increase 
oligodendrocyte survival (Anderson et al. 2005; Gard et al. 1996), a direct link between 
NCAM and the FGFR has not previously been demonstrated in these cells.  We have 
provided evidence that the ability of FRM peptide and NCAM-Fc to increase OPC 
survival is dependent on the FGFR, using the FGFR inhibitor PD173074.  This inhibitor 
fully blocked the survival response of FRM peptide, NCAM-Fc and FGF2, suggesting 
that both FRM peptide and NCAM-Fc use the same mechanisms of action and that the 
FGFR forms a crucial part of the NCAM signalling pathway.  The survival effect of 
FRM peptide and NCAM-Fc were observed in the absence of exogenous FGF2, 
suggesting that they do not require FGF2 in order to elicit their effects.  However, a low 
level of FGF2 release by the cells in the culture system cannot be excluded.  
 
Both the 120 kDa and the 140 kDa isoforms of NCAM have been shown to co-
immunoprecipitate with the FGFR (Sanchez-Heras et al. 2006).  Studies in fibroblast 
cells have shown that NCAM expression was distributed across the entire cell surface 
but was further enriched at points of cell-cell contact.  The FGFR also displayed a 
diffuse localisation across the plasma membrane, although it does not appear at cell-cell 
contacts (Sanchez-Heras et al. 2006).  Addition of NCAM antibodies, which mimic 
homophilic NCAM-NCAM binding and result in clustering of NCAM on the cell 
surface, also led to clustering of the FGFR (Sanchez-Heras et al. 2006).  Therefore, it 
appears that the dynamic pool of NCAM expressed across the cell surface contains the 
molecules that are involved in FGFR interaction and activation and subsequent cell 
signalling, whereas those located at cell-cell contact may have a different role in 
stabilising the cell and do not require cell signalling to perform this function (Sanchez-
Heras et al. 2006).    NCAM was present at the cell surface at all times at a 
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concentration of approximately 50 µM, whilst the FGFR was present at 1000 fold lower 
concentration (Kiselyov et al. 2003).  Although the affinity of NCAM for the FGFR 
was relatively low, with a dissociation constant 10-100 µM (Carafoli et al. 2008; 
Kiselyov et al. 2003), due to the abundance of NCAM it has been estimated that 85% of 
FGFR molecules may be bound to NCAM at any one time.  It has been suggested that 
in the absence of NCAM-NCAM trans interactions, NCAM-FGFR binding may prevent 
spontaneous FGFR dimerisation (Jacobsen et al. 2008).  The clustering of FGFRs 
following NCAM-NCAM interactions may also have implications for FGF2 signalling, 
for example by preventing the activation of signalling pathways by FGF2 and leading to 
a switch in signalling by the FGFR in order to produce a different response.  
Furthermore, the discovery that CAMs and FGFs interact with different regions of the 
FGFR led to speculation that they could bind simultaneously.  In support of this, 
peptides and antibodies that bind to the FGF2 binding site did not interfere with CAM-
FGFR interactions (Williams et al. 1994a).  Also, the FGFR acid box was indispensible 
for NCAM-FGFR interactions but not required for FGF-FGFR interactions (Sanchez-
Heras et al. 2006).  It has been suggested that NCAM may regulate the response to 
FGF2, by acting to repress FGF2 signal transduction that leads to cell proliferation 
(Francavilla et al. 2007). Similarly, FGF2 inhibited NCAM-induced neurite outgrowth 
over fibroblast monolayers, possibly by desensitising a common second messenger 
pathway (Williams et al. 1994d).  FGL peptide was shown to dose-dependently 
decrease the binding of FGF2 to the FGFR, in a competitive manner (Francavilla et al. 
2007).  
  
We have shown that OPCs and pre-myelinating oligodendrocytes express mRNA for 
FGFR1, 2 and 3, in agreement with previous studies (Bansal et al. 1996).  The 
expression of FGFR mRNA has been shown to mimic that of receptor protein levels in 
oligodendrocytes (Fortin et al. 2005).  However, we were unable to detect activated 
FGFR in primary OPCs, suggesting that the level of receptor expression may be too 
low, that the activation occurs transiently, or that only small quantities of the receptor 
become activated in order to transduce the NCAM signal.  Activation of the FGFR was 
detected in CG4 cells even in the absence of FGF2 stimulation, which implied that the 
FGFRs are constitutively active in these cells, that the cells released their own source of 
FGF, or that binding of NCAM on adjacent cells resulted in FGFR activation.  The 
B104-CM that CG4 cells are routinely grown in contains FGF2 and PDGF, at levels 
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presumed to maximally activate signalling pathways.  However, prior to Western 
blotting CG4 cells were starved of growth factors using OLP media without insulin, to 
reduce signalling pathway activation.  Interestingly, CG4 cells also expressed FGFR1, 2 
and 3 (data not shown) so this does not explain the reason why FRM peptide and 
NCAM-Fc did not produce an effect in these cells.   
 
FGFR1 has previously been shown to be the important receptor subtype in controlling 
the inhibitory effects of FGF2 on differentiation (Zhou et al. 2006), whilst up-regulation 
of FGFR3 in late progenitors may provide a signal that promotes myelination (Oh et al. 
2003).  FGFR3-null mice exhibit delayed myelination and a reduction in the number of 
mature oligodendrocytes, independent of an effect on the level of oligodendrocyte cell 
death.  It was suggested that cessation of proliferation is not sufficient to induce 
differentiation and that an independent signal is required to promote terminal 
differentiation, which may involve signalling via FGFR3 (Oh et al. 2003).  FGFR2 was 
the predominant FGFR on mature oligodendrocytes where it frequently localised to 
lipid rafts (unlike FGFR1 which is predominantly located in non-raft compartments) 
and was phosphorylated even in the absence of FGF stimulation in vitro (Bryant et al. 
2009).  Therefore, it may be that NCAM can activate FGFR2 on mature 
oligodendrocytes and it would be interesting to test whether FRM peptide and NCAM-
Fc increase survival of more mature cells than we have used.  However, FGFR2 was 
shown to signal via PI3K rather than MAPK in oligodendrocytes (Bryant et al. 2009), 
the opposite of that seen in this study.  The FGFR2-null mouse is embryonically lethal; 
however, use of a cre-loxP system to conditionally ablate FGFR2 in oligodendrocytes 
and Schwann cells produced a very mild phenotype (Kaga et al. 2006).  From our 
studies we cannot conclude which FGFR subtype was responsible for transducing the 
survival signal stimulated by FRM peptide and NCAM-Fc.  It would be intriguing to 
address this using siRNA to knock-down the expression of one receptor subtype at a 
time.  However, this would be hindered by the inability to detect whether protein levels 
of the receptors had been reduced by siRNA sequences.  Another approach would be to 
use the receptor subtype specific blocking antibodies used by Fortin et al (2005).  
Alternative splicing of FGFRs can result in removal of the acid box, the region shown 
to be essential for CAM-FGFR interactions (Sanchez-Heras et al. 2006).  It would be 
useful to investigate whether the FGFRs expressed in our OPCs all contained this region 
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or not, as this would help elucidate which of the three receptor subtypes was responsible 
for transducing the NCAM survival signal. 
  
3.4.2 FRM peptide and NCAM-Fc signal through MAP kinase and Fyn to mediate 
oligodendrocyte survival 
To investigate downstream signalling, we began by using a multiplex protein array. 
This showed a small increase in phosphorylation of ERK and Akt following treatment 
with insulin, FRM peptide and NCAM-Fc.  However, whilst the duplicate spots in one 
experiment were consistent for each antibody, there was variation between the two 
experiments.  This may have reflected slight changes in protein concentration or 
changes in background.  Also, the kit available targeted human proteins rather than 
rodent proteins so may not have been as specific.  Therefore, it was decided to pursue 
Western blotting and the use of pharmacological inhibitors to further examine the 
pathways involved in OPC survival.   
 
3.4.2.1 MAPK signalling 
The MAPK signalling pathway represents a point of convergence of intracellular 
signalling and can be activated by several upstream targets, such as receptor and non-
receptor tyrosine kinases, GPCRs and PKC.  The presence of MAPK has been 
demonstrated in oligodendrocytes and myelin (Bhat and Zhang 1996).  All MAPKs 
require dual phosphorylation on tyrosine and threonine residues in order to fully 
activate them.  Our study showed that FRM peptide and NCAM-Fc signal through the 
MAPK pathway, producing a transient increase in ERK1/2 activation, in order to 
promote OPC survival.  In contrast to other reports (Cui et al. 2005-no effect seen using 
50 µM), we also found that this pathway was important for insulin mediated survival.  
A basal level of ERK1/2 activation was observed in control cells, which is consistent 
with other reports of sustained ERK activation in differentiating cells (Bhat and Zhang 
1996).  Basal levels of ERK phosphorylation may in part be mediated by NCAM-
NCAM interactions between adjacent cells.  Transient activation of ERK1/2 following 
FGF2 treatment led to increased proliferation (Baron et al. 2000; Frederick et al. 2007), 
indicating that FGF2 and NCAM can signal via the same receptor, resulting in the 
activation of the same substrates but eliciting differing responses.  Transient MAPK 
activation in neuronal PC12 cells stimulated proliferation whilst a prolonged signal 
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promoted differentiation, thus highlighting the importance of the duration of MAPK 
signalling in determining the precise cellular response (Marshall 1995). 
 
Several lines of evidence have pointed to a role for the MAPK cascade in NCAM 
signalling both via Fyn and the FGFR, leading to neurite outgrowth and neuronal 
survival (Kolkova et al. 2000a; Niethammer et al. 2002).  The FGL peptide stimulated 
neuronal survival, which was blocked by inhibitors of the FGFR, MEK and PI3K 
(Neiiendam et al. 2004).  The MEK inhibitor was a more potent suppressor of neuronal 
survival than neurite outgrowth, suggesting that the major function of NCAM-mediated 
MAPK activation is to promote survival. 
 
Ditlevsen et al (2008a) investigated the role of upstream activators on phosphorylation 
of ERK, Akt and CREB in neurons treated with C3 peptide.  ERK phosphorylation was 
reduced by inhibitors of the FGFR and MEK, in agreement with our study.  It was also 
reduced by Fyn inhibitor PP2.  CREB phosphorylation occurred downstream of MEK 
and Fyn but not FGFR.  Interestingly none of the inhibitors could completely block the 
phosphorylation induced by C3 peptide singly (Ditlevsen et al. 2008a).   
 
3.4.2.2 PI3K signalling 
The PI3K-Akt signalling pathway is a very well described survival pathway used by 
numerous cell types.  PI3K is activated in OPCs in response to insulin, PDGF, FGF2 
and NT-3 and pharmacological inhibition of PI3K prevents growth factor survival 
effects (Barres et al. 1992).  However, PI3K has not been studied with respect to 
NCAM in oligodendrocytes.  PI3K has also been shown to be important for neuronal 
survival and process outgrowth stimulated by the FGL, C3 and P2 NCAM peptides 
using PI3K inhibitors and detection of phosphorylated Akt (Ditlevsen et al. 2003).  We 
were unable to detect phospho-Akt in OPCs in response to FRM peptide or NCAM-Fc 
treatment by Western blotting using an antibody against Akt1, which according to the 
manufacturers should also recognise Akt2 and Akt3.  Oligodendrocytes predominantly 
express Akt2, followed by Akt1 and to a lesser extent Akt3 (Cui et al. 2007).  It may 
have been better to use an antibody that was primarily directed to rodent Akt2.  
Additionally, LY294002 did not significantly affect the FRM peptide or NCAM-Fc 
induced OPC survival, at a concentration that it inhibited the response of insulin and 
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PDGF, indicating that PI3K signalling was not required for FRM peptide and NCAM-
Fc-induced survival.   
  
PI3K is said to be critical for IGF1 stimulated OPC survival, which leads to downstream 
activation of both Akt-dependent and Akt-independent pathways, as IGF1 promoted 
survival in cells transfected with inactive Akt mutants or in the presence of an Akt 
inhibitor (Cui et al. 2005).  PI3K has been reported to lie upstream of MAPK and may 
lead to a transient increase in ERK phosphorylation (Cui et al. 2005).  However, we did 
not observe crosstalk between PI3K and MAPK pathways as PD98059 did not affect 
Akt phosphorylation and LY294002 did not affect ERK1/2 phosphorylation, suggesting 
they can be activated independently by insulin, which is consistent with some other 
studies (Palacios et al. 2005). 
 
3.4.2.3 Fyn pathway 
An alternative way that NCAM may activate intracellular signalling pathways is via 
Fyn, a member of the Src family of non-receptor tyrosine kinases (Beggs et al. 1997; 
Schmid et al. 1999).  The expression of Fyn in oligodendrocytes has been described 
previously (Kramer et al. 1999; Osterhout et al. 1999).  Fyn has been implicated in 
oligodendrocyte development and high levels of activated Fyn have been detected in the 
myelin of the early postnatal brain (Umemori et al. 1994).  Oligodendrocytes also 
express the Src kinase Lyn, but only Fyn has been assigned an essential role in 
myelination (Sperber et al. 2001).  Fyn knock-out mice are hypomyelinated and have 
fewer oligodendrocytes than the wildtype (Umemori et al. 1999; Sperber et al. 2001).  
The reduction in oligodendrocyte number, as well as amount of myelin produced per 
cell, may indicate a role for Fyn in oligodendrocyte survival as well as differentiation.  
However, OPCs isolated from Fyn-null mice produced fewer morphologically and 
antigenically mature oligodendrocytes than wildtype cultures and were unable to 
respond to IGF1 (Sperber and McMorris 2001).  This suggests that Fyn may not only 
function in oligodendrocyte differentiation, but could also have a role in transducing 
insulin/IGF1 and NCAM-mediated survival signals.  Activation of Fyn by IGF1 led to 
downstream activation of Akt and ERK1/2, in a PI3K independent manner (Cui et al. 
2005).   
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Fyn has been shown to co-precipitate with NCAM-120 and contactin/F3 in detergent 
insoluble lipid rafts, to form a functional signalling complex, which is said to be critical 
for signal transduction between the axon and oligodendrocyte during the early stages of 
myelination (Kramer et al. 1999).  As myelination progressed, Kramer et al (1999) 
showed that Fyn progressively associated with lipid rafts, as did NCAM-120, but not 
NCAM-140 or NCAM-180.  However, other studies have shown that all NCAM 
isoforms localised to lipid rafts of neuroblastoma cells, where NCAM-140 was also able 
to associate with and activate Fyn (Niethammer et al. 2002).  Fyn has a well described 
role in NCAM-stimulated neurite outgrowth in PC12, neuroblastoma cells and primary 
neurones and a less well defined role in survival (Beggs et al. 1997; Kolkova et al. 
2000a; Ditlevsen et al. 2007a).  This study shows that Fyn has a role in OPC survival 
because pharmacological inhibition of Fyn using PP2 reduced cell survival.  A previous 
study has suggested that FGL peptide may activate differential signalling pathways 
compared to peptides that mimic homophilic binding (Ditlevsen et al. 2003; Neiiendam 
et al. 2004; Pederson et al. 2004) and this may occur due to lack of activation of Fyn by 
FGL peptide as it is suggested to signal solely via the FGFR.  However, we observed a 
reduction in FRM peptide and NCAM-Fc-induced survival in the presence of PP2, 
suggesting that both the peptide and the protein activate Fyn above basal levels.  FGF2 
is able to activate Fyn downstream of the FGFR (Figure 3.1, Ditlvsen and Kolkova 
2008), so it may be that NCAM can activate Fyn directly or indirectly following FGFR 
activation, which would explain how the FRM peptide response was also affected by 
PP2.  In support of this, an increase in intracellular calcium following NCAM-FGFR 
activation enhanced NCAM-Fyn interactions (Bodrikov et al. 2004), suggesting that 
there is co-operation between the two pathways.  This thesis reports that although Fyn 
phosphorylation was unaffected by either insulin or the FRM peptide, Fyn was activated 
by NCAM-Fc. This shows a discrepancy between the survival assay data and that 
obtained by Western blotting.  It may be that the increased levels of Fyn 
phosphorylation caused by NCAM-Fc do not merely function to stimulate survival and 
they may contribute to other cellular functions not measured here, such as 
differentiation.  To fully activate Fyn phosphorylation on an activating tyrosine (Y420-
rat) and dephosphorylation of an inhibitory tyrosine (Y531) are required.  This dual 
regulation may reflect the requirement for integration of multiple signals in order to 
activate Fyn, and we only measured the activity of the activating phosphorylation by 
Western blotting.  It is possible that NCAM could be having an effect on 
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dephosphorylation of the inhibitory residue.  In contrast to the concentration of PP2 
used by this thesis (1 µM), another study indicated that much higher concentrations (20 
and 50 µM) of  PP2 were required to inhibit OPC survival (Cui et al. 2005). The authors 
also reported a 2-3 fold increase in Fyn phosphorylation in response to IGF1 stimulation 
(Cui et al. 2005), whereas this thesis demonstrated insulin not to affect Fyn 
phosphorylation. Additionally, knock-down of Fyn has been shown to inhibit the 
survival effects of PDGF and NRG, but only in the presence of integrin α6β1 
(Colognato et al. 2004). 
 
3.4.2.4 P38 signalling 
P38 and JNK are also members of the MAPK family of proteins, and are typically 
considered stress-related kinases.  Ceremide-induced apoptosis of oligodendrocytes has 
been reported to be mediated by p38 (Hida et al. 1999).  Furthermore, the activation of 
p38 in non-deleterious signalling leading to cell growth and differentiation has been 
described in many systems (Zarubin and Han 2005).  We have investigated whether p38 
is involved in NCAM-mediated OPC survival because several studies have described a 
role for p38 in myelination (Haines et al. 2008) and the upstream activators of this 
pathway are not known.  The p38 inhibitor did not prevent the survival effects of FRM 
peptide or NCAM-Fc and had cytotoxic effects at high concentrations.  Activated p38 
was not detected in our samples, except following a UV stimulus, which activates 
apoptotic pathways.  This suggests that NCAM is not the upstream activator of p38 in 
OPCs and that the levels of p38 activated during OPC maturation are either low or 
occurs transiently.   
 
In the PNS, p38 inhibitors prevented Schwann cell differentiation and myelination in 
vitro (Fragoso et al. 2003).  A similar role has been found in the CNS, whereby p38 
inhibitors reduced myelin protein expression and prevented the transition of early 
progenitors to late progenitors, resulting in reduced myelination in co-cultures (Baron et 
al. 2000; Bhat et al. 2007; Fragoso et al. 2007).  Fewer mature oligodendrocytes were 
observed in our culture system following treatment with the p38 inhibitor, suggesting a 
decrease in differentiation.  The main substrates of p38 are small heat shock proteins 
and the AIF transcription factors.  Inhibition of p38 results in reduced levels of p27, 
which is normally upregulated as oligodendrocytes mature, and consequently lower 
levels of MBP production (Haines et al. 2008).  Additionally, SB203580 reduced the 
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mitogenic effects of FGF2 and PDGF (Baron et al. 2000), suggesting it also has a role 
on cells earlier in the lineage.  Conversely, Hamanoue et al (2007) showed that p38 was 
required for the survival of mature oligodendrocytes but not A2B5
+
 precursors and 
suggest that a sustained level of p38 phosphorylation may be required to maintain 
oligodendrocyte survival.  This may be different to the transient activation of p38 
following cytotoxic stimuli that results in apoptosis.  In our system, the cells may be at 
an earlier stage and not yet dependent on p38 for their survival, or the levels of activated 
p38 may have been too low to detect.  It appears that in developing oligodendrocytes 
p38 signalling is more important for differentiation than survival (Bhat et al. 2007). 
 
Figure 3.14 Signalling summary. 
NCAM activates intracellular signalling to mediate OPC survival.  This could be blocked by an 
FGFR inhibitor (PD173074) a Fyn kinase inhibitor (PP2) and a MEK inhibitor (PD98059). 
 
3.4.3 Conclusion 
It would appear that whilst there are common signalling pathways involved in survival 
of many different cell types, the nature of these pathways are cell-type, growth factor 
and receptor specific, and vary according to the stage of cell development leading to 
conflicting results.  It is not clear how activation of similar pathways by different 
growth factors or in different cell types leads to very different biological responses.  
This study shows that FRM peptide and NCAM-Fc-stimulated OPC survival was 
blocked by pharmacological inhibitors of the FGFR, Fyn and MAPK.  These pathways 
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have also been shown to be important for NCAM-mediated neuronal survival.  Fyn and 
MAPK are also known to be stimulated by a number of other growth factors in OPCs.  
It appears that PI3K and p38 are not involved in NCAM-mediated OPC survival.  
Furthermore, the majority of data obtained regarding the importance of certain 
signalling molecules in oligodendrocytes has been carried out in vitro, using 
pharmacological inhibitors, so the importance of these pathways in vivo is not clear.  
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Chapter 4 
 
 
 
 
 
Effect of NCAM on oligodendrocyte differentiation 
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4.1 Introduction 
 
4.1.1 Control of oligodendrocyte differentiation 
Myelination involves initial contact between axons and oligodendrocytes, followed by 
the extension and wrapping of oligodendrocyte processes around the axon and finally 
compaction of the myelin.  This requires large scale production and transport of myelin 
proteins and also re-organisation of the cytoskeleton to enable process elongation.  The 
mechanisms by which oligodendrocytes extend their highly branched processes and the 
signals that control their differentiation have not been fully elucidated.  The expression 
of CAMs on the surface of the axon and the oligodendrocyte places them in an ideal 
location to transduce the signals required to stimulate oligodendrocyte differentiation 
and myelination. 
 
4.1.1.1 Role of cell adhesion molecules 
It has been shown that several adhesion molecules, including NCAM, MAG and N-
cadherin, increase outgrowth of oligodendrocytes when presented to cells coated on 
glass coverslips (Gard et al. 1996; Payne and Lemmon 1993).  NCAM and MAG 
stimulated a 2-3 fold increase in the surface area of the myelin-like membrane after 
seven days in culture, compared to polyornithine alone (Gard et al. 1996).  However, L1 
was not able to increase oligodendrocyte outgrowth (Payne and Lemmon 1993), in 
agreement with data showing its down-regulation prior to myelination (Bartsch et al. 
1989).  Fyn strongly associates with MAG (Umemori et al. 1994), one of the earliest 
expressed myelin proteins and a molecule likely to be involved in axon-oligodendrocyte 
interactions.  In response to MAG binding Fyn has been shown to stimulate 
transcription of the MBP gene, suggesting a role for Fyn in myelin production as well as 
morphological differentiation, discussed in 4.1.1.2 (Umemori et al. 1999; Kramer et al. 
1999).  However, other studies have suggested that Fyn inhibition does not block 
expression of myelin proteins (Osterhout et al. 1999).  Additionally, the GPI-linked 
adhesion molecule contactin/F3 has been shown to co-immunoprecipitate with Fyn 
from lipid rafts and clustering induced by contactin/F3 antibodies resulted in Fyn 
activation (Koch et al. 1997; Kramer et al. 1999).  Contactin/F3 has also been assigned 
a role in promoting oligodendrocyte differentiation via an interaction with the Notch 
receptor, leading to increased CNP and MAG expression (Hu et al. 2004).  Activation 
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of integrins by laminin promotes oligodendrocyte process outgrowth and laminin-
deficient mice display hypomyelination (Chun et al. 2003).  Moreover, integrins have 
been shown to interact with Fyn, providing a mechanism to stimulate oligodendrocyte 
differentiation.  This is supported by experiments knocking-down Fyn expression, 
which reduced MBP expression and process outgrowth in response to laminin 
(Colognato et al. 2004).  Control of the morphological differentiation of 
oligodendrocytes is said to involve a pathway consisting of integrin-Fyn-Fak-Rac1-
Cdc42, leading to regulation of the actin cytoskeleton (Hoshina et al. 2007; Liang et al. 
2004).   
 
4.1.1.2 Role of Fyn 
Several lines of evidence have suggested Fyn has a role in myelination.  Fyn levels are 
high in both neurons and glial cells and phosphorylation of Fyn is highest during early 
postnatal development, coincident with myelination (Umemori et al. 1994).  This has 
been supported by in vitro studies indicating a role for Fyn in the morphological 
differentiation of oligodendrocytes, whereby Fyn activation occurred within 24 hours of 
switching OPCs from proliferation media to media that promotes differentiation.  
Furthermore, Fyn activation occurred prior to morphological changes to the OPC, 
suggesting a role in the initial events of myelination (Osterhout et al. 1999).  Fyn-
deficient mice are hypomyelinated, displaying reduced myelin thickness and fewer 
oligodendrocytes (Sperber et al. 2001; Umemori et al. 1999).  This has been supported 
by evidence from Fyn dominant negative constructs and tyrosine kinase inhibitors PP1 
and PP2, all of which reduce process outgrowth of cultured oligodendrocytes (Osterhout 
et al. 1999).  A microarray study carried out on Fyn-deficient mice showed that seven 
proteins with roles in myelination were repressed compared to wildtype, including 
MOG, MAG and PLP and a number of genes involved in differentiation and 
cytoskeletal organisation (Goto et al. 2004).  However, it has been suggested that the 
decreased levels of gene expression may be attributable to the reduced number of 
mature oligodendrocytes in Fyn-deficient mice rather than the effect of Fyn on gene 
transcription (Osterhout et al. 1999).  Fyn associates with Tau and α-tubulin in 
oligodendrocytes, providing a mechanism by which Fyn could influence cytoskeletal 
dynamics (Klein et al. 2002).  In addition, expression of mutant Tau, which is unable to 
associate with Fyn reduces process outgrowth (Klein et al. 2002).  The upstream 
activators of Fyn are largely unknown.  Growth factors such as FGF2 and PDGF are 
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unable to increase levels of Fyn phosphorylation in cultured cells (Osterhout et al. 
1999).  Transferrin accelerates the differentiation of oligodendrocytes in culture via 
increased expression and activation of Fyn (Perez et al. 2009) and transferrin-mediated 
Fyn activation leads to an interaction with Tau and microtubule organisation, resulting 
in process elongation (Perez et al. 2009). 
 
4.1.2 Effect of NCAM on neuronal differentiation 
The ability of several CAMs including NCAM, N-cadherin and L1 to promote neurite 
outgrowth in vitro has been well described (Doherty et al. 1989; Doherty et al. 1991; 
Meiri et al. 1998; Williams et al. 1994a). 
 
4.1.2.1 Fibroblast co-culture system 
In vitro co-culture systems have been used to investigate the effects of CAMs on neurite 
outgrowth.  PC12 cells, neuroblastoma cells or primary neurones have been grown on 
top of a monolayer of CAM-expressing fibroblasts, which significantly increased the 
length of neurites compared to growth over untransfected fibroblasts (Doherty et al. 
1989; Doherty et al. 1991; Williams et al. 1994a).  Doherty and colleagues (1990b) 
showed that all NCAM isoforms were able to induce outgrowth and that a threshold 
level of expression was required, above which small increases in expression produced a 
substantial increase in neurite length.  Additionally, neurite outgrowth was inhibited 
when cells were cultured on fibroblasts expressing NCAM-VASE, an isoform that is 
upregulated in the mature CNS, providing a mechanism to developmentally down-
regulate the response to NCAM (Saffell et al. 1994).  Using a similar co-culture system 
with Hela cells expressing NCAM or PSA-NCAM, Nakayama et al (1995) showed that 
growth of neurons on PSA-NCAM-expressing cells further increased neurite outgrowth 
compared to those grown on NCAM-expressing cells.  It is suggested that PSA 
facilitates neurite outgrowth and branching.  However, PSA-NCAM is thought to 
provide an inhibitory substrate for oligodendrocyte outgrowth (Charles et al. 2000) and 
may instead facilitate cell migration. 
 
4.1.2.2 Soluble proteins and peptides 
Soluble chimeric proteins consisting of the full extracellular domain of NCAM or L1 
fused to the Fc portion of antibody IgG have been shown to promote neurite outgrowth 
to the same extent as substrate bound NCAM (Meiri et al. 1998).  More recently soluble 
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peptides that mimic the effects of NCAM have also been shown to increase neurite 
outgrowth (Anderson et al. 2005; Kiselyov et al. 2003; Neiiendam et al. 2004; Pedersen 
et al. 2004; Soroka et al. 2002).  Peptides derived from regions of the two FnIII 
domains of NCAM have been shown to function as agonists of the FGFR (Hansen et al. 
2008b).  The FRM and FGL peptides increase neurite outgrowth, exhibiting a bell-
shaped dose-response curve with very high concentrations actually inhibiting outgrowth 
(Anderson et al. 2005; Neiiendam et al. 2004), similar to the biphasic dose-response 
curve observed in response to FGF2 (Garcia-Maya et al. 2006; Williams et al. 1994d).  
In addition, the concentration of the peptide that induced optimal levels of neurite 
outgrowth varied depending on cell type, indicating the importance of the type or 
developmental stage of the neurons (Neiiendam et al. 2004).  Importantly, peptides 
derived from the FnIII domains of NCAM are able to stimulate neurite outgrowth as 
effectively as substrate bound NCAM, suggesting the bioactive part of the NCAM 
molecule is located within the FnIII domains (Anderson et al. 2005).   
 
4.1.2.3 NCAM signalling 
Multiple signalling pathways have been implicated in NCAM-mediated neurite 
outgrowth, as summarised in Figure 4.1.  NCAM induced outgrowth has been shown to 
be dependent on the FGFR (Anderson et al. 2005; Williams et al. 1994a; Saffell et al. 
1997) and activation of PLC and DAG, culminating in calcium influx (Doherty et al. 
1991; Williams et al. 1994c).  Fyn is also required for NCAM-mediated neurite 
outgrowth (Beggs et al. 1994; Beggs et al. 1997).  Studies on neurons isolated from Fyn 
knock-out mice have demonstrated that Fyn is required for NCAM but not integrin-
induced neurite outgrowth (Beggs et al. 1994).  In agreement, Src kinase inhibitors and 
dominant negative FAK reduced outgrowth (Kolkova et al. 2000a; Schmid et al. 1999).  
The co-localisation of NCAM in lipid rafts is important for Fyn activation.  Disruption 
of lipid rafts or mutation of the palmitoylation sites of NCAM, which are required for 
raft targeting, attenuated Fyn activation and neurite outgrowth (Niethammer et al. 
2002).  Pharmacological inhibition of MEK or expression of dominant negative forms 
of the GTPases such as Ras inhibited NCAM-mediated neurite outgrowth in primary 
cerebellar neurones and PC12 cells (Kolkova et al. 2000a; Schmid et al. 1999).  
Furthermore, expression of constitutively active forms of Ras, Raf or MEK stimulated 
neurite outgrowth in the absence of NCAM expression (Kolkova et al. 2000a), 
suggesting that activation of the MAPK cascade is both necessary and sufficient to 
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trigger neurite outgrowth.  Increased phosphorylation of MAPK and the transcription 
factor CREB were detected following NCAM binding (Jessen et al. 2001; Schmid et al. 
1999).  Kolkova et al (2000a) suggest that NCAM induces sustained activation of 
MAPK, which is required for neurite outgrowth.  However, it is debatable whether 
MAPK has a specific role in neurite outgrowth or whether it has a more general action 
in stimulating differentiation, of which neurite outgrowth forms a part, as the level of 
inhibition varies between cell types (Povlsen et al. 2003).  
 
 
Figure 4.1 Signalling pathways proposed to be important in NCAM-mediated neurite 
outgrowth (Ditlevsen and Kolkova 2008). 
Multiple signalling pathways are believed to cooperate to stimulate neurite outgrowth following 
NCAM binding.  Dashed lines represent putative interactions.  NCAM shown in orange, tyrosine 
kinases in green, other kinases in blue, non-proteins in purple, phosphatases in yellow, 
transcription factors in pink and other factors in grey. 
 
4.1.3 Hypothesis 
We addressed the hypothesises that: 
1. FRM peptide, NCAM-Fc and cellular NCAM could increase OPC 
differentiation, as measured by an increase in process outgrowth and myelin 
protein expression 
2. This differentiation was dependent on activation of intracellular signalling 
pathways. 
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4.1.4 Aims 
The ability of several substrate bound adhesion molecules to promote neurite outgrowth 
via the activation of intracellular signalling have been well characterised.  However, far 
less is understood regarding the mechanisms involved in oligodendrocyte process 
outgrowth and the molecules involved.  Contact-dependent signals from the axon are 
likely to play a role in stimulating the differentiation of oligodendrocytes, and NCAM is 
a candidate molecule to transduce these signals.  We aimed to use the well described 
fibroblast co-culture system to present cell bound NCAM to OPCs and to investigate 
whether this would promote process outgrowth as it does for neurons and PC12 cells.  
NCAM protein bound to glass coverslips has been shown to increase the size of myelin 
membranes produced by oligodendrocytes in culture (Gard et al. 1996).  However, the 
effects of soluble FRM peptide and NCAM-Fc on OPC outgrowth or the expression of 
mature oligodendrocyte markers have not previously been characterised.  We examined 
whether FRM peptide and NCAM-Fc could increase the mRNA and protein levels of 
myelin proteins, such as MBP and PLP.  
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4.2 Methods 
 
4.2.1 Co-culture of OPCs with fibroblasts 
Mouse NIH 3T3 fibroblasts constitutively expressing the human 140 kDa 
transmembrane isoform of NCAM at the cell surface (Doherty et al. 1989) and 
untransfected 3T3 fibroblasts were maintained at 37°C and 5% CO2 in DMEM 
supplemented with 2 mM L-glutamine, 100 units/ml penicillin-streptomycin and 10% 
HI FCS and routinely passaged twice a week 1:4.  For co-culture experiments fibroblast 
cells were plated onto glass 13 mm coverslips coated sequentially with PDL and 
fibronectin (10 µg/ml, Sigma-Aldrich) at a density of 1X10
5
 cells per well and allowed 
to form confluent monolayers overnight.  24 hours later O4
+
 OPCs were isolated from 
neonatal rats by immunopanning (as described in Chapter 2.2.1) and plated on top of the 
monolayers at a density of 3X10
4
 cells per well in 500 µl DMEM plus 10% HI FCS.  
After 1-2 hours media was switched to OLP medium containing insulin with or without 
the addition of FRM peptide (0.5-50 µg/ml), NCAM-Fc (5-50 µg/ml), or inhibitors of 
FGFR (PD173074, 50 nM), MEK (PD98059, 10 µM) or Fyn (PP2, 1 µM).  
 
4.2.2 Assessment of OPC process outgrowth 
Measurement of OPC process outgrowth was performed on cells one day after isolation, 
as an early marker of differentiation.  This time point enabled examination of cells when 
they have a relatively simple morphology, thus simplifying quantitative analysis.  Cells 
that were grown directly on PDL-coated coverslips or grown on top of fibroblast cells 
were stained live with O4 antibody (1:5 in MEM-HEPES + 0.3% BSA for 20 minutes 
on ice) followed by anti-IgM  chain FITC conjugate (1:100 in MEM-HEPES + 0.3% 
BSA for 15 minutes on ice) and fixed for 15 minutes at RT in 4% PFA/PBS.  Cells were 
washed with PBS and incubated for five minutes with nuclear stain DAPI (1:5000 in 
PBS) before mounting in Vectorshield hardset fluorescent mounting medium. 
 
OPC morphology was visualised using epifluorescence illumination on a Nikon Eclipse 
1000 microscope and digital images were captured using a QICAM Fast 1394 camera.  
Image ProPlus version 5.1 software was used to create composite images.  Images of 
150 cells per condition were captured at X20 magnification and the number of primary 
processes per cell counted manually. The lengths of all processes per cell were 
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measured using the manual trace tool (Figure 4.2). Coverslips were analysed in 
triplicate and the mean process length calculated for each condition.  Total cell area for 
the same 150 cells was also measured using Image Pro Plus 5.1. 
 
4.2.3 Quantification of galactocerebroside positive cells 
To assess the effect that NCAM has on OPC antigenic differentiation, O4
+
 OPCs were 
differentiated for two days in OLP with or without insulin (5 µg/ml), FGF2 (0.1 ng/ml), 
FRM peptide (5-50 µg/ml) or NCAM-Fc (5-50 µg/ml) and stained live with anti-O1 
antibody (1:5 dilution in MEM-HEPES + 0.3% BSA for 20 minutes on ice), which 
recognises GalC, a marker expressed by immature and mature oligodendrocytes but not 
OPCs.  Cells were then incubated with anti-IgM  chain FITC conjugate (1:100 in 
MEM-HEPES + 0.3% BSA for 15 minutes on ice) and fixed for fifteen minutes at RT in 
4% PFA/PBS. Cells were then washed with PBS and incubated for five minutes with 
DAPI (1:5000 in PBS) before mounting in Vectorshield hardset fluorescent mounting 
medium. Cells were visualised using epifluorescence illumination on a Nikon Eclipse 
1000 microscope and to quantify differentiation the number of O1
+
 cells were counted 
and expressed as a proportion of the total number of cells, as assessed by counting the 
number of DAPI
+
 nuclei. Ten fields were counted at X20 magnification on three 
coverslips per condition.  
 
4.2.4 Western Blotting 
Western blotting was used to investigate whether FRM peptide or NCAM-Fc increased 
the level of expression of the myelin proteins CNP, MBP or MOG.  OPCs were plated 
onto PDL coated 6 cm dishes and expanded in B104-CM (DMEM, 30% B104-CM, 1% 
N1 supplement, 2 mM L-glutamine, 100 units/ml penicillin-streptomycin, 5 ng/ml 
FGF2, 1 ng/ml PDGF and 10 ng/ml biotin).  They were then switched to OLP with or 
without insulin (5 µg/ml), FRM peptide (5 µg/ml) or NCAM-Fc (5 µg/ml) and cells 
lysed in RIPA buffer after 0, 1, 3 or 6 days differentiation. Western blotting was 
performed, as described in Chapter 2.2.10 (Table 4.1 for details of antibodies used).   
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Antibody Diluent Secondary Antibody 
Anti-CNP (Millipore) 1:2000 5% milk TBS 0.1% Tween 20 Anti-mouse HRP 1:2000 
Anti-MBP (in house RR) 
1:2000 
5% milk TBS 0.1% Tween 20 Anti-rabbit HRP 1:2000 
Anti-MOG (Z12 hybridoma, in 
house) 1:2000 
5% milk TBS 0.1% Tween 20 Anti-mouse HRP 1:2000 
 
Table 4.1 Antibodies used for Western blotting 
 
4.2.5 qRT-PCR 
qRT-PCR was carried out to investigate whether stimulation of OPCs with FRM 
peptide or NCAM-Fc affected the levels of mRNA of MBP and PLP, as a measure of 
cell differentiation.  RT and PCR were carried out as described in Chapter 3.3.4, using 
the QuantiTect® primers listed in Table 4.2. 
  
Gene symbol Official gene name Entrez 
gene ID 
Accession 
no. 
Amplicon 
length 
Catalogue 
no. 
Mbp Myelin basic protein 24547 NM_0010252
91 
117 bp QT00199255 
Plp1 Proteolipid protein 24943 NM_030990 97 bp QT00176414 
Gapdh Glyceraldehyde-3-
phosphate 
dehydrogenase 
24383 NM_017008 149 bp QT00199633 
 
Table 4.2 Primers used for RT-qPCR 
 
4.2.6 Statistics 
Significant differences between groups were analysed by unpaired Student’s t-test using 
Prism 4 software (GraphPad Software Inc, San Diego, USA) and p values <0.05 were 
considered significant. Data presented graphically is from a minimum of three 
independent experiments. 
 
  
159 
 
4.3 Results 
 
4.3.1 Effect of FRM peptide and NCAM-Fc on OPC process outgrowth 
To determine whether soluble versions of NCAM, could influence OPC differentiation 
we measured OPC process outgrowth, as this provides an early marker of 
morphological differentiation.  O4
+
 OPCs were plated onto PDL-coated coverslips and 
cultured overnight in OLP with insulin (to maintain OPC survival at an optimal level) in 
the presence or absence of FRM peptide and NCAM-Fc (both 5 and 50 µg/ml).  We had 
previously determined that FRM peptide and NCAM-Fc did not have a significant 
additive survival effect to that produced by insulin alone (Chapter 2.3).  Cell 
morphology was assessed following O4 immunocytochemistry, with the majority of 
cells elaborating several small processes after 24 hours in culture (Figure 4.2a).  To 
quantify process outgrowth the number of processes per cell were counted manually and 
the length of each primary process was measured using the trace tool in Image Pro Plus 
(Figure 4.2b).  FRM peptide and NCAM-Fc caused a slight but non-significant increase 
in the mean process length (Figure 4.3b).  They caused a small reduction in the number 
of cells with one process and an increase in the number of cells with five or more 
processes per cell (Figure 4.3a).  In addition, cell area (area covered by a network of 
processes) was measured using Image Pro Plus.  Again FRM peptide and NCAM-Fc did 
not have a significant effect (Figure 4.3c). 
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4.3.2 Effect of cellular NCAM on OPC process outgrowth 
Several studies have used a co-culture system to assess the effects of NCAM on neurite 
outgrowth, whereby cells are plated on top of a confluent monolayer of untransfected 
(control) or NCAM-transfected fibroblasts (Doherty et al. 1989; Doherty et al. 1990b).  
Therefore, the same system was used for co-culture with OPCs to investigate whether 
the effect of cellular NCAM differed from that of soluble NCAM.  
 
Fibroblasts were plated onto coverslips coated sequentially with PDL and fibronectin, 
24 hours prior to the addition of OPCs at a density that ensured they would be confluent 
the following day.  1X10
5
 fibroblasts per well was determined to be the optimal cell 
number.  Firstly, expression of NCAM on the transfected fibroblasts was confirmed 
using immunocytochemistry.  No NCAM expression was observed on untransfected 
cells but robust expression was apparent on transfected fibroblasts, in particular at 
points of cell-cell contact (Figure 4.4a-b).   
 
OPC process outgrowth was assessed after 24 hours culture on the fibroblast cells using 
O4 immunocytochemistry and image analysis.  The morphology of cells differed 
depending on the cell line they were grown upon, with OPCs cultured on untransfected 
fibroblasts retaining an immature phenotype with no or very few processes (Figure 
4.4c).  In contrast, most of OPCs grown on NCAM expressing fibroblasts had 
elaborated processes with the majority having three or more per cell (Figure 4.4d).  
There were statistically significantly fewer cells with zero or one process per cell, and 
significantly more cells with four, five or greater than five processes per cell when 
OPCs were cultured on NCAM-expressing fibroblasts compared to untransfected 
fibroblasts (Figure 4.4e).  Culture on NCAM-expressing cells significantly increased the 
mean number of processes per cell from 1.5 ± 0.4 to 3.5 ± 0.5 (130% increase, Figure 
4.5a).  Furthermore, the average process length was significantly increased from 23.0 ± 
6.2 µm on untransfected fibroblasts to 35.1 ± 6.5 µm on NCAM-expressing fibroblasts 
(52% increase, Figure 4.5b). 
 
To investigate whether FRM peptide or NCAM-Fc could influence OPC process 
outgrowth in the co-culture system they were added to the culture media of OPCs 
grown on untransfected and NCAM-expressing fibroblasts and cell morphology 
assessed after 24 hours, as described above.  FRM peptide and NCAM-Fc (both at 5 and 
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50 µg/ml) did not affect OPC process outgrowth over fibroblasts, as examined by 
measuring the number of processes per cell and the mean process length (Figure 4.5).  
They were unable to stimulate outgrowth over the untransfected fibroblasts and did not 
inhibit cellular NCAM-mediated outgrowth.  
 
4.3.3 Involvement of intracellular signalling in OPC process outgrowth 
To investigate whether the ability of cellular NCAM to increase OPC process outgrowth 
was dependent on activation of cell signalling pathways, the effect of several 
pharmacological inhibitors of intracellular signalling were investigated in the outgrowth 
assay.  Firstly, it was determined whether the presence of the inhibitors in the culture 
media would affect the viability and NCAM expression on the fibroblasts.  Fibroblast 
monolayers appeared intact following a 24 hour incubation with PD173074 (50 nM), 
PD98059 (10 µM) or PP2 (1 µM).  Western blotting confirmed that these inhibitors did 
not influence the level of NCAM expression (Figure 4.6a).   
 
As before, OPCs were grown on fibroblasts for 24 hours prior to O4 
immunocytochemistry, but this time in the presence of the pharmacological inhibitors.   
A slight increase in the number of cells with no processes per cell was observed in the 
presence of the inhibitors, with PP2 having the greatest effect (Figure 4.6b-c).  It was 
anticipated that this would not be due to an effect on cell survival because insulin was 
included in all media and after the short time point of 24 hours in culture cell survival 
should not have been greatly affected.  Additionally, the same number of cells were 
present on untransfected and NCAM-transfected fibroblasts.  Quantification of the 
average number of processes per cell and process length revealed that none of the 
inhibitors significantly affected process outgrowth over untransfected fibroblasts 
(Figure 4.7a-b).  PD173074 and PD98059 did not significantly affect outgrowth over 
NCAM-expressing monolayers.  However, PP2 significantly reduced the number of 
processes per cell over NCAM-expressing fibroblasts from 3.1 ± 0.2 to 2.3 ± 0.3 (Figure 
4.7a), but not that of mean process length (Figure 4.7b).   
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Figure 4.4 Effect of co-culture with NCAM-expressing fibroblasts on OPC morphology. 
3T3 fibroblasts were stably transfected with the human 140 kDa isoform of NCAM, to produce 
the N24 cell line. Immunocytochemistry using anti-NCAM antibody was used to confirm NCAM 
expression (red, DAPI stained nuclei blue). NCAM expression was not visible on parental 3T3 
cells (A), whilst robust expression was observed on transfected cells (B). OPCs isolated by 
immunopanning for O4 were plated on top of confluent fibroblast monolayers and their 
morphology examined after 24 hours in culture using O4 immunocytochemistry. Cells grown on 
control (untransfected) 3T3 cells showed an immature phenotype with few processes (C), 
whereas those grown on NCAM-expressing fibroblasts had a more complex morpholgy (D). 
Quantification of the number of processes per cell revealed a significant reduction in the number 
of cells with 0 or 1 process per cell and a significant increase in the proportion with 4+ 
processes, when grown on NCAM-expressing cells compared to control cells (E). Results are 
shown as mean ± SEM of four independent experiments and a minimum of 150 cells were 
analysed per experiment.  Asterisk indicates a significant difference (*p<0.05, **p<0.01, 
***p<0.001) compared to the same number of processes on control cells, assessed by unpaired 
Student’s t-test.  Scale bars: 50 µm. 
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Figure 4.5 Effect of FRM peptide and NCAM-Fc on OPC outgrowth over fibroblasts. 
OPCs isolated by immunopanning for O4 were plated on top of confluent fibroblast monolayers 
in the presence or abscence of FRM peptide (5 and 50 µg/ml) or NCAM-FC (5 and 50 µg/ml).  
OPC morphology was examined after 24 hours in culture using O4 immunocytochemistry and 
image analysis. Cells grown on control (untransfected) 3T3 cells had significantly fewer 
processes per cell compared to those grown on NCAM-expressing fibroblasts (A).  Addition of 
FRM peptide or NCAM-Fc to both cells grown on control and NCAM-expressing fibroblasts did 
not alter the number of processes per cell (A). Measurement of all primary processes per cell 
showed that NCAM-expressing cells significantly increased process length.  However, FRM 
peptide and NCAM-Fc did not have an effect (B). Results are shown as mean ± SEM of 3-4 
independent experiments and a minimum of 150 cells were analysed per experiment. Asterisk 
indicates a significant difference (*p<0.05) between cells grown on control cells compared to 
those on NCAM-expressing cells, assessed by unpaired Student’s t-test. 
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Figure 4.6 Effect of signalling inhibitors on NCAM-mediated OPC process outgrowth. 
The effect of inhibitors of the FGFR (PD173074 50 nM), MAP kinase (PD98059 10 µM) and Fyn 
kinase (PP2 1 µM) on OPC process outgrowth over untransfected 3T3 fibroblasts and NCAM-
expressing fibroblasts (N24) after one day in vitro were assessed.  Western blotting was used to 
confirm that the addition of these inhibitors did not affect the expression of NCAM on 3T3 
fibroblasts (lanes 1-4) and NCAM-expressing fibroblasts (lanes 5-8) (A).  The addition of 
PD173074 (lanes 2 and 6), PD98059 (lanes 3 and 7) and PP2 (lanes 4 and 8) did not alter 
NCAM expression, compared to total protein, using actin as a loading control (A).  Images show 
representative immunoblots of an experiment repeated three times. OPC morphology was 
assessed by O4 immunocytochemistry and the number of processes per cell were quantified (B, 
C).  Addition of PD173074, PD98059 and PP2 to OPCs grown over untransfected fibroblasts 
(B) and NCAM-expressing fibroblasts (C) only had a small effect on process number, increasing 
the number of cells with zero processes, with PP2 having the greatest effect. Results are shown 
as mean ± SEM of three independent experiments and a minimum of 150 cells were analysed 
per experiment. 
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Figure 4.7 Effect of signalling inhibitors on OPC process number and process length. 
OPCs isolated by immunopanning for O4 were plated on top of confluent monolayers of either 
untransfected 3T3 fibroblasts or NCAM-expressing fibroblasts in the presence or absence of an 
FGFR inhibitor (PD173074, 50 nM), MAP kinase inhibitor (PD98059, 10 µM) or Fyn inhibitor 
(PP2, 1 µM) and the morphology examined after 24 hours in culture using O4 
immunocytochemistry. The number of processes per cell were counted manually (A) and the 
length of all primary processes measured using image analysis (B). Results are shown as mean 
± SEM of three independent experiments and a minimum of 150 cells were analysed per 
experiment. Asterisk indicates a significant difference (*p<0.05) assessed by unpaired Student’s 
t-test. 
  
173 
 
4.3.4 Effect of FRM peptide and NCAM-Fc on GalC expression 
As an alternative measure of differentiation, the proportion of cells expressing GalC (as 
recognised by the O1 antibody) were quantified after two days in vitro.   GalC 
expression is observed when cells differentiate into post-mitotic immature 
oligodendrocytes and also on mature oligodendrocytes (Ranscht et al. 1982).  
Incubation with insulin, FRM peptide and NCAM-Fc (all 5 µg/ml) caused a slight 
increase in the number of O1
+
 cells, whereas FGF2 (0.1 ng/ml) produced a small 
decrease.  However, none of these factors significantly affected the proportion of O1
+
 
cells observed after two days in vitro, compared to control cells where 20.0 ± 9% cells 
were O1
+
 (Figure 4.8) as determined by an unpaired Student’s t test. 
 
4.3.5 Effect of FRM peptide and NCAM-Fc on myelin protein expression 
The effect of FRM peptide and NCAM-Fc on myelin protein expression was also 
investigated.  Western blotting was performed on lysates from untreated cells and cells 
stimulated with insulin, FRM peptide and NCAM-Fc (all 5 µg/ml) for three days, using 
antibodies to CNP and MOG (Figure 4.9).  As a positive control, lysates from OPCs 
stimulated with insulin for six days were also included, which expressed high levels of 
both CNP and MOG.  Robust CNP expression was observed after three days 
differentiation and a small increase was detected following stimulation with insulin, 
FRM peptide and NCAM-Fc compared to untreated cells (Figure 4.9a).  Whilst MOG 
expression was greatly increased after six days differentiation it was low under all 
treatments after three days and no significant differences were found between control 
and treated cells, as determined by qualitative assessment (Figure 4.9b). 
 
To investigate if greater changes could be detected at an earlier time point following 
FRM peptide and NCAM-Fc treatment (5 µg/ml), mRNA from OPCs was extracted 
after 24 hours stimulation (Figure 4.10).  Quantitative RT-PCR was carried out using 
primers to two different myelin proteins, MBP and PLP, and relative mRNA was 
assessed by comparing to the house keeping gene GAPDH, whose expression did not 
vary with OPC differentiation.  RT-PCR showed that insulin significantly increased 
levels of MBP and PLP mRNA by approximately three fold, when compared to 
untreated cells (Figure 4.10).  FRM peptide and NCAM-Fc did not significantly alter 
levels of MBP or PLP mRNA.    
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Figure 4.8 Effect of FRM peptide and NCAM-Fc on galactocerebroside expression. 
OPCs isolated by O4 immunopanning were differentiated in OLP media with insulin (5 µg/ml), 
FRM peptide (5 µg/ml, B), NCAM-Fc (5 µg/ml, C), FGF2 (1 ng/ml, D) or without growth factors 
(control A) and immunocytochemistry for O1 (galactocerebroside, green) performed after two 
days in culture. The number of O1
+
 cells were counted and expressed as a proportion of the 
total number of cells, as determined by DAPI staining of nuclei (blue).  Insulin, FRM peptide and 
NCAM-Fc caused a slight increase in the number of O1
+
 cells but this did not reach significance.  
Data shown is mean ± SEM from 4-5 separate experiments with three coverslips analysed per 
experiment, and ten fields per coverslip quantified.  Scale bars: 100 µm. 
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4.4 Discussion 
 
Several different methods have been used to define oligodendrocyte differentiation in 
culture.  In vitro assessments of oligodendrocyte maturation typically assess the degree 
of process outgrowth or cell area, which is a measure of morphological differentiation 
and reflects alterations in cytoskeletal organisation.  Additionally, the level of 
expression of myelin proteins, such as MBP or PLP, or the mature oligodendrocyte 
marker GalC, can be quantified and represent a measurement of antigenic 
differentiation or myelin membrane elaboration.   In vivo studies can assess myelin 
protein levels, the degree of myelin thickness and the number of mature 
oligodendrocytes, to directly measure an effect on myelination.  The expression of 
NCAM along axons and oligodendrocyte processes prior to myelination has been 
previously described (Bartsch et al. 1989), suggesting that NCAM may play a role in 
the stimulation of myelination.  This study aimed to examine whether soluble NCAM 
and NCAM expressed as part of a cellular substratum could increase the morphological 
differentiation of OPCs by measuring process outgrowth and expression of myelin 
protein. 
 
4.4.1 Cellular NCAM but not FRM peptide and NCAM-Fc promoted OPC process 
outgrowth 
NCAM peptides derived from the FnIII domains (Anderson et al. 2005; Kiselyov et al. 
2003; Neiiendam et al. 2004) and Ig domains of NCAM (Ditlevsen et al. 2003; Li et al. 
2005; Pedersen et al. 2004) and full-length NCAM-Fc (Meiri et al. 1998; Schmid et al. 
1999) have been shown to increase neurite outgrowth in vitro.  Monomeric FRM 
peptide behaved as an inverse agonist, with low concentrations inhibiting cellular 
NCAM-mediated neurite outgrowth, whereas cyclised and dendrimic versions of the 
peptide were more potent and enhanced neurite outgrowth up to a maximum (at 1-2 
µM), with higher concentrations reducing outgrowth (Anderson et al. 2005).  A similar 
pattern was seen in response to the P2 and FGL peptides (Li et al. 2005; Neiiendam et 
al. 2004).  FRM peptide has been shown to produce some of the same effects as FGF2 
on fibroblasts (Anderson et al. 2005).  These observations coupled with the fact that 
FRM peptide and NCAM-Fc stimulated OPC survival, led us to hypothesise that soluble 
NCAM would have similar effects on oligodendrocytes and would therefore increase 
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OPC process outgrowth.  However, FRM peptide and NCAM-Fc were not able to 
stimulate a significant increase in the number of processes per cell or the average 
process length of OPCs after one day in vitro.   
 
The use of fibroblasts stably transfected with the NCAM-140 isoform of NCAM is a 
well characterised assay system and has the advantage of presenting an endogenous 
neuronal isoform of NCAM in the context of a cellular substratum, making it more 
physiologically applicable to investigating cell-cell interactions, as compared to using 
soluble proteins or peptides.  The levels of NCAM expressed by the fibroblasts have 
been shown to be within the physiological range and approximate interactions found in 
vivo (Doherty et al. 1989; Doherty et al. 1990b).  The co-culture system has the 
disadvantage that NCAM is expressed by a cell type that an OPC would not normally 
encounter in the CNS.  Several studies have confirmed that culture of neurons on a 
monolayer of NCAM-expressing fibroblasts significantly increases the neurite 
outgrowth compared to that on control untransfected fibroblasts (Doherty et al. 1989; 
Doherty et al. 1990b; Kolkova et al. 2000a; Saffell et al. 1992).  We have shown that 
cellular NCAM had a similar effect on OPCs as it does on neurons, in that culture on 
NCAM-expressing fibroblasts resulted in a significant increase in the number of 
processes per cell and the average process length.  We have previously demonstrated 
that growth of OPCs on NCAM-expressing and untransfected fibroblasts does not affect 
proliferation, as assessed by BrdU incorporation (Palser et al. 2009). 
 
Interestingly, addition of FRM peptide or NCAM-Fc to this co-culture system did not 
affect the process outgrowth.  This suggested that neither the peptide nor the protein 
were able to antagonise the effect of substrate-bound NCAM, nor were they able to 
stimulate outgrowth over the control fibroblasts.  This indicates that the extension of 
neurites from neurons and PC12 cells may be different from OPC process outgrowth, 
because FRM peptide and FGL peptide were able to increase neurite outgrowth 
(Anderson et al. 2005; Neiiendam et al. 2004).  Additionally, FRM peptide behaved as 
an inverse agonist and was able to inhibit the effects of cellular NCAM (Anderson et al. 
2005), at concentrations similar to those used in the OPC outgrowth assay here, where 
no such activity was observed.  Therefore, whilst soluble versions of CAMs mimicked 
the response of cellular NCAM in neurons, the same was not true for OPCs, which 
instead required NCAM to be substrate bound in order to evoke outgrowth.  The 
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function of OPC outgrowth is very different to that of neurite outgrowth, and it is 
possible that a soluble molecule does not provide the same stimulus as encountered 
during cell-cell adhesion.  In the previous chapter we demonstrated that FRM peptide 
and NCAM-Fc were able to activate intracellular signalling pathways that increased 
OPC survival.  It appears that activation of these pathways in the OPC does not also 
stimulate outgrowth, and that adhesion to a substratum provides an additional level of 
stability or molecular interaction that is required for process extension.  Another study 
that examined the effect of NCAM on oligodendrocyte outgrowth showed that purified 
NCAM protein increased myelin-membrane formation (Gard et al. 1996).  In this study, 
the NCAM protein was bound to coverslips rather than cells, so this may present the 
NCAM in a more stable form or more optimal conformation, compared to the soluble 
versions used here.  Also, process outgrowth was measured at a much later time point 
(six days in vitro compared to one day in our study) so it is possible that the effect of 
NCAM on survival as well as differentiation was being measured at the later stage 
(Gard et al. 1996).  Coating of coverslips with a protein does not enable accurate 
determination of the final concentration of the protein because it is unknown how much 
of it binds to the surface so it may not be at a physiologically relevant concentration.  
Additionally, when the adhesion molecule NFasc was presented to cells as NFasc-Fc, it 
induced neurite outgrowth when immobilised on an inert surface (substrate bound) but 
not as a soluble protein (Volkmer et al. 1996).   
 
4.4.2 Possible mechanisms of cellular NCAM-mediated process outgrowth  
Previous studies have characterised the signalling pathways involved in neurite 
outgrowth (as reviewed by Ditlevsen et al. 2008b; Ditlevsen and Kolkova 2008, Figure 
3.1) but NCAM-induced signalling in oligodendrocytes has not been investigated.  The 
first signalling molecule shown to be involved in NCAM-mediated neurite outgrowth 
was calcium, whereby an increase in cytosolic calcium was detected following NCAM-
NCAM binding that could be inhibited by calcium channel blockers (Doherty et al. 
1991) and this also occurred in response to N-cadherin (Saffell et al. 1992).  Release of 
intracellular calcium occurs following PLC activation, production of DAG and AA and 
activation of PKC.  PKC may then activate Raf in the MAPK cascade.  Neurite 
outgrowth over NCAM-expressing fibroblasts has been shown to be dependent on PI3K 
(Ditlevsen et al. 2003) and MAPK (Perron and Bixby 1999; Schmid et al. 1999).  
Combined activation of MAPK via FGFR-PLC-PKC and via Fyn-FAK-Ras may be 
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required to initiate optimal neurite outgrowth induced by NCAM (Kolkova et al. 2000a; 
Niethammer et al. 2002; Schmid et al. 1999).  However, inhibition of MEK resulted in a 
partial (60%) inhibition of NCAM-mediated neurite outgrowth in these studies, 
suggesting that mechanisms outside of MAPK activation operate.   
 
4.4.2.1 Increased OPC process outgrowth by cellular NCAM was not dependent on 
signalling via FGFR or MAPK 
Several studies have shown that the activity of NCAM peptides involves signalling via 
the FGFR.  FGL peptide-mediated neuronal survival was dependent on the FGFR, 
MAPK and PI3K pathways (Neiiendam et al. 2004).  Neurons isolated from mice 
lacking functional FGFRs were unable to respond to FRM peptide or cellular NCAM  
(Anderson et al. 2005; Saffell et al. 1997).  Immunoprecipitation of FGFRs from 
fibroblasts stimulated by FRM peptide detected an increase in tyrosine phosphorylation, 
suggesting that the effect of FRM peptide was dependent on FGFR signalling 
(Anderson et al. 2005).  The mechanisms involved in NCAM-mediated process 
outgrowth in oligodendrocyte lineage cells had not been previously investigated.  
Therefore, we examined whether pharmacological inhibitors prevented the effect of 
cellular NCAM.  Inhibition of the FGFR using PD173074 did not significantly affect 
process outgrowth, suggesting that this was not the mechanism responsible for 
transducing the signal to increase OPC outgrowth, in contrast to the effect we observed 
on cell survival.   
 
MAPK and p38 have been shown to be important for the morphological differentiation 
of OPCs, using PD98059 and SB203580, respectively (Baron et al. 2000).  Activation 
of PKC using with the phorbol ester PMA, resulted in downstream activation of MAPK 
and enhanced process outgrowth, which could be blocked by PD98059 (Stariha et al. 
1997).  It was therefore somewhat surprising given that MAPK had been shown to be 
important for OPC process outgrowth and NCAM signalling in neurons that PD98059 
(10 µM) did not significantly inhibit the process outgrowth stimulated by cellular 
NCAM in our system.  This suggests that cellular NCAM uses alternative pathways to 
stimulate OPC outgrowth.  In support of this PD98059 has been shown to be less active 
at preventing neurite outgrowth compared to survival mediated by FGL peptide (50 µM 
only decreased outgrowth by 20%, whereas it reduced survival by 50%, (Neiiendam et 
al. 2004), suggesting that the main actions of ERK activation by NCAM peptides may 
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be to promote survival.  Kolkova et al (2000a) used a much higher concentration 
PD98059 (25 µM) in their PC12/fibroblast co-cultures, which may be why they observe 
100% inhibition (back to control fibroblast levels).  However, 10 µM PD98059 was 
sufficient to reduce FGF2, N-cadherin and laminin-mediated neurite outgrowth (Perron 
and Bixby 1999), but the pathways involved in outgrowth may vary depending on the 
stimulus. 
 
ERK is thought to target both cytosolic and nuclear proteins and the distribution of ERK 
following its activation may determine the eventual response.  Translocation of ERK 
from the cytoplasm to the nucleus was observed following PMA stimulation, suggesting 
that nuclear targets are involved in OPC process extension (Stariha et al. 1997).  Culture 
of neurons on N-cadherin resulted in rapid ERK activation and a punctuate 
redistribution to the plasma membrane that was blocked by PD98059 (in contrast to 
ERK signalling to induce mitosis where redistribution to the nucleus occurs) (Perron 
and Bixby 1999), suggesting that cytosolic targets of ERK function in outgrowth.    
Duration of the phospho-ERK signal is also important in determining outcome.  A 
transient exposure of ten minutes to PMA was required to stimulate measureable 
outgrowth 72 hours later, indicating that prolonged activation is not necessary (Stariha 
et al. 1997).  However, it has been suggested that sustained activation of ERK is 
required to induce differentiation/neurite outgrowth following NCAM binding (Kolkova 
et al. 2000a).  The duration of the MAPK signal induced by NCAM varies between 
studies: the C3 peptide induced ERK phosphorylation that lasted at least 40 minutes and 
ERK was still activated after 24 hours in PC12 cells grown over NCAM-expressing 
fibroblasts (Kolkova et al. 2000a), whereas antibody-induced NCAM clustering of 
already differentiated cells produced ERK activation lasting ten minutes (Schmid et al. 
1999).  Our study found that the duration of ERK activation was less than one hour 
following FRM peptide and NCAM-Fc stimulation (Chapter 3.3).  Another possibility is 
that effect of ERK activation is not sufficiently blocked by the inhibitor in this assay 
because OPCs are plated onto monolayers for one hour in serum-containing media, 
prior to switching to OLP with inhibitors.  Activation of ERK may have occurred upon 
initial plating of cells and this may have already had an effect which could not be 
blocked by subsequent MEK inhibition. 
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In the previous chapter we demonstrated that FRM peptide and NCAM-Fc do not 
activate p38, so we did not investigate this signalling molecule in the outgrowth assay. 
 
4.4.2.2 Cellular NCAM-mediated process outgrowth was dependent on Fyn signalling  
Fyn is an important regulator of cytoskeletal structure, cell adhesion and cell 
morphology and therefore it is not surprising that it has a role in the formation of 
morphologically complex cells such as oligodendrocytes, where it has been shown to be 
involved in differentiation and myelination (Sperber et al. 2001; Umemori et al. 1994; 
Osterhout et al. 1999).  Fyn activity was lower in the NCAM-null mouse compared to 
the wildtype, suggesting that NCAM is a major activator of Fyn (Bodrikov et al. 2005).  
Additionally, Fyn can be activated by NCAM in culture, leading to neurite outgrowth 
(Beggs et al. 1994; Kolkova et al. 2000a; Schmid et al. 1999).  Therefore, Fyn is an 
ideal candidate to act downstream of NCAM signalling in oligodendrocytes and may 
contribute to NCAM-mediated oligodendrocyte differentiation.  We showed that 
inhibition of Fyn using PP2 significantly inhibited the number of processes per cell but 
not the average process length after one day in vitro, pointing to a possible role in 
initiation of process outgrowth rather than elongation of processes.  However, PP2 did 
not cause a complete reduction in the number of processes per cell compared to cells 
grown on untransfected fibroblasts, suggesting the presence of alternative mechanisms 
independent of Fyn to stimulate outgrowth.  Osterhout et al (1999) also suggested that 
Fyn was required for initial outgrowth as it was activated as soon as cells are switched 
to differentiation medium and prior to visible morphological changes.  However, they 
examined process outgrowth at a later stage, finding a 10% reduction after four days 
with 1 µM PP2 (Osterhout et al. 1999).  It may be that we would have observed a 
greater effect after longer incubations with the inhibitor.  Sperber and McMorris (2001) 
showed in cultures of OPCs isolated from Fyn-null mice that whilst mature 
oligodendrocytes were formed, they were fewer in number and appeared less complex, 
and suggested that Fyn might be required to produce the elaborate network of fine 
processes in mature oligodendrocytes, as opposed to initiation of process outgrowth.  In 
addition, there are reports that PP2 has cytotoxic effects on OPCs (used at 5 µM for 1-2 
days), indicating it may act on targets other than Fyn (Sperber and McMorris 2001).  
Other studies have shown that a much higher concentration of 24 µM PP2 was required 
to completely abolish NCAM-mediated neurite outgrowth (Kolkova et al. 2000a), but it 
may be that neurons are less sensitive to the compound.  As discussed earlier, MAPK 
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are said to be activated downstream of Fyn, but we have shown that inhibition of MEK 
does not affect OPC process outgrowth.  It is unclear what pathways may be operating 
downstream of Fyn in this system.  
 
4.4.3 Role of different NCAM isoforms in OPC process outgrowth 
Another explanation for the difference between the response of OPCs and neurons to 
NCAM may be the differential expression of NCAM isoforms.  Immature 
oligodendrocytes express NCAM-120 and NCAM-140 (as shown in Chapter 2.3) and 
the predominant isoform on mature oligodendrocytes is the 120 kDa isoform, whereas 
neurons express the 180 kDa isoform and to a lesser extent NCAM-140 (Bhat and 
Silberberg 1986; Trotter et al. 1989).  There are contradictory reports in the literature 
stating which of the NCAM isoforms are important for stimulating neurite outgrowth.  
Doherty and co-workers demonstrated that expression of any NCAM isoform on a 
fibroblast monolayer increased neurite outgrowth (Doherty et al. 1989).  However, this 
is likely to be due to the fact that the extracellular domains of the different NCAM 
isoforms are identical so they would present in the same way to another cell.  It is the 
NCAM isoforms expressed by the neuron that act as the receptor and will determine 
what signalling molecules they couple to.   
 
The cytoplasmic domains, present only within NCAM-140 and NCAM-180, are thought 
to be essential for neurite outgrowth (Buttner et al. 2004; Kolkova et al. 2000b; Saffell 
et al. 1995).  PC12 cells transfected with NCAM-140 and NCAM-180 displayed neurite 
outgrowth in response to NCAM, whereas those expressing the GPI-linked NCAM-120 
isoform did not, suggesting NCAM-120 cannot act as a neuronal receptor (Saffell et al. 
1994;Saffell et al. 1997).  Overexpression of the cytoplasmic domain of NCAM-140 
reduced neurite outgrowth, whereas that of NCAM-180 had no effect, suggesting that 
NCAM-140 is the important isoform in controlling neurite outgrowth (Buttner et al. 
2004; Kolkova et al. 2000b).   In agreement with this Beggs et al (1997) showed that 
only NCAM-140 co-precipitated with Fyn and the receptor protein tyrosine phosphatase 
(RPTPα), which activates Fyn (Bodrikov et al. 2005).  This suggested that NCAM-120 
might not be able to activate Fyn and therefore signalling via Fyn may be less important 
in oligodendrocytes than neurons.  However, as NCAM-120 is not typically expressed 
by neuronal cells its inability to stimulate their neurite outgrowth when overexpressed 
may not be physiologically relevant.  In contrast, NCAM-120 is the predominant 
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isoform expressed by oligodendrocytes so may be relevant to process outgrowth in 
these cells.   
 
It has been shown that Fyn compartmentalises in lipid rafts with GPI-linked molecules, 
including NCAM-120 and contactin/F3 in oligodendrocytes (Kramer et al. 1999).  
Beggs et al (1997) carried out their study on brain tissue from postnatal day four mouse 
cerebellum and NCAM-120 increases in abundance after this point (Bhat and Silberberg 
1988a), so it may be that only a small amount of NCAM-120 co-precipitated with Fyn 
at this time point because NCAM-140 is the major isoform.  All NCAM isoforms can 
be found in lipid rafts in the postnatal brain (Niethammer et al. 2002).  Whilst it appears 
that NCAM-120 is predominantly raft-associated, NCAM-140 and NCAM-180 are 
present in raft and non-raft compartments (Kramer et al. 1999; Neithammer et al. 2002; 
He and Meiri 2002).  Inhibition of sphingolipid synthesis using a fungal toxin, 
prevented raft formation and strongly reduced process outgrowth from an OPC cell line 
(Klein et al. 2002), suggesting that raft domains provide important signalling platforms 
for OPC outgrowth.  NCAM-120 and NCAM-140 but not NCAM-180 were shown to 
activate ERK in the presence of an FGFR inhibitor, suggesting they do not require 
functional FGFRs to signal (Niethammer et al. 2002), which may be why PD173074 did 
not affect OPC process outgrowth in our assay.  It is suggested that in raft 
compartments, NCAM-120 and NCAM-140 predominantly signal via Fyn, whereas in 
non-raft compartments NCAM-140 signals via the FGFR and that both pathways must 
co-operate to stimulate outgrowth (Niethammer et al. 2002).  Due to the low density of 
FGFR in lipid rafts, Niethammer et al (2002) speculate that NCAM-120 would be 
unlikely to interact with the FGFR.  However, their experiments were carried using 
CHO cells transfected with one NCAM isoform at a time or neuroblastoma cells, and 
this may not be physiologically relevant to signalling in oligodendrocytes.  It could be 
that NCAM-140 is also the important isoform for outgrowth in oligodendrocytes and 
that it is down-regulated as cell maturation increases because an outgrowth response is 
no longer required once myelination is complete.  The studies examining the effect of 
NCAM on neurons focus on FGFR1, but it is possible that NCAM could have interacted 
with FGFR2 or FGFR3 in our system, as both are also expressed by oligodendrocyte 
lineage cells.  In particular, FGFR2 has been shown to co-localise to lipid raft 
compartments of oligodendrocytes (Bryant et al. 2009), where it would be in close 
proximity to NCAM-120.  It is possible that the function of NCAM signalling may be 
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different in pre-myelinating oligodendrocytes compared to mature oligodendrocytes, 
where further outgrowth is not required.  Targeting of NCAM-120 to raft compartments 
in mature oligodendrocytes could serve to prevent NCAM from interacting with FGFR1 
in non-raft compartments. 
 
Process outgrowth depends on the continuous assembly, disassembly and stabilisation 
of actin filaments and microtubules.  The most extensively investigated cytoskeletal 
protein to interact with NCAM is spectrin, which is a scaffolding protein that links the 
plasma membrane to motor proteins and actin filaments and associates with lipid rafts.  
Brain spectrin has been shown to co-purify with only NCAM-180 (Pollerberg et al. 
1987), but when expressed in CHO cells all NCAM isoforms co-precipitated with β1 
spectrin (Leshchyns'ka et al. 2003).  NCAM-140 and NCAM-180 also interacted with α 
and β-tubulin (Buttner et al. 2003).  Raft localisation of NCAM enabled interaction with 
the growth associated protein, GAP-43, which is an actin-binding protein activated by 
PKC and found in growth cones (He and Meiri 2002; Meiri et al. 1998).  It has been 
suggested that GAP43 is primarily involved in NCAM-180-mediated neurite outgrowth 
via the formation of a complex with spectrin, although this mechanism was less 
important in PC12 cells where outgrowth depended on NCAM-140 (Korshunova et al. 
2007).  Other studies have suggested that the primary function of NCAM-180 is to 
stabilise cell-cell contacts, and therefore, it may not be involved in signalling to 
stimulate neurite outgrowth (Buttner et al. 2003). 
 
GAP43 is expressed by OPCs and down-regulated by mature oligodendrocytes (Curtis 
et al. 1991).  It has also been found in OPC growth cones (Fox et al. 2006), so could 
potentially contribute to oligodendrocyte process outgrowth.  It appears that the 
mechanisms of neurite outgrowth differ between hippocampal neurons and PC12 cells 
(Korshunova et al. 2007), indicating that caution should be taken when extrapolating 
data from one cell type to another.  Non-neural cells and cell lines are likely to provide 
a different signalling environment and interaction partners when compared to primary 
neurons and oligodendrocytes.   
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4.4.4 Possible reasons why cellular NCAM but not soluble NCAM could stimulate 
OPC process outgrowth 
It was somewhat surprising that FRM peptide and NCAM-Fc did not have similar 
effects to cellular NCAM on OPC process outgrowth, particularly as the FnIII domain 
of NCAM found in the FRM peptide is thought to confer the biological activity required 
for outgrowth (Anderson et al. 2005).  As we have discussed earlier, this may be due to 
the requirement for adhesion as well as activation of intracellular signalling to stimulate 
OPC outgrowth.  However, there are several other factors that could play a role.  The 
degree of process outgrowth of OPCs grown on coverslips in the absence of soluble 
NCAM was in between that of cells grown on NCAM-expressing fibroblasts and 
untransfected fibroblasts (mean process length of 27.5 ± 0.5, 35.1 ± 3.3 and 23.0 ± 3.0, 
respectively).  Therefore, the untransfected fibroblasts may have an inhibitory effect on 
OPC outgrowth, which is then overcome by culture on cells that express NCAM, 
perhaps making the environment more permissive.  Another possibility is that the 
untransfected fibroblasts released factors that inhibited OPC differentiation or expressed 
inhibitory molecules on their surface.  However, these cell lines have been used 
extensively by other groups and have not been shown to be inhibitory to other neural 
cells.  OPC process outgrowth may be delayed rather than inhibited on untransfected 
fibroblasts, and it may be that at later time point there would be no difference in 
outgrowth.  We were unable to use the fibroblast co-culture system for time points 
longer than two days with the OPCs, as the fibroblasts did not survive adequately in the 
serum-free OLP medium required for OPC differentiation.  Gard et al (1996) quantified 
outgrowth after seven days in vitro and were able to detect a large difference between 
cells grown on NCAM and those grown on polyornithine, indicating that at longer time 
points the growth-promoting effect of NCAM was still apparent. 
 
Members of the Ig superfamily of CAMs are able to bind homophilically and 
heterophilically.  Therefore, it is possible that the NCAM expressed by the fibroblasts 
was not interacting homophilically with NCAM on the OPCs, and that instead it bound 
heterophilically with other molecules expressed by OPCs.  In particular, the structure of 
many members of the Ig superfamily are very similar and we and others have shown 
that OPCs also express Nfasc and contactin/F3 (Collinson et al. 1998; Koch et al. 
1997).  However, it is unclear why NCAM-Fc would not have the same ability to bind 
to other adhesion molecules on the surface of the OPC as cellular NCAM. 
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It is possible that technical factors could have contributed to the lack of a response seen 
to FRM peptide and NCAM-Fc.  For example, the concentrations that we used, which 
also stimulated OPC survival and neurite outgrowth may be different to those required 
for OPC outgrowth.  Clustering of NCAM at the cell surface in the N24 cell line could 
provide a higher local concentration compared to binding of the peptide or protein, 
which may serve to activate different signalling pathways.  Therefore, higher 
concentrations of soluble proteins may be required for maximal process outgrowth.  
Alternatively, the time point that we made our measurements may not have been 
optimal to see a difference between control and treated cells.   
 
4.4.5 FRM peptide and NCAM-Fc do not affect differentiation 
Oligodendrocyte differentiation is characterised by increased expression of myelin 
proteins, such as MBP and MOG (Hardy and Reynolds 1991).  To measure 
differentiation we examined whether FRM peptide and NCAM-Fc could increase the 
expression of myelin proteins and GalC.  GalC expression is first detected on immature 
post-mitotic oligodendrocytes (Ranscht et al. 1982).  We did not detect a change in the 
proportion of O1/GalC
+
 cells after two days in culture in response to FRM peptide or 
NCAM-Fc.  No significant effect was observed on the mRNA of MBP or PLP or on the 
expression of CNP or MOG protein.  This is in agreement with a previous study by our 
group, which showed that cellular NCAM did not increase the number of MBP
+
 cells 
after two days in vitro, indicating that the effects of cellular NCAM on OPC 
morphology were independent of an effect on myelin gene expression (Palser et al. 
2009).  In contrast, insulin caused up-regulation of MBP and PLP mRNA, which 
concurs with previous studies demonstrating that IGF1 increased oligodendrocyte 
mRNA transcription and protein synthesis (Bibollet-Bahena and Almazan 2009) and 
insulin increased MBP protein expression (Palacios et al. 2005).  Our study implies that 
whilst insulin and NCAM mimetics may function in a similar way to promote OPC 
survival, they have different effects on differentiation, in particular myelin gene 
expression. This also indicates that different aspects of the differentiation process, 
namely process outgrowth and myelin gene expression, are controlled independently.  
 
ECM molecules, such as fibronectin and laminin, have been shown to promote 
morphological differentiation of OPCs but not to affect the number of MBP
+
 cells 
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(Buttery and ffrench-Constant 1999), further supporting the suggestion that these 
different aspects of OPC differentiation are controlled separately.  Pharmacological 
inhibition of Fyn did not prevent the expression of mature oligodendrocyte markers 
GalC and MOG (Osterhout et al. 1999).  Earlier studies proposed that induction of 
differentiation requires prolonged MAPK activation (Marshall 1995) and this is 
supported by evidence that PD98059 inhibited MBP expression (Clark et al. 1998; Du 
et al. 2006).  However, Palacios et al (2005) showed that IGF1 caused a transient 
activation of ERK that had returned to basal levels after 24 hours, suggesting that 
prolonged ERK activation was not required to increase myelin production.  There is 
also dispute over whether cAMP and PKA inhibit or promote IGF1-dependent myelin 
expression (Clark et al. 1998; Palacios et al. 2005).  MBP is a late response gene with 
increased mRNA detected six hours after stimulation and continuing until 72 hours post 
stimulus (Clark et al. 1998).  MBP expression is enhanced by over-expression of the 
p85 regulatory subunit of PI3K, in a kinase independent manner, possibly involving an 
interaction with Fyn (Clark, Jr. et al. 2002; Scarlato et al. 2000).  Fyn has been 
suggested to regulate myelin expression in other studies (Goto et al. 2004; Umemori et 
al. 1999).  However, our data implies that NCAM is not the upstream activator of Fyn-
induced myelin gene expression.   
 
In vitro kinase assays have shown that MAPK can phosphorylate MBP, and as MAPK 
are located in proximity to the membrane, MBP may be regulated by MAPK in vivo 
(Bhat and Zhang 1996).  This indicates a cytoplasmic role for ERK in MBP regulation, 
which may be separate from its role in stimulating gene expression via nuclear targets 
(Stariha et al. 1997).  Pharmacological inhibition of p38 has been shown to prevent the 
morphological and antigenic differentiation of OPCs and to inhibit myelination in co-
cultures (Bhat et al. 2007; Haines et al. 2008).  We have shown that p38 was not 
involved in NCAM-mediated OPC survival, but have not investigated its effect on 
differentiation.  The downstream target of p38 is believed to be CREB, but the upstream 
activators are unknown (Bhat et al. 2007).  The point of action of p38 is believed to be 
as the OPC exits the cell cycle and begins terminal differentiation (Bhat et al. 2007), 
which may operate earlier than a contact-dependent signal such as NCAM. 
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4.4.6 Conclusion 
Changes in NCAM expression during development, for example down-regulation of 
PSA-NCAM, increased expression of NCAM-VASE and greater expression of NCAM-
120 as opposed to NCAM-140, may all serve to regulate the response of 
oligodendrocytes to NCAM and thus influence myelination.  We have shown that OPC 
process outgrowth was increased when cells were grown on NCAM-expressing 
fibroblasts compared to untransfected fibroblasts.  This was partially dependent on 
signalling via Fyn, as demonstrated using PP2.  Therefore, a possible mechanism for 
NCAM-mediated process outgrowth is NCAM on the fibroblasts binding to NCAM-
120/140 on the OPCs, leading to activation of Fyn and cytoskeletal re-arrangement.  
The lack of an effect of the FGFR and MEK inhibitors suggests that the same signalling 
pathways that operate to control neurite outgrowth are not involved in NCAM-mediated 
OPC outgrowth.  However, the fact that NCAM-Fc and FRM peptide did not have an 
effect on OPC process outgrowth, but had previously been shown to promote neurite 
outgrowth, suggests that binding of a soluble protein or peptide is not sufficient to 
stimulate morphological differentiation into an oligodendrocyte.  This provides 
evidence that the response to NCAM initiated in OPCs is different to that in neurons 
and also highlights differential regulation of OPC survival and outgrowth. In 
conclusion, cellular NCAM promoted OPC process outgrowth, but soluble NCAM did 
not affect outgrowth or differentiation. 
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Chapter 5 
 
 
 
 
 
Effect of NCAM on myelination 
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5.1 Introduction 
 
5.1.1 Axon-oligodendrocyte interactions 
It has been shown that axonal signals are important for regulating the proliferation, 
survival and differentiation of oligodendrocytes.  The number of oligodendrocytes 
produced during development exceeds the number required; this redundancy ensures 
that all of the necessary axons become myelinated.  Only oligodendrocytes that make 
the correct axonal contact and, therefore, receive the contact-dependent signals to 
maintain their survival and to initiate myelin formation will persist, the remainder will 
die via apoptosis (Barres et al. 1993a).  This is also controlled in part by a limited 
supply of the mitogen and survival factor PDGF (Barres et al. 1992).  Initiation of 
myelination depends on a balance between positive signals, which have to be expressed 
for myelination to proceed, and negative factors that must be removed in order for the 
axon to be permissive to myelination.  Adhesion molecules are candidate molecules to 
mediate target-dependent signalling between the axon and oligodendrocyte. Other 
positive factors include electrical activity (Demerens et al. 1996) and ATP release 
(Stevens et al. 2002), whilst PSA-NCAM, Notch and LINGO have been shown to 
negatively influence myelination (Charles et al. 2000; Mi et al. 2005; Wang et al. 
1998), as described in more detail in Chapter 1. 
 
5.1.2 Control of oligodendrocyte myelination 
How axon-oligodendrocyte interactions ensure target-dependent survival and initiation 
of myelination remains poorly understood.  It is difficult to uncouple oligodendrocyte 
differentiation from myelination, as an undifferentiated oligodendrocyte cannot 
myelinate so the processes are not mutually exclusive.  Myelination is an asynchronous 
process, beginning at two days postnatally and continuing for several weeks or months, 
depending on the brain region.  It is proposed that the regional differences arise either 
because OPCs are a heterogeneous population capable of forming myelin at different 
times, or because the appearance of environmental cues varies across brain regions 
(Rosenberg et al. 2007).  For example, myelination in the optic nerve follows a rostro-
caudal gradient, but OPC differentiation does not (Colello et al. 1995), leading to the 
suggestion that differentiation and myelination may be uncoupled.  Additionally, axons 
mature and initiate electrical signalling at different times across brain regions. 
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In contract to the PNS where NRG 1 type III has been shown to be essential for 
myelination and to regulate myelin sheath thickness (Michailov et al. 2004; Taveggia et 
al. 2005), no single molecule has been shown to have such an instructive role in the 
CNS.  NRG has been shown to play a role in CNS myelination but was not crucial, 
indicating that several factors probably co-operate to stimulate oligodendrocyte 
myelination.  Hypermyelination occurred when NRG 1 was overexpressed in vivo 
(Brinkmann et al. 2008) and thinner myelin was produced in NRG 1 haplo-insufficient 
mice (Taveggia et al. 2008).  Interestingly, the degree of hypomyelination varied 
depending on brain region, suggesting that additional local signals operate (Taveggia et 
al. 2008).  Addition of soluble NRG to DRG/OPC co-cultures increased myelination; 
conversely blocking antibodies and ErbB4-Fc chimeras completely inhibited 
myelination (Wang et al. 2007).  The effects may have been more pronounced in vitro 
due to less opportunity for compensatory mechanisms to act.  
 
The binding of ECM molecules to pre-myelinating oligodendrocytes may also help to 
regulate myelination.  Oligodendrocytes express dystroglycan, which is a laminin 
receptor and has been shown to have a role in differentiation but not survival 
(Colognato et al. 2007).  Dystroglycan blocking antibodies and siRNA reduced 
myelination in a co-culture system (Colognato et al. 2007), indicating that interactions 
with the ECM are necessary for correct myelination.  NGF is a soluble growth factor 
released by neurons that has been shown to have a role in myelination, exerting 
opposing effects on Schwann cells and oligodendrocytes in culture.  NGF promoted 
Schwann cell but inhibited oligodendrocyte myelination, suggesting that different 
mechanisms control CNS and PNS myelination.  It is thought to act indirectly on 
oligodendrocytes via modulation of axonal signals (Chan et al. 2004).  Signalling via 
p38 has been shown to be essential for CNS myelination, whereby terminal 
differentiation of oligodendrocytes and accumulation of myelin lipids was prevented in 
the presence of p38 inhibitors (Bhat et al. 2007; Fragoso et al. 2007; Haines et al. 
2008). 
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5.1.3 Effect of cell adhesion molecules on myelination 
Multiple CAMs have been shown to be expressed by oligodendrocytes during 
development, including NCAM, contactin/F3, NFasc, MAG and N-cadherin (Bartsch et 
al. 1989; Bhat and Silberberg 1988a; Grumet 1991; Koch et al. 1997; Payne and 
Lemmon 1993; Tait et al. 2000) and hence may be involved in adhesion between axons 
and oligodendrocytes.  However, the identity of the molecules mediating axon-
oligodendrocyte contact during myelination remains elusive.  Several studies have 
demonstrated that Fyn has a role in oligodendrocyte myelination (Osterhout et al. 1999; 
Sperber et al. 2001; Umemori et al. 1994), but the molecules that activate Fyn in 
oligodendrocytes are largely unknown.  The binding of axonally expressed L1 to 
contactin/F3 has been suggested to have a role in myelination, as addition of L1-Fc to 
DRG/OPC co-cultures increased the number of MBP
+
 cells and myelin segments 
(Laursen et al. 2009).  Contactin/F3 was shown to associate with α6β1 integrin and 
activate Fyn (Laursen et al. 2009).   In a separate study L1 binding to OPCs increased 
the expression of MBP and this was also dependent on Fyn (White et al. 2008), 
providing a mechanism for the increased myelination.   
 
Two studies have shown the importance of Necl proteins in axon-Schwann cell contact, 
whereby Necl4 expressed by the Schwann cell binds to Necl1 on the axon.  Interruption 
of this interaction using siRNA or chimeric fusion proteins that blocked cell-cell 
interactions reduced myelination by up to 90% (Maurel et al. 2007; Spiegel et al. 2007).  
In particular, Necls were shown to be important for myelin wrapping rather than initial 
contact and appear to mediate the major axon-Schwann cells interactions along the 
internode (Maurel et al. 2007; Spiegel et al. 2007).  Necls are also expressed by 
oligodendrocytes but their roles in CNS myelination are not as well documented 
(Pellissier et al. 2007).  A recent study showed that Necl1 is exclusively expressed by 
neurons in the CNS in vivo and Necl1 mutant mice were hypomyelinated, suggesting a 
similar role for Necls in the CNS to the PNS (Park et al. 2008). 
 
Oligodendrocytes express Netrin-1 and its receptor DCC, which have been shown to be 
important for OPC process outgrowth, branching and myelin sheath formation, via a 
signalling mechanism involving Fyn and FAK, which was independent of integrins 
(Rajasekharan et al. 2009).  A role in the maintenance of paranodal axo-glial junctions 
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has also been described, where absence of either Netrin-1 or DCC resulted in 
disorganised paranodes (Jarjour et al. 2008).  
 
5.1.4 Myelinating co-cultures 
Over the past 20 years extensive research on cells of the oligodendrocyte lineage has 
shown that their default program is to differentiate and that in vitro differentiation 
closely mimics that seen in vivo (Hardy and Reynolds 1991; Raff et al. 1983a; Reynolds 
and Hardy 1997).  The majority of in vitro studies have been carried out using relatively 
pure OPC cultures, which have been extremely informative as to which factors control 
proliferation, survival and differentiation.  However, the absence of neurons and 
therefore myelination in the system denotes that axon-oligodendrocyte interactions 
cannot be studied per se.  On the contrary, the complexity and inaccessibility of the 
intact CNS makes in vivo studies of myelination also difficult.  This has led to several 
myelinating culture models being set up, in which compact myelin and internodes are 
formed, as determined using immunocytochemistry and transmission electron 
microscopy (TEM).  In addition, several transgenic mice with conditional ablation of 
genes in oligodendrocyte lineage cells have also helped to elucidate the molecules and 
pathways important for myelination.  For example by crossing mice that express Cre 
recombinase under the CNP promoter with mice expressing Cdc42, Rac1 or Yin Yang1 
between loxP sites, these three genes were shown to be essential for proper myelination 
(He et al. 2007; Thurnherr et al. 2006).  
 
The DRG-myelinating cell co-culture system was originally established by Wood and 
co-workers (Wood et al. 1976; Wood and Williams 1984) and was used to investigate 
Schwann cell myelination, although it can also be used with oligodendrocytes.  It 
utilises separately purified DRG neurons from embryonic tissue and OPCs isolated from 
the neonatal cortex.  DRG neurons have axons that project into the spinal cord, meaning 
that they are myelinated by both Schwann cells and oligodendrocytes in vivo, and have 
been useful in the analysis of CNS myelination (Chan et al. 2004; Colognato et al. 
2007; Fragoso et al. 2007; Taveggia et al. 2008; Wang et al. 2007).  This should have 
the advantage of enabling the study of myelination without the confounding effects of 
other cell types and the factors they may release.  Although the neurons are 
differentiated in the presence of serum, serum-free defined medium is used to induce 
myelination, allowing the relative contribution of individual factors to be assessed.  
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Moreover, the co-culture of two independently isolated cell populations permits 
manipulation of cells separately, for example transfection, so that the molecular 
mechanisms of myelination can be better dissected.   
 
5.1.5 Hypothesis 
This chapter addressed the hypothesis that the inhibition of axon-oligodendrocyte 
NCAM-NCAM binding will inhibit myelination. 
 
5.1.6 Aims 
The aims of this study were to set up a neuron-oligodendrocyte co-culture system to 
investigate the role if NCAM in myelination.  To do this we investigated the use of a 
neural cell line and primary neurons.  We also aimed to create shRNA constructs to 
knock-down the expression of NCAM on oligodendrocytes and investigate if this 
affected the ability of FRM peptide and NCAM-Fc to induce OPC survival and if it 
affected myelination in the co-culture system. 
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5.2 Methods 
 
5.2.1 NSC34 cell culture 
The neuronal cell line (NSC34), which is a hybrid of a mouse neuroblastoma and a rat 
spinal cord motor neuron (a kind gift from Dr. Neil Cashman, as described in Cashman 
et al. 1992) was investigated for use in a co-culture system with primary OPCs.  NSC34 
cells were maintained in DMEM, 2 mM L-glutamine, 100 units/ml penicillin-
streptomycin and 10% HI FCS and routinely passaged twice a week.  A range of cell 
culture medium was tested in order to find one that slowed cell proliferation and 
increased neurite outgrowth and therefore differentiation.  DMEM, neurobasal media 
and DMEM/Hams F12, all with low serum, and without serum but in the presence and 
absence of neuronal growth factors were tested.  For co-culture with OPCs (isolated as 
described in Chapter 2.2.1), NSC34s were plated onto PDL-coated coverslips in a 24-
well plate at a density of 1X10
5
 cells per well in media containing 10% HI FCS.  After 
24 hours this media was changed to OLP defined media with the addition of insulin (5 
µg/ml), CNTF (Sigma-Aldrich, 10 ng/ml), GDNF (Sigma-Aldrich, 100 pg/ml) and 
BDGF (Sigma-Aldrich, 1 ng/ml) to allow differentiation.  After three days the media 
was removed and 2X10
5
 O4
+
 OPCs were added per well in DMEM + 10% HI FCS.  
This media was switched to OLP media plus insulin after one hour and cells were 
cultured together for three to six days. 
 
Immunofluorescence was carried out on NSC34 cells to determine their suitability for 
this system.  NSC34 were fixed for 15 minutes with 4% PFA prior to double staining 
for immunofluorescence with antibodies listed in Table 5.1.  Briefly, after fixation cells 
were washed with PBS, permeabilised for five minutes with PBS + 0.1% Triton X-100 
(PBST) and blocked with 2% normal goat serum (NGS, Sigma-Aldrich) + 0.1% Triton 
X-100 in PBS.  Antibodies were diluted in 2% NGS + 0.05% Triton X-100 PBS and all 
incubations were for 30-60 minutes at RT, as detailed in Table 5.1.  Cells were washed 
with PBST and finally incubated for five minutes with DAPI (1:5000 in PBS), washed 
in PBS and then distilled water and mounted with Vectorshield hardset media.  Co-
cultures were stained with anti-O4 antibody (live staining carried out as described in 
Chapter 2.2.4), fixed and then incubated with anti-neurofilament antibody.  
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5.2.2 DRG neuron / oligodendrocyte co-cultures 
On day one 22 mm coverlips were sterilised by autoclaving and placed in six well tissue 
culture plates.  Coverslips were sequentially coated with PDL (5 µg/ml for one hour) 
and then growth factor reduced matrigel (BD Biosciences), diluted 1:40 in distilled 
water and incubated at 37 C for 2-3 hours.  Coverslips washed with water to remove all 
traces of the matrigel and allowed to dry.   
 
The following day, the embryos were removed from an E15 time-mated SD rat and 
transferred to a 10 cm petri dish containing MEM-HEPES (with 100 units/ml penicillin-
streptomycin and 2 mM L-glutamine).  Embryos were placed on their side and the 
ventral two thirds, limbs and tail cut away.   The remaining dorsal portion containing 
spinal cord and attached tissue was placed in fresh 10 cm dish with MEM-HEPES and 
stored on ice until dissected.  Spinal cords were removed under a dissecting microscope.   
The vertebrae were cut using forceps and the spinal cord removed by pulling from the 
rostral end, making sure that the meninges were attached.  The dorsal route ganglia 
were plucked off with fine no. 5/45 forceps and transferred  to a 15 ml Falcon tube 
containing fresh MEM-HEPES and stored on ice until all the embryos were dissected.   
 
Once dissection was complete, DRGs were centrifuged at 1000 RPM for five minutes at 
4°C.  Meanwhile papain digestion solution was prepared, consisting of 1.2 units papain 
(Worthington, Lorne Labs, Reading, UK), 0.4 mg/ml DNaseI type IV (Sigma-Aldrich) 
and 0.24 mg/ml L-cysteine, in 1 ml of MEM-HEPES.  Papain was incubated with the 
DRGs for one hour in a shaking incubator at 37°C.  To quench the enzyme reaction 8 
ml of DMEM + 10% HI FCS was added and cells pelleted at 1000 RPM for five 
minutes.  Cells were triturated to a single cell suspension using a flame-narrowed 
Pasteur pipette and then counted.  The concentration of the cells was adjusted using 
neuronal medium (DMEM containing 2 mM L-glutamine, 100 units/ml 
penicillin/streptomycin, 10% HI FCS and 100 ng/ml mouse NGF (Serotec, Oxford, UK) 
to 1X10
6
 per ml and 200 µl was placed on the centre of each 22 mm coverslip and 
incubated overnight. 
 
On day three, 1.5 ml of neuronal medium supplemented with 10 µM fluorodeoxyuridine 
(FdU, Sigma-Aldrich), to remove contaminating cells, was added per well.  This media 
was changed every 2-3 days.   
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5.2.2.1 Addition of OPCs 
OPCs were isolated by O4 immunopanning, as described in Chapter 2.2.1.  Following 
the O4 immunopanning step, cells that did not bind were incubated on anti-A2B5 
coated petri dishes (1:5 in MEM-HEPES + 5% HI FCS) to isolate earlier progenitor 
cells. Both cell populations were plated onto 10 cm PDL coated dishes and expanded 
using B104-CM media with 5 ng/ml FGF2 and 1 ng/ml PDGF.  
 
After DRG neurons had been in culture for 21 days media was changed to myelination 
media, consisting of  50:50 mix of neurobasal medium (Invitrogen) and Satos 
modification of DMEM (Bottenstein and Sato, 1979), supplemented with 2 mM L-
glutamine, 100 units/ml penicillin-streptomycin,  2% B27 supplement (Invitrogen), 5 
µg/ml N-acetyl cysteine and 10 ng/ml D-biotin.  Sato’s modification consisted of 50 
µg/ml transferrin, 5 ng/ml sodium selenite, 5 µg/ml insulin, 16 µg/ml putrescine, 100 
µg/ml BSA, 400 ng/ml L-thyroxine, 400 ng/ml tri-iodothyronine and 6.2 ng/ml 
progesterone. 
 
The use of a second myelination medium was also investigated, a modification of that 
described by Peles group (Spiegel and Peles 2009), consisting of Basal Medium with 
Eagles modification (Invitrogen) supplemented with 2 mM L-glutamine, 100 units/ml 
penicillin-streptomycin, 4 mg/ml glucose, 0.5% HI FCS, 10 µg/ml insulin, 5.5 µg/ml 
transferrin and 50 ng/ml sodium selenite. 
 
OPCs were seeded at 1.5-2X10
5
 cells per coverslip and myelination media was changed 
every 2-3 days.  After a further 2-3 weeks coverslips were fixed with 4% PFA for 15 
minutes and rinsed with PBS prior to double immunofluorescence.  
 
Peptides, proteins and antibodies were added with OPCs and included each time 
myelination medium was changed.  FRM peptide, scrambled peptide and NCAM-Fc 
were all added at 1 µg/ml.  Anti-NCAM (Millipore), used as a blocking antibody, was 
added at 0.1 µg/ml.  A control antibody, which was also an anti rabbit IgG was used: 
anti-CD22 (Santa Cruz) at 0.1 µg/ml.  
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Primary Antibody 1 Secondary Antibody 
1 
Primary Antibody 2 Secondary Antibody 
2 
Mouse anti O4 
(hybridoma 
supernatant, 
ECACC) 1:5 
Goat anti mouse IgM 
FITC (Sigma Aldrich, 
1:100) 
Anti-neurofilament 
RT97 (Millipore, 
1:500) 
Goat anti mouse IgG1 
Texas Red 
(Cambridge 
Bioscience, 1:100) 
Rabbit anti MAP2 
(Dako) 1:250 
Biotinylated goat anti 
rabbit (Vector Labs, 
1:200) + Streptavidin 
Alexa 488 (Invitrogen) 
1:1000 
Mouse anti 
neurofilament RT97 
Goat anti mouse IgG1 
Texas Red  
Mouse anti O4 1:5 Goat anti mouse IgM 
Alexa 546 (Invitrogen, 
1:500) 
Anti-neurofilment 
(Millipore, 1:5000) 
Goat anti chicken 
Alexa 488 (Invitrogen, 
1:500) 
Mouse anti O4 1:5 Goat anti mouse IgM 
Alexa 546 
Rabbit anti MBP 
(Dako) 1:2000 
Goat anti rabbit Alexa 
488 (Invitrogen, 
1:500) 
Mouse anti A2B5 
(hybridoma 
supernatant, 
ECACC) 1:5 
Goat anti mouse IgG 
Alexa 546 (Invitrogen, 
1:500) 
Anti-neurofilment Goat anti chicken 
Alexa 488 
Rabbit anti MBP 
(Dako) 1:2000 
Goat anti rabbit cy3 
(Jackson Immuno 
Research) 1:500 
Anti-neurofilment Goat anti chicken 
Alexa 488 
Rabbit anti MBP (in 
house) 1:500 
Goat anti rabbit cy3 Anti-neurofilment Goat anti chicken 
Alexa 488 
Rabbit anti NG2 
(Millipore, UK) 1: 200 
Goat anti rabbit cy3 Anti-neurofilment Goat anti chicken 
Alexa 488 
Mouse anti-MOG 
(hybridoma 
supernatant, Dr S 
Piddlesden, Cardiff) 
1:500 
Goat anti mouse IgG 
Alexa 546  
Anti-neurofilment Goat anti chicken 
Alexa 488 
 
Table 5.1 Antibodies combinations used for double immunofluorescence of co-cultures 
 
5.2.2.2 Co-culture Immunofluorescence 
Following fixation, coverslips were blocked for 30 minutes with PBS containing 40% 
NGS and 0.4% Triton X-100 (blocking buffer).  Primary antibodies were diluted in 
blocking buffer and incubated for two hours at RT.  For O4 and A2B5 antibodies, 
primary antibody was incubated on live cells for 20 minutes on ice and cells were fixed 
afterwards and second primary antibodies added subsequently. Coverslips were then 
washed three times with PBS 0.4% Triton X-100 and incubated with secondary 
antibodies diluted 1:500 in blocking buffer, for two hours at RT.  Coverslips were 
washed three times, then incubated for five minutes with DAPI (1:5000 in PBS) before 
washing again and mounting on Superfrost Plus slides with Fluoromount G (Cambridge 
Bioscience).  Negative controls were performed whereby no primary antibody was 
added and secondary antibody was added as normal. Some background staining was 
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observed in areas where there were large clusters of neuron cell bodies and bundles of 
axons.  
 
5.2.3 NCAM knock-down 
In order to investigate further the effects that NCAM signalling has on OPC survival 
and differentiation, siRNA was used to knock-down NCAM expression.  A vector based 
system was used, using the pSUPER.retro.neo+GFP vector (Oligoengine, as described 
by Brummelkamp et al. 2002, Figure 5.1), which expresses short-hairpin RNA (shRNA) 
and GFP protein. 
 
5.2.3.1 Preparation of vector 
DH5α E.coli bacteria which had been previously transformed with 
pSUPER.retro.neo+GFP vector were a kind gift from Dr. Jane Saffell.  E.coli were 
streaked on an agar plate containing 10 μg/ml ampicillin and grown overnight at 37ºC. 
Single colonies were picked and grown overnight in 10 ml LB in a shaking incubator at 
37 ºC.  DNA was isolated using a plasmid mini-prep kit, as per kit instructions 
(Qiagen).  
 
A restriction digest was used to linearise the vector.  The restriction enzymes HindIII 
and BglII and buffer 2 (all New England Biolabs) were used.  The reaction was carried 
out using 10 μg vector DNA and 1 µl of each enzyme, for three hours at 37 ºC.  To heat 
inactivate the reaction the temperature was raised to 65-80°C for 20 minutes. 
 
Digested DNA was diluted with six times sample buffer (40% glucose, 0.1% 
bromophenolblue) and run on a 1% agarose gel with ethidium bromide, for 
approximately one hour at 80 volts, in conjunction with single cut and uncut DNA, as 
controls.  The total uncut vector is 8371 bp, when digested the 976 bp stuffer sequence 
is removed, leaving the linearised vector as 7395 bp.  Bands were visualised using a UV 
light box and the linearised vector band was cut from the gel and the DNA purified 
from the gel using a gel extraction kit, following kit instructions (Qiagen).  To check 
that the DNA was not damaged during purification, a small quantity was re-run on an 
agarose gel with a quantitative DNA ladder.  The vector concentration was normalised 
to 0.2-0.5 mg/ml in sterile distilled water. 
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Key Sites 
BglII: 2424 
HindIII: 1441 
EcoRI: 2645 
SalI: 1426 
XhoI: 1420 
 
Vector Features 
PGK promoter: 2770-3168 
EGFP ORF: 3186-3919 
Neo ORF: 3926-4895 
H1 promoter: 2430-2650 
Ampicilin resistance ORF: 7443-6577 
3’ delta LTR: 4910-5277 
5’ LTR: 8369-513 (homologous to other MSCV LTR) 
Stuffer Sequence: 1447-2423 
Sequencing primer 5’-GGAAGCCTTGGCTTTTG-3’ binding site: 1241-1257 
Sequencing primer 5’-CGAACGTGACGTCATC-3’ binding site: 2645-2629 
Figure 5.1 pSUPER.retro.neo+GFP vector (Oligoengine, Brummelkamp et al. 2002) 
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5.2.3.2 Design of siRNA oligonucleotides 
siRNA sequences to the rat NCAM sequence were chosen based on the commercially 
available design tools from Oligoengine, Invitrogen, Sigma and Ambion.  Three NCAM 
sequences and a scrambled sequence (the same amino acids as one of the target 
sequences but in a random order) were chosen.  19 amino acid sequences were ordered 
from Invitrogen (Table 5.2) as 60 amino acid oligonucleotides, as per Oligoengine 
instructions, so that they contained the shRNA sequences and restriction site staggered 
ends. 
 
Oligo 19 bp siRNA sequence Mass µg Volume water 
to add µl 
NCAM 1 
antisense 
5’-AGAUCCUUAGUUCGCAGCA-3’ 118.53 39.51 
NCAM 1 sense 5’-UGCUGCGAACUAAGGAUCU-3’ 132.85 44.28 
NCAM 2 
antisense 
5’AUCUGCAGGUAGUUGUUGG-3’ 207.84 69.28 
NCAM 2 sense 5’-CCAACAACUACCUGCAGAU-3’ 111.83 37.28 
NCAM 3 
antisense 
5’-CCCCGCUUUGCCGCACAGG-3’ 82.80 27.60 
NCAM 3 sense 5’-CCUGUGCGGCAAAGCGGGG-3’ 130.10 43.34 
NCAM 4 
antisense 
5’-TCATCAAGTGCTACTGGCA-3’ 184.08 61.36 
NCAM 4 sense 5’-GTCCAGTAGCACTTGATGA-3’ 97.25 32.42 
 
Table 5.2 NCAM siRNA sequences used 
 
Sense and antisense oligonucleotides were diluted to 3 mg/ml in distilled water and 1 μl 
of each oligonucleotide was added to 48 μl annealing buffer (100 mM NaCl, 50 mM 
HEPES, pH 7.4). Annealing was carried out in a heatblock, heated to 94ºC, then turned 
off and allowed to cool slowly to RT. 
 
5.2.3.3 Ligation of oligonucleotides into vector 
The cloning reaction consisted of 2 µl annealed oligonucleotides, 300 ng vector, 2 µl 
10X T4 DNA ligase buffer, 1 µl T4 DNA ligase (both New England Biolabs), and 
distilled water to make the volume up to 20 µl.  As a negative control a reaction 
containing the vector but no oligonucleotide was set up in parallel.  Ligation was carried 
at 16°C for 30 minutes.  The BglII site is destroyed upon successful cloning of the 
oligonucleotide pair, so the ligated reaction was treated with 1µl BglII (for 30 minutes 
at 37°C), as this will cut vector that does not contain the insert and remove background 
204 
 
in the transformation. The reaction was cleaned up to remove excess oligonucleotides, 
enzymes and salts using a Qiaex II kit (Qiagen). 
 
5.2.3.4 Transformation 
High efficiency competent DH5α strain E.coli (New England Biolabs) were thawed on 
ice and 2 µl of ligation reaction added to 30 µl of bacteria and incubated for 30 minutes 
on ice. DNA uptake was aided by heatshock (30 seconds at 42°C), followed by five 
minutes on ice.  950 µl LB (without antibiotics) was added and bacteria were incubated 
at 37°C for one hour in a shaking incubator to allow the cells to recover and express the 
antibiotic resistance gene. Bacteria were pelleted by centrifugation, resuspended in 50 
µl LB and streaked across an agar plate containing 10 µg/ml ampicillin.  Plates were 
incubated overnight at 37°C. 
 
Several colonies were picked from each plate and grown up overnight in LB plus 10 
µg/ml ampicillin.  DNA was isolated using a miniprep kit and digested using HindIII 
and EcoRI restriction enzymes (New England Biolabs).  Digested samples were run on 
a 2% agarose gel to identify which colonies contained the shRNA insert (a band of 281 
bp).  Those colonies containing the insert were diluted and grown up overnight so that 
enough DNA was obtained for future transfections.  To ensure that the shRNA sequence 
was inserted correctly vector DNA was submitted for sequencing.  The following 
sequencing primers were used (Invitrogen): 
5’-GGAAGCCTTGGCTTTTG-3’ binding site 1241-1257 
5’-CGAACGTGACTCATC-3’ binding site 2645-2629. 
 
5.2.5 Transfection 
To determine if the shRNA sequences were able to knock-down the expression of 
NCAM, the CG4 OPC cell line was used.  Two methods of transfection were evaluated: 
1.) Amaxa nucleofection using the rat oligodendrocyte kit (Lonza, Basel, 
Switzerland) on cycles A-33 and O-17 
2.) Lipofectamine LTX with and without Plus reagent (Invitrogen). 
 
The Amaxa kit caused a very high level of cell death amongst CG4 cells so it was 
decided not to use this method for shRNA validation and instead Lipofectamine LTX 
was pursued. Various concentrations of DNA (500 ng and 1 µg) and LTX reagent 
205 
 
(0.625 µl, 1.25 µl and 2.5 µl), as well as transfection time (1, 3, 6 and 18 hours) were 
investigated.  The best results were achieved with 500 ng plasmid DNA, 1.25 µl LTX, 
0.5 µl Plus reagent, diluted in 500 µl Optimem media (Invitrogen), per well of a 24 well 
plate.  Transfection was carried out for six hours in B104-CM media without antibiotics, 
after which it was switched to regular B104-CM media with antibiotics. Transfection 
efficiency was still low – typically 5% of the cells expressed GFP after 48 hours.  As 
well as the vectors containing the shRNA sequences, cells were also transfected with 
the empty GFP-expressing vector and incubated with transfection reagents in the 
absence of DNA as positive and negative controls, respectively. 
 
To increase the proportion of transfected cells, cells with the vector stably incorporated 
into their genome were selected using the G418 antibiotic (Sigma-Aldrich).  Cells were 
transfected in 6 well plates (2.5 µg DNA, 6.25 µl LTX, 2.5 µl Plus reagent) and 
subsequently passaged 1:10 and 1:20. A kill curve for CG4 cells was established, 
whereby 350 µg/ml was determined to the optimum concentration, which killed 
untransfected cells after one week.  
 
Transfected cells were plated onto 13 mm coverslips and fixed with 4% PFA/PBS for 
20 minutes, after 48 hours in culture. Immunofluorescence for NCAM (Millipore, 
1:250) and A2B5 (1:5) was carried out.  The number of GFP positive cells was greatly 
increased following selection.  
 
Transfected cells were also plated onto PDL-coated 6 cm dishes and then lysed with 
RIPA lysis buffer containing protease and phosphatase inhibitors.  Lysates were 
prepared for SDS-PAGE separation and Western blotting, as described in Chapter 
2.2.10.  Immunoblotting was carried out using rabbit anti-NCAM (Santa Cruz, 1:200), 
rabbit anti-GFP (Abcam, 1:10000) and mouse anti-actin antibodies (Millipore, 
1:10000). 
 
5.2.5.1 Transfection of OPCs 
Primary OPCs were isolated by O4 immunopanning, as described in Chapter 2.2.1 and 
expanded in B104-CM.  They were then transfected with the Amaxa nucleofection kit 
for rat oligodendrocytes and O-17 programme. This was less toxic to primary cells 
compared to the CG4 cell line, but still resulted in the death of at least 50% of the cells.  
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Amaxa nucleofection proved more successful that transfection with Lipofectamine 
LTX, where very few cells expressed GFP, presumably because the primary cells are 
cycling more slowly and with Lipofectamine the DNA is not introduced to the nucleus 
unless the cell divides so will not be expressed, whereas nucleofection delivers the 
DNA directly to the nucleus, resulting in more robust expression.  
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5.3 Results 
 
5.3.1 Assessment of NSC34 cells for use in neuron-oligodendrocyte co-cultures 
To further investigate the role of NCAM in mediating axon-oligodendrocyte 
interactions, we explored the suitability of a neuronal cell line to co-culture with 
primary OPCs.  The advantages of using a cell line over primary neurons are an 
unlimited number of cells that are easier to manipulate, for example to carry out 
transfections.  We investigated the use of a spinal cord motor neuron cell line (NSC34), 
which has been used extensively and shown to display many of the properties of 
primary neurons (Cashman et al. 1992).  NSC34 cells can be cultured in 10% HI FCS 
whereby they proliferate rapidly and most retain a neuroblastoma-like phenotype.  They 
can be differentiated, using low serum or serum-free media with the addition of CNTF, 
GDNF and BDNF, whereby they extend multiple processes (Figure 5.2a).  The 
expression of neuronal markers was examined using immunocytochemistry.  MAP2, a 
dendritic marker, was weakly expressed in the processes (Figure 5.2a).  High molecular 
weight neurofilament protein, which is predominantly an axonal marker, was observed 
and was abundant towards the end of processes (Figure 5.2a).  However, we were 
unable to detect dephospho-tau expression, another axonal marker (data not shown) and 
this should be enriched in the process specified as an axon.  NCAM expression was 
detected on the cell body and processes of all cells and was enriched at points of cell-
cell contact (Figure 5.2b).  Western blotting was carried out on NSC34 cell lysates and 
confirmed the expression of NCAM-140 and to a lesser extent the NCAM-180 isoform 
(Figure 5.2e).  However, even in serum-free media cell proliferation still occurred and 
aggregates of undifferentiated cells were apparent (Figure 5.2b, white arrow).  After 
three days differentiation, O4
+
 OPCs isolated by immunopanning were added to NSC34 
cells and co-cultured for 3-6 days in OLP medium containing insulin.   
Immunocytochemistry demonstrated that the OPCs differentiated in the presence of the 
NSC34 cells, displaying a multi-processed morphology and some processes appeared to 
be contacting the NSC34 cell axons (Figure 5.2c-d, white arrow).  However, a high 
density of axon-like processes was not attained with the NSC34 cells, due to the fact 
that many do not differentiate and this is likely to be required to initiate myelination.  
Therefore, it was decided that primary neurons would be a better option for 
investigating axonal contact and myelination.   
 
D NF Red, O4 Green
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140 kDa
E       i        i
208
209 
 
5.3.2 Optimising DRG / OPC co-cultures for investigation of neuron-
oligodendrocyte interactions 
Several groups have used primary DRG neurons to set up myelinating co-cultures 
(Chan et al. 2004; Fragoso et al. 2007; Taveggia et al. 2008; Wang et al. 2007).  DRGs 
were isolated from the E15-16 rat spinal cord, dissociated and plated onto matrigel-
coated coverslips.  DRG neurons were differentiated for three weeks in media 
containing 10% HI FCS and 100 ng/ml NGF, whereby they extended long axons and 
dendrites.  Immunocytochemistry was used to characterise the neuronal cultures, 
revealing that the neuronal cell bodies were positive for the transcription factor NeuN 
(Figure 5.3a).  The density of neurofilament protein positive processes varied across 
coverslips, but in general there were many dense bundles of processes extending in 
parallel (Figure 5.3b), with neurites becoming sparser towards the edges of the 
coverslips.  Despite the addition of FdU to the medium, to eliminate proliferating and 
therefore non-neuronal cells, whilst neurons were differentiating, a number of 
contaminating cells still persisted.  Processed vimentin
+
 cells were visible in amongst 
neurofilament
+
 cells, thought to be neural precursors (Figure 5.3c).  Vimentin
+
 
fibroblasts were also observed and located beneath the neuronal cells (Figure 5.3d).  A 
variable number of GFAP
+
 astrocytes were present in the neuronal cultures, with some 
areas having no cells visible whilst others contained larger clusters of cells, presumably 
the result of rapid proliferation of a small number of cells (Figure 5.3e-f).  It was 
unclear why these cells continued to proliferate in the presence of FdU.  We also 
investigated the use of another anti-mitotic agent, cytosine arabinoside (Ara-C, Sigma 
Aldrich).  However, Ara-C proved cytotoxic to the neurons at 10 µM and ineffective at 
1 µM so was not pursued further.  
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5.3.2.1 Differentiation of oligodendrocytes 
OPCs isolated by A2B5 or O4 immunopanning from the P4 cortex and expanded using 
B104-CM were added to DRG cultures after they had been differentiated for 21 days.  
Medium was switched to myelination medium and cells were cultured together for a 
further 2-3 weeks, with media changed every 2-3 days.  Co-cultures were then fixed and 
immunocytochemistry carried out using anti-neurofilament and various oligodendrocyte 
lineage and myelin markers.  Negative controls using secondary antibody only were 
carried out to determine whether there was non-specific antibody binding, (Figure 5.4).  
In areas where there were dense bundles of cells, some non-specific staining was 
observed despite the high (40%) serum used in the blocking buffer (Figure 5.4a, white 
arrow), but in the large part background staining was minimal (Figure 5.4b). 
 
We confirmed the expression of NCAM within the system using immunocytochemistry 
(Figure 5.5).  NCAM staining was observed on axonal bundles (Figure 5.5b, white 
arrows), and glial cells with astrocytic (Figure 5.5b, yellow arrows) and OPC-like 
morphology (Figure 5.5a, c, blue arrows), suggesting that all cells in the co-culture 
system expressed NCAM.   
 
Numerous, multi-processed NG2
+
 OPCs were found amongst neurofilament
+
 processes 
(Figure 5.6a), suggesting that a significant proportion of cells did not differentiate in the 
system.  Additionally, the multi-processed morphology is characteristic of adult OPCs 
rather than bipolar neonatal precursor cells.  A similar population of cells were found to 
be A2B5
+
 (Figure 5.6b).  However, the A2B5 antibody did not appear to be as specific 
as the NG2 antibody. 
 
Numerous O4
+
 cells were visible in amongst different dendrites of neurofilament
+
 axons 
(Figure 5.7).  Many of the cells had acquired a complex morphology (Figure 5.7c) and 
processes could be seen contacting and aligning with axons, including possibly 
wrapping around them (white arrows).  Immunocytochemistry for MBP revealed that a 
significant proportion of the cells were MBP
+
 and that their processes appeared to be 
contacting axons (Figure 5.8, white arrows).  A similar pattern was observed with MOG 
immunocytochemisty, but fewer cells were MOG
+
 as this is a later appearing myelin 
protein (data not shown).  However, no compact myelin was observed, suggesting that 
whilst some of the OPCs differentiated they did not initiate myelination.  The 
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abundance of cells and dense bundles of axons made analysing single-cell morphology 
difficult.  Previous studies using this protocol have found extensive myelination 14 days 
after adding OPCs, which could be quantified by measuring the percentage of 
oligodendrocytes forming myelin sheaths relative to the neurite density (Wang et al. 
2007).  The proportion of myelinating oligodendrocytes was found to correlate with 
increased neurite density (Wang et al. 2007).   
 
Several experimental conditions were followed in order to try and achieve myelination.  
Other groups that have co-cultured OPCs and DRGs have isolated their OPCs from P1 
rat brain, as mixed glial cultures and expanded them for ten days before shaking flasks 
to remove OPCs (Wang et al. 2007).  This results in a less pure population than we 
isolate by immunopanning.  However, it may be an advantage to have a greater 
proportion of astrocytes in the system as they may release growth factors that promote 
myelination.  Furthermore, Watkins et al (2008) showed that the more differentiated the 
progenitor cells, the less likely they were to myelinate.  Therefore, O4
+
 OPCs may be 
too late in the lineage.  However, we did expand the cells using B104-CM, which 
results in some de-differentiation to the bipolar precursor stage.  Additionally, we 
carried out immunopanning with A2B5 antibody to isolate earlier precursors. This also 
isolated a population of cells containing a greater proportion of astrocytes.  Inhibition of 
γ secretase using DAPT was shown to favour myelination in retinal ganglion cell 
(RGC)/OPC co-cultures (Watkins et al. 2008), so we also added 1 µM DAPT to our 
myelination media.  Gamma secretase has several substrates and is believed to act in 
part by activating Notch on the axon and also by restricting oligodendrocyte 
myelination.  However, addition of DAPT did not lead to myelination in our co-cultures 
(Figure 5.8).   We cultured OPCs for up to 21 days (compared to the suggested 14 days) 
with DRGs to see if myelination could be observed at longer time points, but this was 
not the case. 
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5.3.3 Knock-down of NCAM expression 
To investigate the effect that an absence of NCAM expression on the oligodendrocyte 
would have on survival and differentiation, we used a vector-based shRNA procedure.  
The pSUPER GFP vector enables vector-based suppression of gene expression in 
mammalian cells (Brummelkamp et al. 2002).  19 bp siRNA sequences were cloned as 
part of a 60 oligonucleotide sequence into the pSUPER vector, where they were under 
the control of the H1-RNA promoter.  The parental vector was digested using BglII and 
HindIII restriction enzymes, to remove the approximately 1000 bp stuffer sequence 
(Figure 5.9a).  The annealed oligonucleotides were ligated into the empty vector and 
transformed into competent bacteria by heat-shock.  Transformed bacteria were streaked 
on agar plates and several colonies were picked and expanded overnight.  Plasmid DNA 
was isolated and digested with EcoR1 and HindIII to confirm whether they contained 
the shRNA insert (281 bp in length, Figure 5.9b, black arrow).  Colonies that contained 
the inserts were further expanded to obtain enough DNA for future transfections and 
were submitted for sequencing to ensure that the insert had been cloned successfully.   
 
To test the efficiency of the shRNA sequences at knocking-down the expression of 
NCAM we first transfected them into cell lines that also expressed NCAM.  The 
fibroblast cell line expressing NCAM-140 that has been used in previous chapters was 
not suitable because it expresses the human isoform of NCAM, whereas our sequences 
were directed towards rat NCAM.  We tested the suitability of two rodent cell lines, 
B104 neuroblastoma cells and CG4 cells.  The expression level of NCAM detected by 
immunocytochemistry was much greater on the CG4 cells compared to the B104 cells, 
where NCAM staining was weak and diffuse and so it would be difficult to determine 
whether the NCAM expression had been reduced.  CG4 cells were transfected using 
Lipofectamine LTX and Plus reagent.  The pSUPER vector also expressed GFP so that 
transfected cells could be identified using fluorescent microscopy.  Transfection 
efficiency was low using Lipofectamine LTX, despite attempts to optimise the protocol 
and increase DNA uptake.  Only a small proportion of the CG4 cells (approximately 
5%) were transfected, as identified by GFP expression in conjunction with A2B5 
staining (Figure 10a, c and e).  Robust GFP expression was observed 24, 48 and 72 
hours after transfection with vectors expressing shRNA sequences 1, 2 and the empty 
pSUPER vector.  The brightness of the GFP varied between cells, presumably 
dependent on the number of copies of the vector they had taken up.  Additionally, the 
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intensity of NCAM staining was variable and not completely absent from the GFP
+
 cells 
that were transfected with the shRNA vectors (Figure 5.10b,d).  
 
To increase the proportion of cells that were expressing the vector, cells were grown in 
the presence of 350 µg/ml G418, as only transfected cells would have antibiotic 
resistance.  Clones were expanded and then lysed in RIPA buffer for Western blotting.  
Expression of NCAM and GFP were detected in all clones, indicating that the vector 
was being expressed but that the shRNA constructs had not abolished NCAM 
expression (Figure 5.11).  Clone iv, transfected with shRNA sequence 2, showed a high 
level of GFP expression and lower NCAM expression (Figure 5.11).  Therefore, the 
sequences we designed did not abrogate NCAM expression, but may have caused a 
partial knock-down.  
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5.4 Discussion 
 
5.4.1 Neuron-oligodendrocyte co-cultures 
Myelinating co-cultures provide an effective way to assess the effect different 
molecules have on CNS myelination.  In particular DRG/OPC co-cultures have been 
used effectively to investigate the roles that NRG, NGF, L1, contactin/F3, dystroglycan, 
integrins and p38 have on oligodendrocyte myelination (Chan et al. 2004; Colognato et 
al. 2007; Fragoso et al. 2007; Taveggia et al. 2008; Wang et al. 2007).  NCAM is 
expressed by axons and oligodendrocytes and is upregulated prior to the onset on 
myelination (Bartsch et al. 1989; Bhat and Silberberg 1988a), suggesting it may be 
involved in signalling to initiate myelination.  The results described in Chapter 4 
showing that oligodendrocyte process outgrowth is increased when they are grown on a 
NCAM-expressing cellular substratum supports this idea.  We set up OPC/DRG co-
cultures using previously described methods.  However, whilst we observed 
oligodendrocyte differentiation, there was no myelination.  Consequently, we were 
unable to assess the effects of FRM peptide, NCAM-Fc, NCAM blocking antibodies 
and NCAM knock-down on myelination in vitro. 
 
A similar approach has been used to investigate the effects of axonal L1 binding to 
contactin/F3 expressed by the oligodendrocyte.  Addition of L1-Fc to DRG/OPC co-
cultures resulted in increased numbers of MBP
+
 cells and enhanced myelination 
(Laursen et al. 2009).  This study also demonstrated interdependence between 
contactin/F3 and integrin signalling in oligodendrocytes to maintain survival, which 
required Fyn.  L1 binding to contactin/F3 increased Fyn phosphorylation on Y420, 
whilst laminin/integrin binding decreased phosphorylation of the inhibitory Y531 
residue.  However, this contrasts with a study looking at Schwann cell myelination 
where L1 antibodies had an inhibitory effect, preventing GalC expression (Wood et al. 
1990).  It also contradicts Barbin and co workers (Barbin et al. 2004), who found that 
both L1 antibodies and L1-Fc had an inhibitory effect on myelination, attributed to 
competitive inhibition of an axon-oligodendrocyte interaction.  Other studies have 
shown that addition of Fc chimeras to Necl proteins reduced myelination, presumed to 
be due to inhibition of axon-glial adhesion (Maurel et al. 2007; Spiegel et al. 2007).  
Addition of NFasc155-Fc or anti-NFasc155 both inhibited myelination in a co-culture 
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system, suggesting that NFasc/Caspr/contactin axo-glial interactions are also important 
for myelination (Charles et al. 2002b).  Based on these studies we would have predicted 
that NCAM-Fc and NCAM blocking antibodies would have reduced myelination, by 
interrupting axo-glial contact.  It is difficult to speculate whether FRM peptide would 
have had the same effect, due to its small size and direct binding to the FGFR, rather 
than NCAM itself.  The ability of FRM peptide and NCAM-Fc to increase OPC 
survival would be expected to have a positive effect on the number of oligodendrocytes 
in the system as cells require adequate survival signals in order to reach maturity.  
However, not all factors that stimulate OPC survival increase myelination.  PDGF and 
FGF2 increased survival but reduced myelination in co-cultures (Wang et al. 2007).  
Moreover, studies from the AMV have also shown that mitogenic growth factors inhibit 
myelination (Butt and Berry 2000). 
 
5.4.2 Possible reasons for myelination failure 
The main difference between the DRG/OPC co-cultures that we set up and those that 
have been described previously was the way in which the OPCs were isolated and 
cultured prior to addition to the DRGs.  We isolated our cells by O4 immunopanning 
which isolates a homogeneous population of late progenitor cells, whereas other groups 
dissociated cortices from slightly earlier neonates and grew these as mixed glial cultures 
before shaking off the OPCs (McCarthy and de Vellis 1980; Wang et al. 2007).  
Therefore, these OPCs may be at a slightly different developmental stage and could 
have increased ability to myelinate.  It has been shown that OPCs lose myelination 
capacity as they mature and that the period when they are myelination competent is very 
brief.  More mature cells were able to extend MBP
+
 processes but did not engage 
actively in myelination (Watkins et al. 2008), similar to our own findings.  Therefore, 
we also tried A2B5 immunopanning to isolate more immature cells, which was the 
antigen used to isolate cells from the optic nerve for co-culture with RGC neurons 
(Watkins et al. 2008).  However, these cells did not myelinate either.  Similarly addition 
of the gamma secretase inhibitor, DAPT, which is reported to increase myelination 
(Watkins et al. 2008), did not affect our system.  The differentiation of 
oligodendrocytes in vitro to produce a mature myelinating cell, demonstrates the 
presence of a cell intrinsic timer that directs differentiation. There may only be a small 
window of opportunity whereby an immature oligodendrocyte expresses the necessary 
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repertoire of molecules needed to make axonal contact so that it receives the correct 
signals to initiate myelination.   
 
In other in vitro myelinating systems it has been observed that myelinated fibres were 
rarely isolated and myelination mostly occurred in regions of high cell density 
(Lubetzki et al. 1993; Watkins et al. 2008).  Areas of neurites were at a high density in 
our system so this is unlikely to account for the failure of myelination. 
 
Astrocytes have been shown to have a number of effects on myelination in co-cultures.  
They have been shown to promote myelination via the release of soluble factors, 
including LIF (Ishibashi et al, 2006; Sorensen et al, 2008), enhance myelin compaction 
(Watkins et al. 2008) and in some cases reduce oligodendrocyte differentiation.  Mixed 
glial cultures typically contain around 10% astrocytes, which are more than found in the 
immunopanned OPC preparations (approximately 5%) we have used.  Therefore, the 
lack of astrocytes may have had negative effects on myelination in our co-cultures.  
However, we did observe GFAP
+
 astrocytes in our co-cultures both before and after 
addition of the OPCs, but it is unclear whether they were at the necessary quantity.  
Another possibility is that there were too many peripheral glial cells contaminating the 
DRG cultures, which may have prevented oligodendrocytes gaining access to the axons.  
However, immunocytochemistry for peripheral myelin markers, such as P0, did not 
reveal the presence of peripheral myelin (data not shown).  
 
It has been shown that NGF is inhibitory to oligodendrocyte myelination and that 
myelination could be enhanced in DRG/OPC co-cultures following the addition of 
TrkA-Fc to neutralise the effects of NGF (Chan et al. 2004; Taveggia et al. 2008).  
Other studies have found that TrkA-Fc did not have any benefit (Wang et al. 2007) and 
we did not add it to our cultures.  By the time we added the OPCs, the neurons were no 
longer dependent on NGF for their survival so we did not continue to add it to the 
media.   
 
5.4.3 Alternative ways of generating myelinating cultures 
The DRG co-culture system is well established (Wood 1976) and has been used to 
investigate PNS and CNS myelination, providing robust myelination and the 
opportunity to manipulate OPCs prior to adding them to the DRGs (Chan et al. 2004; 
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Laursen et al. 2009; Wang et al. 2007).  The disadvantage of these cultures is that it 
takes three weeks for the neurons to differentiate and lose their dependency on NGF for 
survival, followed by a week of OPC proliferation and another week in order to observe 
myelination.  Transient transfections typically last a maximum of one week so would 
not still be expressed in this system by the time that myelination was achieved.  
Therefore, infecting cells with adenoviral or lentiviral vectors, which achieves a high 
efficiency of stable incorporation of the DNA would be more suitable (Cui et al. 2005; 
Flores et al. 2000; Maurel et al. 2007).  A system where myelination occurs more 
rapidly would be more suited to transiently transfecting OPCs before adding them to 
DRGs.  Recently, a rapidly myelinating CNS co-culture system has been described by 
Watkins et al (2008), whereby reaggregates of RGCs, which provide a dense bed of 
axons, are seeded with OPCs isolated from the optic nerve, producing myelin after just 
3-6 days in culture. 
 
Several other types of myelinating cultures have been used to investigate CNS 
myelination.  Mixed cultures consist of all the cells from a particular area of the CNS, 
such as forebrain, cerebellum or spinal cord, and can be maintained for several weeks 
and are myelinated by endogenous glial cells (Lubetzki et al. 1993; Sorensen et al. 
2008; Svenningsen et al. 2003; Thomson et al. 2006).  They have the advantage of 
having all cells normally present in the CNS and relying on endogenous cells to 
myelinate, but this is also a disadvantage as it increases complexity and makes 
manipulating individual cell populations impossible.  The presence of astrocytic 
neurospheres enhanced myelination of mixed spinal cord cultures, suggesting again that 
the presence of soluble factors released by astrocytes is beneficial to myelin production 
(Sorensen et al. 2008).   
 
A major problem with DRG cultures is the overgrowth of fibroblasts in FCS-containing 
media required to support survival and differentiation of the neurons.  Mixed cultures of 
DRGs (where endogenous Schwann cells myelinate) and cerebellar cultures have been 
described, which can be grown in serum-free medium from the outset, so proliferation 
of fibroblasts and other contaminating cells is minimised and therefore anti-mitotics are 
not required (Svenningsen et al. 2003).  However, cerebellar cultures contain a 
heterogeneous population of neurons, most of which are not normally myelinated in 
vivo, compared to DRG preparations that consist of one neuronal type.   
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Similarly, organotypic cultures contain all cells normally present in the CNS.  Perinatal 
cerebellar slice cultures become myelinated after 2-4 weeks in culture (Notterpek and 
Rome 1994).  However, because cell density is high they are not well suited for 
investigating cell-cell interactions. 
 
The rat anterior medullary velum (AMV) allows in vivo studies as it has a relatively 
simple structure and growth factors can be delivered via the ventricular system, making 
the region easy to manipulate experimentally (Butt and Berry 2000).  These studies 
have shown that PDGF and FGF2 halt myelination whereas insulin promotes it.  The 
AMV can be used to investigate myelination during development and in the adult 
following a demyelinating insult. 
 
5.4.4 Transfection of OPCs 
Although the NCAM-null mouse is viable and has a relatively mild phenotype, the 
effects of NCAM in myelination may be under-estimated in these studies due to 
compensation by other similar adhesion molecules.  Therefore, we wanted to suppress 
NCAM expression in pre-myelinating oligodendrocytes to see whether this would affect 
cell survival and myelination in a co-culture system.  RNA interference enables 
abrogation of specific gene expression.  As discussed earlier, due to the short expression 
period following transient transfections, they are not well suited to myelinating co-
cultures that take several weeks to complete.  Therefore, selection of stable clones that 
permanently express the vector using resistance antibiotics would be a better approach.  
However, OPCs typically only go through a small number of cell cycles in vitro before 
they begin to differentiate, so they will not proliferate indefinitely, even in the presence 
of growth factors (Raff et al. 1988), which can make selection of single clones difficult.   
Therefore, we predict that infection of OPCs using adenoviral or lentiviral vectors 
would be a more viable method to obtain higher efficiency and long term expression of 
constructs.   
 
We opted to use a vector based system to introduce RNA silencing sequences into 
OPCs because this enables co-expression of GFP, the sequence of which is also 
encoded by the vector.  This allows easy identification of cells that have been 
transfected and would allow subsequent FACs sorting.  This method was chosen over 
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direct transfection with siRNA sequences because it would be difficult to evaluate the 
degree of knock-down when the proportion of transfected cells was not known.  As the 
shRNA sequences we evaluated did not produce a complete knock-down it would be 
worth testing sequences that have been previously tested by commercial companies to 
see if they could abolish NCAM expression. 
 
5.4.5 Conclusion 
Understanding neuron-glial interactions is essential for advancing our knowledge of 
nervous system development and may help understand why remyelination in MS fails.  
Cell culture models of neuron-glial interactions enable investigations that are difficult to 
assess in vivo.  However, the extent to which these models mimic in vivo processes are 
difficult to determine accurately.  At this point in time we are unable address the 
hypothesis that NCAM plays a role in myelination because our myelinating co-cultures 
were not successful and we did not achieve complete knock-down of NCAM expression 
using shRNA. 
 
 
 
 
 
 
 
 
  
229 
 
 
 
 
 
 
 
 
Chapter 6 
 
 
 
 
 
General Discussion 
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Myelination provides axonal insulation and is essential for the rapid saltatory 
conduction of an action potential.  OPCs arise in discreet regions during development 
and migrate and proliferate extensively in order to populate the entire CNS.  The 
maturation of OPCs into myelinating cells is regulated by soluble growth factors 
released from neurons and astrocytes and contact-dependent signals obtained from the 
axon.  The correct molecular interactions for the association of oligodendrocyte 
processes with the axonal membrane are not only essential for the process of 
myelination itself, but also for the survival and initial process outgrowth of 
oligodendrocytes (Colognato et al. 2002; Fernandez et al. 2000).  Several molecules 
have been implicated in regulating axon-oligodendrocyte interactions, as summarised in 
Table 6.1, such as NRG, Notch and integrins.  In this study, we have presented data 
suggesting that the cell adhesion molecule NCAM stimulates intracellular signalling 
pathways in oligodendrocytes leading to an increase in survival and process outgrowth 
and, therefore, it may contribute to the axon-oligodendrocyte signalling required to 
initiate myelination in vivo.  
 
NCAM, discovered in 1974 (Jorgensen and Bock 1974), mediates cell adhesion by a 
homophilic binding mechanism, but importantly it does not merely function in 
adherence.  NCAM binding initiates the formation of signalling complexes capable of 
modulating a number of cellular responses, including survival, proliferation and 
differentiation of several cell types.  NCAM interacts with numerous heterophilic 
binding partners, such as L1 and the FGFR, which have been relatively well 
characterised.  More recently NCAM has been shown to regulate signalling via a 
number of other growth factor receptors; GDNF (Paratcha et al. 2003); BDNF (Vutskits 
et al. 2001), EGFR (Povlsen et al. 2008) and PDGFR (Zhang et al. 2004).   
 
The NCAM knock-out mouse is viable and has a relatively mild phenotype, which 
includes reduced size and disorganisation of the olfactory bulb and impaired synapse 
maturation (Cremer et al. 1994; Polo-Parada et al. 2004; Tomasiewicz et al. 1993).  
Lack of NCAM has been suggested to result in perturbation of neuron-glial interactions, 
including an increased number of myelinated axons in the rostral migratory stream of 
adult knock-out mice (Chazal et al. 2000).  However, this may reflect a decrease in 
migration and accelerated differentiation and be a result of lack of PSA-NCAM rather 
than loss of NCAM (Decker et al. 2002).  Loss of function of polysialyltransferase 
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enzymes resulted in a more severe phenotype, which could be overcome by concurrent 
deletion of the NCAM gene, indicating that one of the roles of PSA may be to mask the 
adhesive effects of NCAM (Hildebrandt et al. 2007; Muhlenhoff et al. 2009).  Correct 
temporal and spatial unmasking of NCAM following PSA removal is likely to be 
important for controlling accurate cell-cell interactions.  It is feasible that the role of 
NCAM is underestimated by knock-out studies because of the similarity in structure and 
functions of many of the members of the Ig superfamily.  For example, L1 is 
upregulated in the NCAM-null mouse suggesting that it may compensate for some 
NCAM functions (Aonurm-Helm et al. 2008).   
 
 
Signal Proliferation/ 
Migration 
Survival Differentiation Myelination References 
Electrical 
activity 
+  + (Kir 
channels) 
+ Barres and Raff 1993; 
Demerens et al. 1996; 
Neusch et al. 2001. 
Adenosine -  + + Stevens et al. 2002. 
Notch/Jagged 0  - - Wang et al. 1998. 
Neuregulin + + + +? Brinkmann et al. 2008; 
Canoll et al. 1996, 1999; 
Fernandez et al. 2000; 
Taveggia et al. 2008; 
Vatanian et al. 1999. 
Integrins  + +  Baron et al. 2003; 
Colognato et al. 2002; 
Frost et al. 1999; Watkins 
et al. 2002. 
GluR - (inhibiting K+ 
channel) 
-   Gallo et al. 1996; Itoh et al. 
2002; Rosenberg et al. 
2003; Yuan et al. 1998. 
PSA-NCAM   0 - Charles et al. 2000; 2002a. 
NCAM 0 + +?  This study, Anderson et al. 
2005; Gard et al. 1996; 
Palser et al. 2009. 
PDGF + +   Armstrong et al. 1990; 
Barres et al. 1992; Barres 
and Raff 1993; Frost et al. 
2009. 
 
Table 6.1 Mediators of axon-oligodendrocyte signalling (adapted from Bozzali and Wrabetz 
2004). 
 
6.1 Soluble NCAM enhances oligodendrocyte survival via the FGFR and MAPK 
signalling pathways  
Homophilic binding of axon-oligodendrocyte NCAM during the initial stages of 
myelination is a candidate mechanism for transducing signals between the axon and the 
oligodendrocyte.  However, the influence of NCAM on oligodendrocyte physiology and 
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signalling has been little studied to date.  In the present study, both the extracellular 
domain of NCAM and peptides derived from the FRM motif induced a dose-dependent 
increase in oligodendrocyte survival but not proliferation. This is in agreement with 
previous findings showing the survival promoting properties of NCAM and other 
CAMs on oligodendrocytes in culture, independent of an effect on proliferation (Gard et 
al. 1996).  These results suggest that the FRM site is critical for the survival effect of 
NCAM.  The survival promoting effects of peptides derived from the FnIII domains of 
NCAM have previously been demonstrated using other cell types (Anderson et al. 2005; 
Kiselyov et al. 2003; Neiiendam et al. 2004), indicating a general role for CAM 
signalling in cell survival.  The FRM peptide stimulated a survival effect comparable to 
FGF2 in 3T3 fibroblasts and stimulated a maximum 95% increase in survival of 
cerebellar neurons (Anderson et al. 2005).   
 
CAM binding to the FGFR has been widely reported and this is suggested to be a major 
way in which CAMs elicit a cellular response, as they do not themselves have intrinsic 
enzymatic activity (Walsh and Doherty 1997).  The use of tyrosine kinase inhibitors, 
FGFR blocking antibodies and expression of dominant negative FGFR constructs 
provided evidence that the FGFR was important for NCAM-mediated signalling in 
neurons (Saffell et al. 1997; Williams et al. 1994a; Williams et al. 1994b).  However, it 
was not clear until more recently whether this involved a direct interaction or if 
intermediate binding partners were involved.  Kiselyov et al (2003) demonstrated that 
the two FnIII domains of NCAM bound directly to the second and third Ig domains of 
the FGFR, using SPR and NMR.  It appears that CAM homophilic binding in trans, 
involving the Ig domains (Ranheim et al. 1996; Rao 1992), is followed by a cis 
interaction between the FnIII domains of the activated CAM and the FGFR (Frei et al. 
1992).  
 
The FRM and FGL sites, located within the first and second FnIII domains of NCAM 
respectively, together form a site that is able to interact with FGFR in neurons and 
stimulate intracellular signalling to increase survival and neurite outgrowth (Anderson 
et al. 2005; Doherty et al. 1990b; Kiselyov et al. 2003; Neiiendam et al. 2004; Williams 
et al. 1994a; Williams et al. 1994c).   
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The survival effect of the FGL peptide on neurons was blocked by inhibitors to FGFR, 
MEK and PI3K indicating that the FGL mediated survival response was dependent on 
activation of the FGFR and subsequent activation of multiple intracellular signalling 
pathways (Neiiendam et al. 2004).  This is the first study to examine this interaction in 
detail in oligodendrocytes and the signalling pathways associated with the effect of 
FRM peptide on survival have yet to be assessed in any cell type.  We have shown that 
the survival effects of FRM peptide and NCAM-Fc on oligodendrocytes were also 
dependent on the FGFR, using a small molecule inhibitor, which can specifically inhibit 
all FGFRs (Bansal et al. 2003).  The expression of different FGFRs on OPCs as they 
mature into oligodendrocytes has been previously demonstrated (Bansal et al. 1996) and 
they are believed to be important in controlling oligodendrocyte differentiation (Oh et 
al. 2003).  The FGFR1 is expressed at all stages of oligodendrocyte development, but 
increases with lineage progression, FGFR3 expression peaks during the late progenitor 
phase, whereas FGFR2 is expressed on mature oligodendrocytes (Bansal et al. 1996).  
We also detected the expression of FGFR1-3 on OPCs and oligodendrocytes, so it is 
possible that FRM peptide and NCAM-Fc may act via any of these receptor subtypes.  
Altered expression of different FGFR isoforms may influence the response to NCAM at 
different stages of the oligodendrocyte lineage.  Using siRNA knock-down of particular 
FGFR subtypes in oligodendrocytes, Zhou et al (2006) showed that FGFR1 was the 
important isoform for controlling the inhibition of differentiation produced by FGF2.  
Expression of a dominant negative FGFR1, under control of the MBP promoter, 
increased myelin sheath thickness (Harari et al. 1997).  This suggests that FGFR1 may 
not be the receptor involved in mediating the NCAM response because we did not 
observe an inhibition of differentiation.  Alternatively, NCAM and FGF2 may elicit 
differing responses via the same receptor, or NCAM may function to alter the response 
to FGF2.  FGFR3 is reported to be the subtype involved in regulating the onset of 
terminal differentiation (Bansal et al. 1996; Oh et al. 2003).  Additionally, whereas 
FGF2 stimulated down-regulation of myelin proteins on mature oligodendrocytes, 
FGFR2 stimulation by other FGF ligands, such as FGF9 and FGF18, led to 
oligodendrocyte process outgrowth and no such decrease in myelin expression (Fortin et 
al. 2005).  
 
In this study, the survival responses of FRM peptide and NCAM-Fc were blocked by an 
inhibitor of MEK but not the PI3K pathway, and increased phosphorylation of ERK1/2 
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was detected in response to FRM and NCAM-Fc stimulation.  Together this implicates 
the MAPK/ERK pathway in the survival effect mediated by the FRM peptide and 
NCAM-Fc.  Activation of the MAPK pathway is associated with increased cell survival, 
and whilst activation of the PI3K pathway is important for NCAM-mediated cell 
survival in neurons, it does not appear to play a role in NCAM-induced oligodendrocyte 
survival.  This suggests that different pathways operate to promote neuronal and glial 
survival in response to the same ligand.  Moreover, a developmental switch in survival 
signalling pathways in response to soluble growth factors such as NRG and PDGF, 
which is contact-dependent, is reported to take place in oligodendrocytes (Colognato et 
al. 2002; Frost et al. 1999).  NRG induced oligodendrocyte survival was shown to be 
dependent on PI3K signalling (Flores et al. 2000), but in the presence of the ECM 
molecule laminin binding  to oligodendroglial integrins, this dependency switched to a 
MAPK pathway, enabling the NRG signal to maintain survival and allow differentiation 
(Colognato et al. 2002).  We hypothesise that whilst early progenitors may be 
dependent on PI3K signalling for their survival (Vemuri and McMorris 1996), at the 
maturation stage investigated here, contact-dependent signalling may operate through 
MAPK instead, in agreement with Colognato and colleagues (2002, 2004).  As PI3K 
has been suggested to be essential for oligodendrocyte survival via other stimuli 
(Vemuri and McMorris 1996), it is likely that a number of extracellular signals are 
required to optimally maintain oligodendrocyte survival (Barres et al. 1993b).  
However, in vivo studies have pointed to a role for Akt in myelination rather than 
survival or proliferation, whereby constitutively active Akt increased myelin thickness 
but not oligodendrocyte number (Flores et al. 2008), highlighting possible discrepancies 
between in vivo and in vitro studies.   
 
PDGF induced oligodendrocyte survival can be amplified by culture on laminin which 
activates integrins, or culture with L1-Fc that binds to contactin/F3 (Laursen et al. 
2009), suggesting that contact-dependent signals in conjunction with soluble growth 
factors may act to regulate target-mediated survival.  Furthermore, L1 and laminin had 
additive affects, indicating that several ligands co-operate to achieve maximal survival.  
Laursen et al (2009) showed that knock-down of NCAM using siRNA did not affect 
PDGF-mediated survival or prevent L1-Fc-induced survival.  This suggests that L1 is 
not an axonal binding partner for oligodendrocyte NCAM.  However, NCAM may be 
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acting in a similar way to regulate FGF rather than PDGF signalling in a contact-
dependent manner.   
 
Several studies have described a role for Fyn in myelination (Kramer et al. 1999; 
Osterhout et al. 1999; Umemori et al. 1994).  This study highlights a role for signalling 
via Fyn in NCAM-mediated oligodendrocyte survival, as demonstrated using the 
inhibitor PP2.  Activation of Fyn provides an alternative method of activating 
intracellular signalling by NCAM, and may act instead of, or in conjunction with FGFR 
activation (Bodrikov et al. 2005).   
 
6.2 Cellular NCAM stimulates process outgrowth of OPCs but does not influence 
myelin protein expression 
The role of NCAM in promoting OPC process outgrowth was examined using the well 
characterised transfected fibroblast co-culture system (Doherty et al. 1989; Doherty et 
al. 1990b).  OPCs grown on a confluent monolayer of NCAM-transfected fibroblasts 
showed a marked change in morphology, with a significant increase in the number of 
processes per cell and process length, suggesting that NCAM is able to stimulate their 
radial process outgrowth.  Previous studies have demonstrated an increase in surface 
area when oligodendrocytes are grown on glass coverslips coated with NCAM, MAG 
and N-cadherin, although this was measured at later time points than our study (Gard et 
al. 1996; Payne and Lemmon 1993).  The increase in OPC process outgrowth in 
response to NCAM-expressing cells demonstrated in this study is in agreement with 
studies showing that NCAM stimulates process outgrowth in primary neurons.  In a 
similar co-culture system NCAM-transfected fibroblasts stimulated neurons to extend 
neurites approximately twice the length of those grown on untransfected fibroblasts 
(Doherty et al. 1990b; Williams et al. 1994a), indicating that NCAM elicits similar 
physiological responses in a range of cell types.   
 
Soluble NCAM-Fc and several NCAM peptides have been shown to increase neurite 
outgrowth (Anderson et al. 2005; Hansen et al. 2008a; Kiselyov et al. 2003; Meiri et al. 
1998; Neiiendam et al. 2004; Pedersen et al. 2004; Soroka et al. 2002).  The FnIII 
domains of NCAM have been shown to be important in stimulating neurite outgrowth, 
whereby an antibody to the first FnIII domain prevented the effects of cellular NCAM 
in the co-culture system, suggesting this region is functionally important for both 
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survival and outgrowth (Anderson et al. 2005).  However, in contrast to NCAM 
expressing cells, soluble versions of NCAM were unable to stimulate an increase in 
OPC process outgrowth.  Additionally, they were unable to block the effects of cellular 
NCAM.  This suggests that different signalling pathways may be required to stimulate 
process outgrowth compared to survival in OPCs or that activation of signalling may 
not be sufficient to induce process outgrowth and CAM-CAM interactions in trans may 
also be required.  Process outgrowth in OPCs may also differ considerably to neuronal 
neurite outgrowth. 
  
A number of studies have shown MAPK signalling to be important for neurite 
outgrowth induced by several stimuli, including NCAM, N-cadherin, laminin and 
FGF2, and it is suggested that ERK is a point of convergence for many different 
molecules that activate axonal outgrowth (Hinsby et al. 2004; Kolkova et al. 2000a; 
Perron and Bixby 1999; Schmid et al. 1999).  In contrast p38 was not required for 
neurite outgrowth (Perron and Bixby 1999).  When we investigated the signalling 
pathways involved in cellular NCAM-mediated OPC process outgrowth, an inhibitor of 
Fyn kinase but not FGFR or MEK significantly blocked the number of processes per 
cell.  Therefore, different pathways are involved in OPC process outgrowth compared to 
survival.  Fyn plays an important role in myelination, with its activity peaking in the 
postnatal brain at a time coinciding with the initiation of myelination (Umemori et al. 
1994).  Mice that are Fyn-deficient (Umemori et al. 1994) or express a Fyn molecule 
that lacks kinase activity (Sperber et al. 2001) display hypomyelination.  Both of these 
mutant animals produced some myelin and OPCs isolated from Fyn-deficient mice 
differentiated in vitro (Sperber and McMorris 2001), suggesting that there are 
alternative signalling pathways that can stimulate myelin-production, although they may 
be less efficient.  This may explain why PP2 did not completely inhibit NCAM-induced 
process outgrowth.  Laursen et al (2009) showed that axonal contact is important for 
Fyn activation, and therefore, as we have shown that Fyn signalling is important in 
NCAM-mediated survival and outgrowth, NCAM may represent another means of 
activating Fyn. 
 
Oligodendrocyte NCAM isoforms are differentially regulated during development.  
OPCs express both NCAM-140 and NCAM-120, which is polysialylated on immature 
cells (Trotter et al. 1989).  As they matured, NCAM-140 was down-regulated and 
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NCAM-120 localised to lipid raft microdomains (Kramer et al. 1999).  Partitioning of 
NCAM isoforms into topologically distinct regions is reported to contribute to its 
diversity of functions (Niethammer et al. 2002).  Our results show that NCAM-120 and 
NCAM-140 are present on pre-myelinating oligodendrocytes, implying that they may 
both be involved in myelination.  In contrast, neurons express NCAM-140 and NCAM-
180, both of which have been shown to be important for neurite outgrowth in different 
cells (Buttner et al. 2004; Kolkova et al. 2000b; Korshunova et al. 2007; Niethammer et 
al. 2002).  NCAM-180 is found at cell-cell contacts and it displays reduced lateral 
mobility compared to other isoforms, and is proposed to have a greater role in adhesion, 
but it is not known which isoform expressed by the oligodendrocyte participates in 
adhesion.  Adhesion is likely to provide membrane stability and may enhance the 
interaction of signalling molecules located within close proximity to each other.  
NCAM-120 has also been shown to associate with spectrin, despite its lack of an 
intracellular domain which is thought to be essential for the interaction with NCAM-
140 (Leshchyns'ka et al. 2003).  The co-localisation of NCAM and spectrin to the raft 
membrane compartment may enhance their interaction.  An additional level of 
regulation may occur, whereby when a process reaches its appropriate target, stable 
trans interactions occur, which will prevent translocation of CAMs to sub-
compartments of the cell membrane and exclude FGFR from the NCAM clusters, thus 
preventing the outgrowth promoting signalling (Hansen et al. 2008b).  Formation of 
heterodimers between the different NCAM isoforms may further complicate signalling 
as some isoforms preferentially bind to and interact with different signalling proteins.   
The formation of heterodimers has not been demonstrated experimentally.  However, as 
most cells express multiple isoforms, which have identical extracellular binding 
domains and it is suggested that NCAM signals as a dimer, this may explain some of the 
discrepancies are observed between different studies (Ditlevsen and Kolkova 2008).    
 
 
6.3 An important role for NCAM in oligodendrocyte development and myelination 
During development, the presence of PSA-NCAM on developing axons inhibits 
myelination and the removal of PSA is an important regulator of the onset of 
myelination (Charles et al. 2000).  At the onset of myelination PSA is stripped from 
NCAM on the axon and oligodendrocyte, allowing oligodendrocyte processes to attach 
to axons.  A recent study demonstrated that oligodendrocytes derived from transgenic 
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mice over-expressing PSA-NCAM displayed a less mature morphology with fewer 
processes and less extensive myelin-like sheaths (Fewou et al. 2007).  Consistent with 
our results there was no effect on the number of GalC
+
 oligodendrocytes or in myelin 
protein expression, indicating that neither NCAM nor PSA-NCAM influences the 
differentiation of oligodendrocytes in vitro.  Together these data support a putative 
inhibitory role for PSA-NCAM in myelination (Charles et al. 2000; Charles et al. 
2002a) and a stimulatory role for non-polysialylated NCAM in OPC survival.  Axon-
oligodendrocyte interactions, involving NCAM-NCAM homophilic binding or other 
heterophilic CAM interactions, may lead to activation of oligodendrocyte survival and 
process outgrowth via activation of intracellular signalling.  Pre-myelinating 
oligodendrocytes that do not contact axons and receive the correct survival signals will 
die by apoptosis (Barres et al. 1993a; Trapp et al. 1997).  Thus, NCAM/FGFR 
signalling may contribute to the target dependent survival of oligodendrocytes, most 
likely in conjunction with other signalling pathways (Baron et al. 2005). 
 
6.4 Future experiments 
To further our investigations it would be useful to establish the role of NCAM in a 
myelinating co-culture system.  Because the way in which we set up the DRG/OPC co-
cultures did not result in successful myelination, it would be good to try different 
conditions, for example isolating the OPCs from earlier neonates and expanding them as 
mixed glial cultures, rather than isolating them by immunopanning.   
 
Transgenic mice that are null for NCAM, MAG or L1 have a relatively mild phenotype, 
most likely due to some degree of redundancy amongst adhesion molecules from the 
same families, but also due to compensatory mechanisms that may operate when a 
molecule is completely absent throughout life.  Therefore, it would be interesting to 
have a mutant where NCAM is conditionally ablated from oligodendrocyte lineage cells 
early in postnatal life so there is less opportunity for other CAMs to compensate.  The 
only conditional NCAM knock-out to be reported was under the control of calcium-
calmodulin-dependent kinase II promoter, reducing NCAM expression in the 
hippocampus and resulting in abnormal learning and memory formation (Bukalo et al. 
2004).   
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Shorter term knock-downs using siRNA are a valuable tool for investigating the 
requirement of molecules without time for compensatory mechanisms to set in.  
However, it is difficult to achieve a high transfection efficiency using primary cells and 
transient transfections are typically expressed for a maximum of one week so are not 
suitable for many myelinating co-culture systems that need to be maintained for longer 
periods.  Colognato et al (2007) used fluorescent siGLO siRNA where they reported 
transfection efficiency of 90% using Amaxa nucleofection.  We did not observe as high 
efficiency for plasmid transfection (approximately 30%) of primary OPCs and found 
Amaxa to be highly toxic to CG4 cells.  Virally infecting primary cells is a better way to 
achieve high efficiency and stable expression of constructs.  Necl4 was knocked-down 
in Schwann cells prior to addition to DRG cultures using lentiviral expression of 
shRNA (Maurel et al. 2007).  Additionally, adenoviral infection resulted in an 
efficiency of 75-95% (Cui et al. 2005; Flores et al. 2000), compared to approximately 
30% transfection efficiency using an Effectine transfection kit.   
 
In the absence of viral vectors a way to increase the proportion of transfected cells 
would be to sort them for GFP
+
 cells via FACs.  Furthermore, to have a complete 
absence of NCAM in all cells it would be useful to isolate OPCs from NCAM-null mice 
and see whether they responded to FRM peptide and NCAM-Fc or would myelinate 
wild-type axons.   
 
Our results were obtained in the absence of exogenous FGF2 so it would be interesting 
to investigate how NCAM modulates the FGF2 response.  Furthermore, to determine 
which FGFRs were responsible for promoting OPC survival in response to NCAM, 
siRNA could be used to ablate individual FGFR subtypes (Zhou et al. 2006).  
Moreover, it would be beneficial to examine which FGFR isoforms contain the acid box 
region which is said to be essential for CAM-FGFR interactions, as this would help 
elucidate which subtypes were responsible for transducing the NCAM signal (Sanchez-
Heras et al. 2006). 
 
6.5 Therapeutic implications 
This study has shown that NCAM can promote the survival and process outgrowth of 
OPCs in vitro.  Therefore, NCAM may have a therapeutic potential to promote OPC 
maturation in the CNS and could aid repair in MS.  This study was carried out using 
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neonatal OPCs so it would be important to clarify whether progenitor cells in the adult 
CNS respond in the same way.  Culture of adult OPCs on NCAM-expressing fibroblasts 
increased their process outgrowth (Dr Anne Palser, unpublished observations).  FRM 
peptide did not appear to affect adult OPC morphology but survival was not 
investigated, so it would be interesting to determine whether FRM peptide and NCAM-
Fc could promote adult OPC survival as they do to neonatal cells.  This would have 
important implications for the biology of remyelination and whether NCAM could 
prove a therapeutic target for MS.  CAMs are likely to be important for re-establishment 
of axon-oligodendrocyte contact following demyelination.  Signals from the axon are 
thought to be involved in remyelination; accordingly changes in CAM expression 
following demyelination could determine whether remyelination is successful.  
Accumulating damage following repeated episodes of inflammatory demyelination may 
render axons incapable of stimulating oligodendrocytes to myelinate.  OPCs and pre-
myelinating oligodendrocytes have been found in chronic MS lesions, where they 
appear to make axonal contact but do not undertake myelination (Chang et al. 2000; 
Chang et al. 2002).  However, the number of OPCs is lower in chronic than acute 
lesions (Kuhlmann et al. 2008).  It is believed that remyelination failure may occur 
because OPCs are not receiving the correct signals to induce differentiation and myelin 
formation.  As NCAM stimulated survival and process outgrowth in vitro it may be able 
to enhance endogenous remyelination in vivo.  The expression of NCAM in the adult 
brain and following demyelination has not been fully investigated.  PSA-NCAM was 
shown to be upregulated on demyelinated but not remyelinated axons within MS lesions 
(Charles et al. 2002a), suggesting that PSA-NCAM may be inhibitory to remyelination.  
Loss of NCAM expression or a change to PSA-NCAM within lesions may limit the 
capacity for repair by blocking the re-attachment of oligodendrocytes to axons and 
inhibiting the survival and process outgrowth of adult OPCs.  Therefore, administration 
of NCAM could benefit remyelination by increasing oligodendrocyte survival and 
outgrowth.  However, NCAM protein would be too large to administer for in vivo 
testing.  Small soluble peptides have a significant advantage over recombinant proteins 
in that they are suitable as pharmacological agents.  NCAM peptides have already been 
tested successfully in a number of animal disease models, where they have proved 
neuroprotective and enhanced memory formation (Klementiev et al. 2007; Klementiev 
et al. 2008; Skibo et al. 2005).  FGL peptide restored FGFR1 phosphorylation levels 
and signalling in the hippocampus of NCAM-null mice (Aonurm-Helm et al. 2010).  
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Furthermore, FGL peptide has proved a success in pre-clinical and phase I trials for 
Alzheimer’s disease (Anand et al. 2007).  The C3 peptide showed potential for reducing 
developmental defects following exposure to teratogens (Klementiev et al. 2002).  
Other NCAM peptides have shown therapeutic potential as anti-cancer drugs by 
blocking the effects of FGF.  They have yet to be tested in models of MS.  
 
6.6 Conclusion 
In conclusion, this study highlights the possible role of CAMs as contact dependent 
mediators of signalling cues to oligodendrocytes during myelination.  Axonal NCAM 
may interact in trans with oligodendrocyte NCAM during the initial stages of 
myelination in vivo.  NCAM contains an FRM motif within the first FnIII domain, 
which is thought to form part of an FGFR binding motif (Anderson et al. 2005; Carafoli 
et al. 2008; Doherty and Walsh 1996; Kiselyov et al. 2003).  This interaction may lead 
to a FRM mediated cis interaction between NCAM and the FGFR in the 
oligodendrocyte membrane and subsequent activation of signalling pathways leading to 
increased survival.  FRM peptide and NCAM-Fc induced an increase in the survival of 
pre-myelinating oligodendrocytes, which could be blocked by FGFR, MEK kinase and 
Fyn inhibitors implicating NCAM-FGFR and NCAM-Fyn interactions and MAPK 
signalling in the survival response, as summarised in Figure 6.1.  These represent novel 
signalling systems not previously explored in oligodendrocytes and are likely to act in 
concert with other factors to influence oligodendrocyte development.  These data also 
further highlight the importance of the FRM domain in the survival bioactivity of 
NCAM.  Several other CAMs, such as N-cadherin and L1 also contain FRM motifs 
within their FnIII domains (Williams et al. 1994a) and binding of these molecules to 
FGFR in vivo may also lead to an increase in oligodendrocyte survival. Furthermore, 
NCAM expressed on a cellular substratum, stimulated a significant increase in OPC 
process outgrowth.  This study also demonstrates that a contact-dependent element is 
required for NCAM to increase process outgrowth, suggesting that the mechanisms of 
survival and outgrowth are different.  Together these data suggest an important role for 
NCAM in axon-oligodendrocyte signalling during development, in addition to its 
known role in adhesion. 
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Figure 6.1 Proposed role of NCAM in axon-oligodendrocyte interactions 
a. OPCs and axons initially express the polysialated (PSA) version of NCAM, which inhibits 
homophilic binding and adhesion. At this stage OPCs are dependent on soluble growth factors 
to maintain their survival, such as FGF2, which also increases proliferation and prevents 
premature differentiation, thought to occur via FGFR1.  b. By the time cells mature to the pre-
myelinating stage PSA has been removed from both axons and oligodendrocytes, enabling 
NCAM-NCAM homophilic binding in trans, which activates intracellular signalling in the 
oligodendrocyte.  NCAM signalling through a cis interaction with the FGFR (which may operate 
via FGFR1, 2 or 3) leads to MAPK activation and promotes cell survival.  Similarly, NCAM may 
activate Fyn, increasing survival and also process outgrowth. 
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